Vous êtes sur la page 1sur 56

EMERGENCY DIAGNOSIS AND TREATMENT OF ACUTE DECOMPENSATED HEART FAILURE (ADHF) - MARCH 2005

Produced by

2005 EMCREG-International
www.emcreg.org

EMERGENCY DIAGNOSIS
AND TREATMENT OF
ACUTE DECOMPENSATED
HEART FAILURE (ADHF)
IN THIS ISSUE

CME Monograph
from the ACEP 2005
Spring Congress Satellite
Symposium
Orlando, Florida
March 4, 2005

EMCREG-International

This educational monograph was supported in part by


an unrestricted educational grant from Scios.

Printed in t h e U S A

Produced by

%-%2'%.#9
$)!'./3)3!.$
42%!4-%.4/&!#54%
$%#/-0%.3!4%$
(%!24&!),52%!$(&

 }>
vi
*x
-}
}i
->ii-
">`]`>
>V{]x

%DITEDBY
!NDRA,"LOMKALNS -$
!SSISTANT0ROFESSOR 2ESIDENCY$IRECTOR
$EPARTMENTOF%MERGENCY-EDICINE
5NIVERSITYOF#INCINNATI
#INCINNATI /( 53!
$IRECTOR #-%AND%NDURING-ATERIALS
%-#2%' )NTERNATIONAL

*`Vi`L

, i>>
Q i}iVi`Vi
>`>V,ii>V
>` `V>R

7"RIAN'IBLER -$
)NTERNATIONAL
W W W  E M C R E G  O R G

0ROFESSOR#HAIRMAN
$EPARTMENTOF%MERGENCY-EDICINE
5NIVERSITYOF#INCINNATI
#INCINNATI /( 53!
0RESIDENT %-#2%' )NTERNATIONAL

)NTERNATIONAL
>x
i>
i>}i\
>Vi>]i>i>ii1i`->i>i>i`>Vi`iVi>i`i>v>i i
>]ii>iLiii`>VVi}`iiviii}iV>>}iivV` >>vi  , i
Vi iVi>i`i>>i >>,i}]`V>i> >i>iii>i`>i`]>`ii>i
>i}>ivL`>`>/i>>}ii>`V>iv>i}i>L>/Viii
>`}ii}>iii>i`>}V>`i>iV`>iv >`}}ii`i
iV>ivii>i>}>`iv  , >Liiii`>``Vi`
/i i}iVi`Vi
>`>V,ii>V>` `V>i>> 
, i>i`iii`V>>
}> >} x 
,  - i i}iV i>i >} >` /i>i v
  i` ">`] `> / }> > >>>Li > > `i>` iL V> i V`i`
," >` >
\>`v`}VVLi}}ixi>>i>`iii}iVV>v>
iVi>i>`v>V>iV>ivi>i>

,  `V>>
/i v 
, i>> `i `>i] i`iVi L>i`] >` VV> iv i`V>> >i>
i>V>i`ii`iV>ivii}iVV`7i>i}i>`i>`ivv`iii>i>vii
vViV>L>7iiii`V>>i`i>>ii`>L`]i>iVLyiVi
L>V>iviii`>`VLi`
ii}>`}>vi`V>>>i>V>Liivii``iV
`> >] ] iVv
 >` `}>i>>JiVi}}
-Vii]

`> >]
>*vi],i`iV iV
i>iv i}iVi`Vi
1iv
V>

V>]"
iV]
 >` `}>i>

, i>>

7 >Li]
*vi>`
>>

i>iv i}iVi`Vi
1iv
V>

V>]"
*i`i] 
, i>>

VVi`>\/i1iv
V>
i}ivi`Vi`i}>ii`V>>>Vv>>vv
>i}Vi`
>`i*V>,iV}>` >VV>`V>i>ii>V>iii`V>>>V
/i1iv
V>>VVi`i`LiVVi`>
Vv
}i`V> `V>

 V}i`V>
i`V>vV>
/i`V>>}>>i`>L>iVi`i`V>>}>v-V
/`ViLii`>>>>`VV>iviiVi>` "/>>Livi>`}i>>Li>`}>Vi`Vi

, Li>Li>iiiv>`iV>`i>V>i>iLi>Viii>i>/
`Vi`ii>Vi``>V>VV>`}i

V>`}i}`ii>Vvi>i}}iLiiwvi>i>}>ivV i]`V>>`i`v
iv`Vivii`}>>iiVi>i>i>`V>i`i>V>}ii>`>Li`ii`vivi>
i>iiVV>Vi
ViiiVL}v>Livi>`i}

/>Liv
i
>}vVi iVi>i`i>>ii
`` >`i]
*vi
i>iv i}iVi`Vi
1iv*i>>]*>`i>]*

/i>ivVi iVi>i`i>>ii x
}>
>]
>*vi
v i}iVi`Vi
7>}1i]-]"

/i },iv *i >}>`/i>iv
\
->vi *
i*>i,i
7>*i>VV]
*vi
6Vi
>],ii>V] i>iv i}iVi`Vi
/i
ii>`
V]
ii>`]"

>V}`>``}i  , /" , -/,9


7>/L>>]
*vi

iv] v
>`>V>i`Vi
/i"->i1i]
L]"

i>i>>}iivVi iVi>i`i>>i\/i  ,
i}iVi`Vi`i
,V>`-i]
*vi
i>iv i}iVi`Vi
1ivi`V>
ii]>V]-

Vi iVi>i`i>>i i>i>>}ii/


-i>*
]
>*vi
i>iv i}iVi`Vi
1iv
V>]
V>]"

}i`V> `V>+i {

II


L}
7>/L>>]
*vi

iv] v
>`>V>i`Vi
/i"->i1i

L]"
}>
>]
>*vi
7>}1i
-]

>*vi
1iv
V>

V>]"

7>*i>VV]
*vi
/i
ii>`
V

ii>`]"

`` >`i]
*vi
1iv*i>>
*>`i>]*i>>

,V>`-i]
*vi
1iv
>V]

-i>*
]


, iLi
7 >Li] ]*i`i
1iv
V>

V>]"

i> i]
1i>>Li}
ii] i}

-}]
i1i
/]>>

*>V]
1iv
V>

V>]"

6>>>>]
-}>iii>>
-}>i

iL>- iV]
1
>i`V>
ii
->V>i]
>v>

`>`
>V]
1iv
V>

V>]"

7>*i>VV]
/i
ii>`
V

ii>`]"

/*v`ii`i]
i`V>
i}iv7V
>ii]7V

i}i>]
1iv
V>

V>]"

,>` >V]
7> i>>
,>">]V}>

>i6*>V]
1iv*i>>>
*>`i>]*i>>

,Li >>]
*
>`>V>
,`i>i] >

>Vii]
>}ii`V>
ii

>>}>]/iiii

 }>]
1
>i`V>
ii
->V>i]
>v>

>-ii>Vi]
i1ii`V>
ii
>]
>>

`> >]
1iv
V>

V>]"

ii>i]

>>i`V>
ii

>i]
>>

i`i]*
1iv
V>

V>]"

7>i-V>`}]
9>
9]*i>>

i>`8 }>]
-i1i>
*>i] i9

> ii]
i`V>

>i]>>`

>`i>]
*
>`>V>
,`i>i] >

i-]
6>`iL1i
>i]/iiii

,V>` >]
i`>
i]V}>

,V>`-i]
1iv
>V]

>>"L>]
>>
>
>>

>,/vv>]
>V>i`V>
ii
*i]>

>" i]
->>
i]V}>

>i 7iLi]
1ivV}>
]V}>

i*">]
i`V>
i}iv6}>
,V`]6}>

,Li<>i]
7>i->i1i
i]V}>

>` ]
>>Viii>>
]>>Vi

III

>]
1iv
V>

V>]"

}>
>]
7>}1i-Vv
i`Vi
-]

>i7i>]
7>ii1i
7->i]
>>

>i
i]
-*>>
6>Vi]
L>

`` >`i]
1iv*i>>
*>`i>]*i>>

-i>*
]
1iv
V>

V>]"

>,`]
1ivLi>>
`]Li>]
>>`>

 "--"
1/
"* -/
 ,/1,  /
*UDD%(OLLANDER -$
$EPARTMENTOF%MERGENCY-EDICINE 5NIVERSITYOF0ENNSYLVANIA
0HILADELPHIA 0!

" 
/6 -\
iwiiiv *`}i>v>ivii}iviv
Li>
ii>iiiv *v>v}>ii>v>i

 /," 1
/"
!SWEHAVEIMPROVEDTHECAREOFPATIENTSWITHACUTECORONARYSYNDROMES!#3 PA
TIENTSWITHCARDIOVASCULARDISEASEARELIVINGLONGERTHANEVER%FFECTIVEINTERVENTIONSTO
DECREASEMORTALITYOFPATIENTSWITH!#3HAVEINCREASEDTHEINCIDENCEOFHEARTFAILURE
4HECOSTOFHEARTFAILURENOWEXCEEDSBILLIONAYEAR MOSTOFWHICHISDUETOHOS
PITALIZATION5NFORTUNATELY HEARTFAILUREISACHRONICCONDITIONANDNEARLYHALFOFPA
TIENTSADMITTEDTOTHEHOSPITALAREREADMITTEDWITHINSIXMONTHS4ODETERMINEOPTIMAL
THERAPYFORPATIENTSWITHACUTEDECOMPENSATEDHEARTFAILURE!$(& THEEMERGENCY
PHYSICIANMUSTBEABLETOCONlDENTLYDIAGNOSEPATIENTSWITHHEARTFAILURE4HISREQUIRES
KNOWLEDGEOFTHEDIAGNOSTICMETHODSUSEDTOIDENTIFYPATIENTSWITHHEARTFAILUREASWELL
ASKNOWLEDGEOFTHEDIFFERENTETIOLOGIESOFHEARTFAILURE
3ORTING/UTTHE%TIOLOGYOF(EART
&AILURE
4HE POTENTIAL ETIOLOGIES OF ACUTE HEART
FAILURE ARE MULTIFACTORIAL AND SHOULD
BE BROADLY DIVIDED INTO TWO CATEGORIES
 THE UNDERLYING ETIOLOGY OF THE HEART
FAILURE AND THEETIOLOGYOFTHEACUTE
PRECIPITANTTHATRESULTSINWORSENINGFROM
THECHRONICCOMPENSATEDSTATE&ORSOME
PATIENTS PARTICULARLYTHOSEPRESENTINGFOR
THElRSTTIME THESETWOCOMPONENTSMAY
BE IDENTICAL 4HE MOST COMMON ETIOLO
GIES OF HEART FAILURE ARE CORONARY ARTERY
DISEASE AND LONG STANDING HYPERTENSION
/THER POTENTIAL ETIOLOGIES INCLUDE DI
LATED HYPERTROPHIC AND RESTRICTIVE CAR
DIOMYOPATHIES MYOCARDITIS PERICARDIAL
TAMPONADE VALVULAR HEART DISEASE AND
SECONDARYEFFECTSOFPULMONARYDISEASES
ORMETABOLICDISORDERS

!LTHOUGHINVESTIGATIONOFTHEUNDERLYING
ETIOLOGY IS IMPORTANT TO HELP DETERMINE
WHETHERTHEREISAREVERSIBLECOMPONENT
OFTHEDISEASE THISISUSUALLYBEYONDTHE
SCOPEOFTHEEMERGENCYPHYSICIAN4HERE
ARE HOWEVER SEVERALETIOLOGIESFORHEART
FAILURE THAT THE EMERGENCY PHYSICIAN
SHOULDBEAWAREOF ASTHEYMAYREQUIRE
MODIlCATIONOFINITIALTHERAPY4HESEARE
SEVERE AORTIC STENOSIS IDIOPATHIC HYPER
TROPHICSUBAORTICSTENOSISORHYPERTROPHIC
OBSTRUCTIVECARDIOMYOPATHY ANDPULMO
NARY HYPERTENSION )DENTIlCATION OF PA
TIENTSWITHTHESECONDITIONSISIMPORTANT
BECAUSEAGGRESSIVEPRELOADANDAFTERLOAD
REDUCTIONCANLEADTOCARDIOVASCULARCOL
LAPSESINCETHESEPATIENTSCANNOTINCREASE
THEIR FORWARD BLOOD mOW THROUGH THE
lXEDMECHANICALLESIONSUCHASAmOW
RESTRICTEDAORTICVALVE 

/ii>i}i
v>Vii>v>i
>iv>V>>`
`LiL>`
``i`
V>i}i\i
`i}i}v
ii>v>i]>`
ii}vi
>ViiV>>
ii}
viVV
Vi>i`>i

%MERGENCY$IAGNOSISAND4REATMENTOF
!CUTE$ECOMPENSATED(EART&AILURE!$(&

3EPARATEANDDISTINCTFROMTHEINITIALETI
OLOGY IS THE CAUSE OF THE ACUTE PRECIPI
TANT#ONGESTIVEHEARTFAILURECANBEEX
ACERBATEDBYWORSENINGOFTHEUNDERLYING
CONDITION BYMEDICATIONORDIETARYNON
COMPLIANCE OR BY DEVELOPMENT OF NEW
ORCOMPLICATINGMEDICALCONDITIONSEG
ISCHEMIA DYSRHYTHMIAS PULMONARYEM
BOLUS ORINFECTION !PPROXIMATELY
OF PATIENTS PRESENTING TO THE EMERGENCY
DEPARTMENT%$ WITHHEARTFAILUREHAVE
APRIORDIAGNOSISOFHEARTFAILURE
,i>ViVV>
i>i
i>``>}V
Vi>LiV>ii
}>`
vi>v>i>i
i>iiVwV

qqqqqqq

/i i>}
*i/>
`i>i`>
*ivv
i`>}v

i

0ROGRESSINTHE$IAGNOSISOF(EART&AILURE
4HE DIAGNOSIS OF HEART FAILURE HAS TRADI
TIONALLYBEENCHALLENGING2ELIANCEUPON
CLINICAL IMPRESSION ALONE LEADS TO DIAG
NOSTIC UNCERTAINTY BECAUSE THE SIGNS AND
SYMPTOMS OF HEART FAILURE ARE RELATIVELY
NONSPECIlC+EYSYMPTOMSSUCHASSHORT
NESSOFBREATHARENONSPECIlCINPATIENTS
WITH COMORBIDITIES SUCH AS REACTIVE AIR
WAYDISEASE,IKEWISE ROUTINELABORATORY
TESTS ELECTROCARDIOGRAMS ANDRADIOGRAPHS
CANNOTBERELIEDUPONTOALWAYSGUIDEAN
ACCURATEANDAPPROPRIATEDIAGNOSIS
$ESPITE THESE CHALLENGES DIAGNOSTIC CA
PABILITIESINHEARTFAILUREHAVEIMPROVED
IN RECENT YEARS WITH RECOGNITION OF THE
ROLETHAT" TYPENATRIURETICPEPTIDE".0
PLAYSINTHEDISEASE)NADDITIONTOBEING
APUMP THEHEARTISANENDOCRINEORGAN
THATFUNCTIONSTOGETHERWITHOTHERPHYSI
OLOGICALSYSTEMSTOCONTROLmUIDVOLUME
4HE MYOCARDIUM PRODUCES NATRIURETIC
PEPTIDES ONEOFWHICHIS".0 AHORMONE
WITH DIURETIC NATRIURETIC AND VASCULAR
SMOOTHMUSCLERELAXINGACTIONS".0IS
A NATURAL ANTAGONIST FOR THE SYMPATHETIC
NERVOUS SYSTEM AND THE RENIN ANGIOTEN
SIN ALDOSTERONEAXIS".0ISSECRETEDIN

RESPONSE TO WALL STRETCH VENTRICULAR DI


LATIONANDORINCREASEDlLLINGPRESSURES
-EASUREMENTOFENDOGENOUS".0ISTHUS
ACLINICALLYSENSIBLEWAYTOASSESSWHETH
ERAPARTICULARPATIENTHASHEARTFAILURE
4HE "REATHING .OT 0ROPERLY STUDY OF
 PATIENTSWHOPRESENTEDTO%$SWITH
SHORTNESSOFBREATHSHOWEDTHAT".0LEV
ELS ALONE WERE MORE ACCURATE PREDICTORS
OFTHEPRESENCEORABSENCEOFHEARTFAILURE
THANANYHISTORICALFACTORS PHYSICALlND
INGS OR LABORATORY VALUES  ".0 LEVELS
WEREMUCHHIGHERINPATIENTSWHOWERE
SUBSEQUENTLY DIAGNOSED WITH HEART FAIL
URETHANINTHOSEDIAGNOSEDWITHNONCAR
DIACDYSPNEAPGD,VSPGD, 
! ".0 CUTOFF VALUE OF  PGM, HAD
ASENSITIVITYOFANDASPECIlCITYOF
FORDIFFERENTIATINGHEARTFAILUREFROM
OTHERCAUSESOFDYSPNEA ANDACUTOFFOF
PGM,HADANEGATIVEPREDICTIVEVAL
UE OF 7ITHOUT KNOWLEDGE OF ".0
LEVELS EMERGENCYPHYSICIANSHADA
INDECISIONRATEINTRYINGTOMAKEADIAG
NOSIS".0LEVELSADDEDSIGNIlCANTLYTO
THE CLINICAL IMPRESSION AS IT WAS FOUND
THATCLINICALDECISION MAKINGINCONJUNC
TIONWITH".0LEVELSCOULDHAVEREDUCED
THEDIAGNOSTICINDECISIONRATETO)N
MULTIVARIATEANALYSES ".0LEVELSALWAYS
CONTRIBUTED TO THE DIAGNOSIS EVEN AFTER
TAKING INTO ACCOUNT lNDINGS FROM THE
HISTORY AND PHYSICALEXAMINATION4HUS
THE"REATHING.OT0ROPERLYTRIALDEMON
STRATED THAT ".0 LEVELS HAVE SIGNIlCANT
CLINICAL UTILITY FOR BOTH THE DIAGNOSIS
AND RISK STRATIlCATION OF HEART FAILURE
PATIENTS IN THE %$  "OTH DIASTOLIC AND
SYSTOLIC DYSFUNCTION ARE ASSOCIATED WITH
HIGH".0LEVELSOFMOREORLESSTHESAME
DEGREE

 "--"
1/
"* -/
 ,/1,  /

".0MUSTBEUSEDWITHCAUTIONINCERTAIN
POPULATIONS!LTHOUGH".0CANHELPDIF
FERENTIATEPULMONARYFROMCARDIACETIOLO
GIESOFDYSPNEA SOMETYPESOFLUNGDIS
EASE SUCH AS COR PULMONALE AND PULMO
NARYEMBOLISMHAVEELEVATED".0LEVELS
HOWEVER".0ISNOTUSUALLYELEVATEDASTO
ASHIGHALEVELASITISINPATIENTSWITHHEART
FAILURE )N A SUBGROUP OF PATIENTS WITH A
HISTORY OF REACTIVE AIRWAY DISEASE IN THE
"REATHING.OT0ROPERLYTRIAL OFSUB
JECTSWITHAHISTORYOFASTHMAORCHRONIC
OBSTRUCTIVE PULMONARY DISEASE WITHOUT A
HISTORYOF#(& WEREFOUNDTOHAVE
NEWLY DISCOVERED #(& /NLY  WERE
IDENTIlED IN THE %$ WHILE A ".0 
PGM,IDENTIlED!DDITIONALLY ".0
LEVELS  PGM, PROVIDED DIAGNOSTIC
INFORMATIONBEYONDTHATOBTAINEDFROMIN
DIVIDUALCHESTRADIOGRAPHICINDICATORS
4HERE IS A SIGNIlCANT INVERSE RELATIONSHIP
BETWEEN BODY WEIGHT BODY MASS INDEX
AND ".0 LEVELS4HIN PATIENTS WITH HEART
FAILUREAREMORELIKELYTOHAVEELEVATED".0
VALUESINTHEABSENCEOFHEARTFAILURE#ON
VERSELY OBESE PATIENTS ARE MORE LIKELY TO
HAVELOWERLEVELSOF".0FORANYGIVENSE
VERITYOFHEARTFAILURE!SARESULT ".0LEV
ELSSHOULDBEUSEDWITHCAUTIONINPATIENTS
WITHOBESITY UNLESSOFCOURSEBASELINE".0
VALUES ARE KNOWN 4HEN THE OBESE PATIENT
CANBEFOLLOWEDFORDECOMPENSATION
4HE "REATHING .OT 0ROPERLY 4RIAL DEM
ONSTRATEDTHAT".0ISUSEFULFORTHEDIAG
NOSIS OF #(& IN THE %$ 4HE 2%$(/4
3TUDY SUGGESTS THAT ".0 MIGHT ALSO BE
USEFULTOIMPROVETRIAGEANDDISPOSITIONOF
PATIENTSWHOPRESENTTOTHE%$WITHHEART
FAILURE4HISTRIALDEMONSTRATEDAhDISCON
NECTvBETWEENTHEPHYSICIANPERCEPTIONOF
THESEVERITYOFHEARTFAILUREANDTHEACTUAL
".0VALUE)NTHElRSTPHASE PATIENTS

VISITING %$S WITH COMPLAINTS OF BREATH


ING DIFlCULTY HAD ".0 MEASUREMENTS
TAKENONARRIVAL0HYSICIANSWEREBLINDED
TO".0RESULTSHOWEVERINCLUSIONINTHE
TRIALREQUIREDA".0PGML0ATIENTS
DISCHARGEDFROMTHE%$HADHIGHER".0
LEVELSTHANTHOSEADMITTEDTOTHEHOSPITAL
PGMLVSPGML 7ITHRESPECTTO
THEADMITTEDPATIENTS HAD".0LEV
ELSPGML WHICHISINDICATIVEOFLESS
SEVERE#(&-OSTOFTHESEPATIENTSWERE
PERCEIVEDTOHAVECLASS)))OR)6HEARTFAIL
URE-ORTALITYFORTHESEPATIENTSWASAT
DAYSANDONLYATDAYS SUGGESTING
THATPATIENTSWITHHEARTFAILUREANDLOWLEV
ELSOF".0MIGHTHAVEACTUALLYBEENSAFE
FORDISCHARGE7ITHRESPECTTOPATIENTSTHAT
WERE ACTUALLY DISCHARGED  HAD ".0
LEVELSPGM,!TDAYS MORTALITY
WAS4HEREWASNOMORTALITYOFTHOSE
DISCHARGEDWITH".0LEVELSPGM,
4HISSUGGESTSTHATUSEOF".0INTHE%$
MIGHTALSOHELPDETERMINEWHICHWELLAP
PEARINGPATIENTSAREHIGHRISKFORABADOUT
COMEOVERTHESHORTTERMDAYS 

i>v *>i
ivv>i}
>wV>>`
}>i
i>v>i

%LEVATED ".0 LEVELS ARE USEFUL FOR AS


SESSING RISK STRATIlCATION AND PROGNOSIS
INPATIENTSWITHHEARTFAILURE".0LEVELS
ARE RELATED TO CHANGES IN LIMITATIONS OF
PHYSICAL ACTIVITIES AND FUNCTIONAL STATUS
(ARRISONETALFOLLOWEDPATIENTSFOR
MONTHSAFTERANINDEXVISITTOTHE%$FOR
DYSPNEA (IGHER ".0 LEVELS WERE ASSO
CIATED WITH A PROGRESSIVELY WORSE PROG
NOSIS 4HE RELATIVE RISK OF  MONTH #(&
ADMISSIONORDEATHINPATIENTSWITH".0
LEVELSPGM,WASTIMESTHERISK
OFPATIENTSWITHLEVELSLESSTHAN7HEN
COMBINEDWITHTROPONIN) BOTHTROPONIN)
AND".0ALONEANDINCOMBINATIONPRE
DICTSURVIVALIN#(&"OTHTOGETHERHAVE
ADDITIVEPROGNOSTICRISK


%MERGENCY$IAGNOSISAND4REATMENTOF
!CUTE$ECOMPENSATED(EART&AILURE!$(&

4HE UTILITY OF ".0 TO DIAGNOSIS #(& IS WELL ESTAB
LISHEDHOWEVER ITSABILITYTODRIVETREATMENTISSTILL
UNDERSTUDY2%$(/4))ISARANDOMIZEDCONTROLLED
TRIAL COMPARING TREATMENT AND OUTCOMES OF PATIENTS
WHERETHERAPYISGUIDEDBYSERIAL".0MEASUREMENTS
IN THE EXPERIMENTAL GROUP 4HIS STUDY SHOULD SHED
SOMELIGHTONTHEUTILITYOF".0TODRIVETREATMENT
$UETOTHEVOLUMINOUSDATAONTHECLINICALUTILITYOF
".0 CONSENSUSPANELGUIDELINESWERERECENTLYPUB
LISHED4HESERECOMMENDATIONSSTATE
% -ANYPATIENTSPRESENTINGTOEMERGENCYSERVICES
WITH DYSPNEA A HISTORY PHYSICAL EXAMINATION
ANDACHESTX RAYAND%#'SHOULDBEUNDERTAKEN
TOGETHER WITH LABORATORY MEASUREMENTS THAT
INCLUDE".0
% !S".0LEVELSRISEWITHAGEANDAREAFFECTEDBY
GENDER COMORBIDITY ANDDRUGTHERAPY THEPLASMA
".0MEASUREMENTSHOULDNOTBEUSEDINISOLATION
FROMTHECLINICALCONTEXT
% )F THE ".0 IS  PGM, THEN HEART FAILURE IS
HIGHLYUNLIKELYNEGATIVEPREDICTIVEVALUE  
% )F THE ".0 LEVEL IS  PGM, THEN #(& IS
HIGHLYLIKELYPOSITIVEPREDICTIVEVALUE 
% &OR".0LEVELSOFn ONESHOULDCONSIDER
THE FOLLOWING CONDITIONS IN THE DIFFERENTIAL
DIAGNOSIS
A "ASELINE".0VALUEDUETOSTABLEUNDERLYING
DYSFUNCTION
B 2IGHTVENTRICULARFAILUREFROMCOR

PULMONALE
C !CUTEPULMONARYEMBOLISM
D 2ENALFAILURE
s 0ATIENTSMAYPRESENTWITH#(&WITHNORMAL
".0 LEVELS OR WITH LEVELS BELOW WHAT
MIGHTONEEXPECTCANOCCURINTHEFOLLOWING
SITUATIONS
A &LASHPULMONARYEDEMAnHOURS
B (EART FAILURE UP STREAM FROM THE LEFT
VENTRICLE IE ACUTE MITRAL REGURGITATION
FROMPAPILLARYMUSCLERUPTURE
C /BESE PATIENTS BODY MASS INDEX 
KGM

,  ,


-AISEL!3 +RISHNASWAMY0 .OWAK2- ETAL2APID


MEASUREMENTOF" TYPENATRIURETICPEPTIDEINTHEEMERGENCY
DIAGNOSISOFHEARTFAILURE.%NGL*-ED 



-C#ULLOUGH0! .OWAK2- -C#ORD* ETAL" TYPENATRIURETIC


PEPTIDEANDCLINICALJUDGMENTINEMERGENCYDIAGNOSISOFHEART
FAILUREANALYSISFROM"REATHING.OT0ROPERLY".0 -ULTINATIONAL
3TUDY#IRCULATION 



-AISEL!3 -C#ORD* .OWAK2- (OLLANDER*% 7U!("


$UC0 /MLAND4 3TORROW!" +RISHNASWAMY0 !BRAHAM74
#LOPTON0 3TEG0' !UMONT-# 7ESTHEIM! +NUDSEN#7
0EREZ! +AMIN2 +AZANEGRA2 (ERRMANN(# -C#ULLOUGH0!
FORTHE".0-ULTINATIONAL3TUDY)NVESTIGATORS"EDSIDE" TYPE
NATRIURETICPEPTIDEINTHEEMERGENCYDIAGNOSISOFHEARTFAILUREWITH
REDUCEDORPRESERVEDEJECTIONFRACTION2ESULTSFROMTHE"REATHING
.OT0ROPERLY".0 -ULTINATIONAL3TUDY*!M#OLL#ARDIOL
 



-C#ULLOUGH0! (OLLANDER*% .OWAK2- ETAL5NCOVERING


HEARTFAILUREINPATIENTSWITHAHISTORYOFPULMONARYDISEASE
RATIONALEFORTHEEARLYUSEOF" TYPENATRIURETICPEPTIDEINTHE
EMERGENCYDEPARTMENT!CAD%MERG-ED  



+NUDSEN#7 /MLAND4 #LOPTON0 7ESTHEIM! !BRAHAM


74 3TORROW!" -C#ORD* .OWAK2- !UMONT-# $UC0
(OLLANDER*% 7U!(" -C#ULLOUGH0! -AISEL!3$IAGNOSTIC
VALUEOF" TYPENATRIURETICPEPTIDEANDCHESTRADIOGRAPHIClNDINGS
INPATIENTSWITHACUTEDYSPNEA!M*-ED  



-C#ORD* -UNDY"* (UDSON-0 -AISEL!3 (OLLANDER*%


!BRAHAM74 3TEG0' /MLAND4 +NUDSEN#7 3ANDBERG+2
-C#ULLOUGH0! FORTHE"REATHING.OT0ROPERLY-ULTINATIONAL
3TUDY)NVESTIGATORS2ELATIONSHIPBETWEENOBESITYANDB TYPE
NATRIURETICPEPTIDELEVELS!RCH)NTERN-ED 



-AISEL! (OLLANDER*% 'USS$ ETAL0RIMARYRESULTSOFTHERAPID


EMERGENCYDEPARTMENTHEARTFAILUREOUTPATIENTTRIAL2%$(/4 A
MULTICENTERSTUDYOFB TYPENATRIURETICPEPTIDELEVELS EMERGENCY
DEPARTMENTDECISIONMAKING ANDOUTCOMESINPATIENTSPRESENTING
WITHSHORTNESSOFBREATH*!MER#OLL#ARDIOL  



(ARRISON! -ORRISON,+ +RISHNASWAMY0 ETAL" TYPE


NATRIURETICPEPTIDE".0 PREDICTSFUTURECARDIACEVENTSINPATIENTS
PRESENTINGTOTHEEMERGENCYDEPARTMENTWITHDYSPNEA!NN%MERG
-EDn



(ORWICH4" 0ATEL* -AC,ELLAN27 ETAL#ARDIACTROPONIN


)ISASSOCIATEDWITHIMPAIREDHEMODYNAMICS PROGRESSIVELEFT
VENTRICULARDYSFUNCTIONANDINCREASEDMORTALITYINADVANCEDHEART
FAILURE#IRCULATION 

 3ILVER-! -AISEL! 9ANCY#7 -C#ULLOUGH0! "URNETT*#


&RANCIS'3 -EHRA-2 0EACOCK7& &ONAROW' 'IBLER7"
-ORROW$! (OLLANDER*".0#ONSENSUS0ANEL!CLINICAL
APPROACHFORTHEDIAGNOSTIC PROGNOSTIC SCREENING TREATMENT
MONITORINGANDTHERAPEUTICROLESOFNATRIURETICPEPTIDESIN
CARDIOVASCULARDISEASES#ONG(EART&AILURE
SUPPL  

#OPYRIGHT%-#2%' )NTERNATIONAL 

/, / /"
1/
"* -/  ,/
1,  /  ,
9 *,/ /
$OUGLAS-#HAR -$
$IVISIONOF%MERGENCY-EDICINE 7ASHINGTON5NIVERSITY
3T,OUIS -/

" 
/6 -\
iVLi>ii>>V>i}iVV>>v >i
 
iwiiiv>`>>i>>vi>v 

 /," 1
/"
!CUTELYDECOMPENSATEDHEARTFAILURE!$(& ISACOMMONREASONFORPATIENTSSEEKING
EMERGENCYDEPARTMENT%$ CAREANDTHELEADING-EDICAREDIAGNOSISFORHOSPITALIZED
PATIENTS OVER THE AGE OF  (OSPITAL READMISSION FOR HEART FAILURE IS COMMON AP
PROXIMATELYOFPATIENTSAREREADMITTEDWITHINDAYSANDWITHINMONTHS
2ECENTADVANCESINTHEUNDERSTANDINGOFTHECOMPLEXPATHOPHYSIOLOGICPROCESSTHAT
EXACERBATEHEARTFAILUREHASLEDTOIMPROVEDDIAGNOSESANDEFFECTIVE%$TREATMENTOF
THISCLINICALENTITY
0ATHOPHYSIOLOGYAND(EMODYNAMIC
!SSESSMENT
)N THE PAST DECOMPENSATED HEART FAILURE
WAS FELT TO BE DUE TO VOLUME OVERLOAD
AND IMPAIRED FORWARD mOW 4REATMENT
WASFOCUSEDONMAXIMIZINGCARDIACOUT
PUT)THASNOWBECOMEAPPARENTTHATIN
MOST !$(&PULMONARY EDEMA THERE IS
INCREASED SYSTEMIC VASCULAR RESISTANCE
SUPERIMPOSEDONREDUCEDMYOCARDIALRE
SERVEBOTHSYSTOLICANDDIASTOLIC -ANY
VARIABLESPLAYAROLEIN!$(&THATEXAC
ERBATE LEFT VENTRICULAR ,6 DYSFUNCTION
AND LEAD TO DETERIORATION ,OW CARDIAC
OUTPUTRESULTSINDECREASEDRENALmOWAND
STIMULATESNEUROHORMONALACTIVATION IN
CLUDINGTHERELEASEOFANGIOTENSIN))$E
CREASEDCARDIACOUTPUTCAUSESPROGRESSIVE
BLOODVOLUMEEXPANSIONFURTHERINCREAS
ING ,6 lLLING PRESSURES AND MYOCARDIAL
OXYGENCONSUMPTION(YPOTENSIONPRO
MOTES BARORECEPTOR ACTIVATION LEADING

TOINCREASEDSYMPATHETICTONEANDVASO
CONSTRICTIONWHICHFURTHERINCREASESSYS
TEMIC VASCULAR RESISTANCE COMPROMISING
SYSTOLIC PERFORMANCE 4HERE IS MARKED
UP REGULATIONOFVASOCONSTRICTORS INCLUD
ING NOREPINEPHRINE ANGIOTENSIN )) AND
ENDOTHELIN ALDOSTERONEANDARGININEVA
SOPRESSINRISECONTRIBUTINGTOTHESALTAND
WATERRETENTION 
4OCOUNTER BALANCETHEEFFECTSOFNEURO
HORMONES RELEASED BY THE SYMPATHETIC
NERVOUS SYSTEM AND THE RENIN ANGIOTEN
SIN ALDOSTERONE SYSTEM 2!!3 AND TO
MAINTAIN CIRCULATORY HOMEOSTASIS THE
BODY PRODUCES A FAMILY OF VASODILATOR
ANTIPROLIFERATIVENATRIURETICPEPTIDESTHAT
PLAY AN IMPORTANT ROLE IN HEART FAILURE
!TRIAL AND " TYPE NATRIURETIC PEPTIDES
ARERELEASEDFROMTHEMYOCARDIUMINRE
SPONSETOINCREASEDATRIALNATRIURETICPEP
TIDE AND VENTRICULAR " TYPE NATRIURETIC

/iii>i>`
`Vvi`
>iVi`i>i
vwViL>>Vi
iy`ii
vi,-

%MERGENCY$IAGNOSISAND4REATMENTOF
!CUTE$ECOMPENSATED(EART&AILURE!$(&
}i

(YLGHQFHIRU/RZ3HUIXVLRQ
1DUURZ3XOVH3UHVVXUH
3XOVXV$OWHUDWLRQV
&RRO)RUHDUPVDQG/HJV
0D\EH6OHHS\2EWXQGHG
$&6,QKLELWRU5HODWHG
6\PSWRPDWLF+\SRWHQVLRQ
'HFOLQLQJ6HUXP6RGLXP/HYHO
:RUVHQLQJ5HQDO)XQFWLRQ

/RZ3HUIXVLRQDW5HVW"

$IAGRAMINDICATINGXTABLEOFHEMODYNAMICPROlLESFORPATIENTS
PRESENTING WITH HEART FAILURE -OST PATIENTS CAN BE CLASSIlED IN A
 MINUTEBEDSIDEASSESSMENTACCORDINGTOTHESIGNSANDSYMPTOMS
SHOWNALTHOUGHINPRACTICESOMEPATIENTSMAYBEONTHEBORDERBE
TWEENTHEWARM AND WETANDCOLD AND WETPROlLES4HISCLASSIlCATION
HELPSGUIDEINITIALTHERAPYANDPROGNOSISFORPATIENTSPRESENTINGWITH
ADVANCEDHEARTFAILURE!LTHOUGHMOSTPATIENTSPRESENTINGWITHHYPO
PERFUSIONALSOHAVEELEVATEDlLLINGPRESSURESCOLDANDWETPROlLE
MANYPATIENTSPRESENTWITHELEVATEDlLLINGPRESSURESWITHOUTMAJOR
REDUCTION IN PERFUSION WARM AND WET PROlLE  0ATIENTS PRESENTING
WITHSYMPTOMSOFHEARTFAILUREATRESTORMINIMALEXERTIONWITHOUT
CLINICALEVIDENCEOFELEVATEDlLLINGPRESSURESORHYPOPERFUSIONWARM
ANDDRYPROlLE SHOULDBECAREFULLYEVALUATEDTODETERMINEWHETHER
THEIRSYMPTOMSRESULTFROMHEARTFAILURE

1R

<HV

PEPTIDE".0 STRESS4HEYINCREASEGLOMERULARlL
TRATION RATE '&2 INHIBIT SODIUM REABSORPTION AND
REDUCEVASCULARSMOOTHMUSCLETONE CAUSINGADIURE
SIS NATRIURESISANDBALANCEDARTERIALANDVENOUSDILA
TION!LLTHESEEFFECTSCONTRIBUTETOREDUCEDPLASMA
VOLUME BLOODPRESSUREANDVENTRICULARPRELOAD".0
HASLUSITROPICRELAXING EFFECTSANDMAYBEANTIlBROT
IC AND ANTIPROLIFERATIVE )N!$(& THE RELEASE AND
PRODUCTION OF STORED NATRIURETIC PEPTIDES ARE INSUFl
CIENTTOBALANCETHEmUIDRETENTIONOFTHE2!!3
2APID BEDSIDE ASSESSMENT OF!$(& CAN BE SIMPLI
lEDBYPLACINGTHEPATIENTINTOONEOFFOURHEMODY
NAMICPROlLESQ}i R4WOKEYHEMODYNAMIC
PARAMETERS ARE THE PRESENCE OR ABSENCE OF ELEVATED
lLLINGPRESSURESWETORDRY ANDADEQUACYOFPERFU
SIONWARMORCOLD #ONGESTIONCORRESPONDSTOEL
EVATEDPULMONARYCAPILLARYWEDGEPRESSURE0#70

/iiivi`>V
*wi,i`Vi`>`ii`
iv >]i ]
-ii7n\n{

(YLGHQFHIRU&RQJHVWLRQ
(OHYDWHG)LOOLQJ3UHVVXUH
2UWKRSQHD
+LJK-XJXODU9HQRXV3UHVVXUH
,QFUHDVLQJ6
/RXG3
(GHPD
$VFLWHV
5DOHV 8QFRPPRQ
$EGRPLQRMXJXODU5HIOX[
9DOVDOYD6TXDUH:DYH

&RQJHVWLRQDW5HVW"
1R

<HV

:DUPDQG'U\

:DUPDQG:HW

&ROGDQG'U\

&ROGDQG:HW

&

ANDIMPAIREDPERFUSIONISSUGGESTEDBYALOWCARDIAC
INDEX'REATERTHANOFPATIENTSPRESENTINGWITH
!$(&ARECONGESTEDWET 4HEYMAYHAVEADEQUATE
ORREDUCEDPERFUSIONWITHTHEMAJORITYEXPERIENCING
ELEVATED SYSTEMIC VASCULAR RESISTANCE #ONGESTION
ELEVATED lLLING PRESSURE IN !$(& IS REPRESENTED
BY DYSPNEA AND ORTHOPNEA AND ELEVATED JUGULAR VE
NOUSPRESSURE2ALESWHILEAHELPFULSIGNAREABSENT
IN  OF PATIENTS WITH CHRONICALLY ELEVATED lLLING
PRESSURESDUETOPULMONARYLYMPHATICCOMPENSATION
0ERIPHERALEDEMAISRELATIVELYINSENSITIVETOELEVATED
lLLINGPRESSURES ANDASSOCIATEDWITHMANYNONCARDI
ACCAUSES4HETHIRDHEARTSOUND3 WHILEASENSITIVE
MARKER ISRARELYAPPRECIATED4HEMOSTREADILYAVAIL
ABLEINDICATOROFPERFUSIONISBLOODPRESSUREANDPULSE
PRESSURE4HISRAPIDASSESSMENTSYSTEMALLOWSFORAP
PROPRIATETARGETINGOFTHERAPYIN!$(&PATIENTS

/, / /"
1/
"* -/  ,/
1,  /  ,
9 *,/ /

$ETERMININGTHE%TIOLOGYOF!CUTE
$ECOMPENSATIONAND3ETTING
4REATMENT'OALS
4HEETIOLOGIESOF!$(&AREMULTIFACTORI
ALBUTCANBEDIVIDEDINTOTWOCATEGORIES
 THE UNDERLYING THE HEART FAILURE AND
 THEACUTEPRECIPITANTTHATRESULTSINDE
TERIORATIONFROMTHECHRONICCOMPENSATED
STATE)NPATIENTSPRESENTINGFORTHElRST
TIME THE TWO COMPONENTS ARE IDENTICAL
4HE MOST COMMON CAUSES OF HEART FAIL
UREARECORONARYARTERYDISEASEANDLONG
STANDINGHYPERTENSION/THERETIOLOGIES
INCLUDEDILATED HYPERTROPHICANDRESTRIC
TIVECARDIOMYOPATHIES MYOCARDITIS PERI
CARDIALTAMPONADE VALVULARHEARTDISEASE
ANDSECONDARYEFFECTSOFPULMONARYAND
METABOLICDISORDERS5NDERSTANDINGTHE
UNDERLYINGETIOLOGYISIMPORTANTINHELP
ING TO DETERMINE IF THERE IS A REVERSIBLE
COMPONENTPRESENT4HEEMERGENCYPHY
SICIANMUSTBEAWAREOFNUMBEROFSPE
CIAL CAUSES OF HEART FAILURE THAT REQUIRE
CONSIDERATION WHEN MAKING THERAPEUTIC
DECISIONS )N SEVERE AORTIC STENOSIS ID
IOPATHIC HYPERTROPHIC SUBAORTIC STENOSIS
OR HYPERTROPHIC OBSTRUCTIVE CARDIOMY
OPATHY ANDPULMONARYHYPERTENSION AG
GRESSIVE AFTERLOAD REDUCTION CAN LEAD TO
CARDIOVASCULARCOLLAPSEASTHESEPATIENTS
CANNOTINCREASETHEIRFORWARDBLOODmOW
INTHEFACEOFAlXEDMECHANICALLESION
'REATERTHANOFPATIENTSPRESENTING
TOTHE%$WITH!$(&HAVEAPRIORDIAG
NOSISOFHEARTFAILURE!NACUTEPRECIPI
TANT CAN OFTEN BE IDENTIlED %XACERBA
TIONORWORSENINGOFTHEUNDERLYINGCON
DITIONCANBEDUETOMEDICATIONORDIETARY
NON COMPLIANCE ORTHEDEVELOPMENTOFA
NEW OR COMPLICATING MEDICAL CONDITION

SUCH AS ISCHEMIA DYSRHYTHMIA PULMO


NARY EMBOLUS OR INFECTION  4REATMENT
DEPENDSONTHESEVERITYOFTHESYMPTOMS
ANDDECOMPENSATIONTIMECOURSE 
4HERAPEUTICGOALSIN!$(&PATIENTSCAN
BEDIVIDEDINTHREEPHASES4HEPRIMARY
GOALINTHE%$ISRESTORATIONOFOXYGEN
ATION ORGAN PERFUSION AND TOTAL BODY
mUID BALANCE 4HIS IS ACCOMPLISHED BY
REVERSINGACUTEHEMODYNAMICABNORMAL
ITIESANDRELIEVINGSYMPTOMS)NTERMEDI
ATE GOALS INCLUDE MINIMIZING END ORGAN
DAMAGE REDUCING HOSPITALIZATION DURA
TION AND INITIATION OF BENElCIAL MEDICAL
THERAPIES AND SHOULD COMMENCE IN THE
%$,ONG TERMGOALSFOCUSONREDUCING
READMISSION AND IMPROVING LONG TERM
SURVIVAL WITH TREATMENT THAT DECREASES
DISEASEPROGRESSION4HISOCCURAFTERTHE
PATIENT LEAVES THE %$ 7HILE NATIONAL
GUIDELINES EXIST FOR MANY ACUTE CARDIO
VASCULARCONDITIONSTHEREARENOCONSEN
SUS GUIDELINES FOR THE MANAGEMENT OF
!$(& 'IVEN THE LACK OF RANDOMIZED
CONTROLLEDTRIALS CONSENSUSTHATINCORPO
RATESEVIDENCE BASEDLITERATUREANDEXPERT
OPINIONSHOULDBEUSEDASGUIDELINES

/ii`>V
>>ii>ii
iiVi>LiVi
vii>i`w}
iii`
>`i>`i>V
viv
>V`

!PPROACHTO)NITIAL4REATMENT
/URIMPROVEDUNDERSTANDINGOFTHEETIOL
OGYOFHEARTFAILUREANDITSPROGRESSIONHAS
IDENTIlEDTHE2!!3ANDNEUROHORMONAL
PATHWAYSASTARGETSOFTHERAPY ANDMAY
EXPLAIN THE BENElTS OF NEUROHORMONAL
BLOCKERS SUCH AS ANGIO CONVERTING EN
ZYME!#% INHIBITORS BETA BLOCKERS AL
DOSTERONEBLOCKERSEG SPIRONOLACTONE
ANDSUPRAPHYSIOLOGICDOSESOFNATRIURETIC
PEPTIDESSUCHAS!.0AND".0 INTHE
TREATMENTOFHEARTFAILURE

%MERGENCY$IAGNOSISAND4REATMENTOF
!CUTE$ECOMPENSATED(EART&AILURE!$(&

)NITIALTHERAPYSHOULDBEGUIDEDBYTHEPATIENTS
HEMODYNAMICPROlLEQ}iR &ORPATIENTS
WITHOUTEVIDENCEOFELEVATEDlLLINGPRESSURESOR
HYPOPERFUSION DRY AND WARM NO IMMEDIATE
INTERVENTION IS NEEDED #ARE SHOULD FOCUS ON
MAINTAININGSTABLEVOLUMESTATUSANDPREVENTING
DISEASEPROGRESSION4HESEPATIENTSRARELYPRES
ENT TO THE %$ )N PATIENTS WITH ELEVATED lLLING
PRESSURESBUTADEQUATEPERFUSIONWETANDWARM
THERAPY AIMS TO DIURESE !SSUMING THEY ARE AL
READYRECEIVING!#%INHIBITORS THEGOALISTOEN
HANCETHEIRDIURETICREGIMEN)NMOREADVANCED
CASES THE USE OF INTRAVENOUS LOOP DIURETICS AND
VASODILATORS SUCH AS NITROGLYCERIN OR NESIRITIDE
CAN ACCELERATE SYMPTOM RESOLUTION 4HE MAIN
CHALLENGE IS AVOIDING HYPOTENSION )N THIS SITU
ATION INOTROPIC THERAPY IS CONTRAINDICATED &OR
CONGESTEDELEVATEDlLLINGPRESSURE PATIENTSWITH
CLINICALHYPOPERFUSIONWETANDCOLD ITISUSUALLY
NECESSARYTOhWARMUPINORDERTODRYOUTv&OR
THESEPATIENTS INWHOMREmEXRESPONSESSUPPORT
THEFAILINGCIRCULATION ` BLOCKERSAND!#%INHIB
ITORSMAYNEEDTOBEWITHDRAWNUNTILSTABILIZATION
ISACHIEVED,OWCARDIACOUTPUTISOFTENASSOCI
ATEDWITHHIGHSYSTEMICVASCULARRESISTANCE AND

}i
Vi`iVi>i`i>v>i i>i
>},ii`iv i
Vi>*>>Vi{n\{

$IWHUGLDJQRVLVRI$'+)LQLWLDWHWKHUDS\EDVHGRQSUHVHQWLQJVLJQVDQGV\PSRPV

$ 6LJQVDQG6\PSRPVRI9ROXPH2YHUORDG
2UWKRSQHD31'
,QFUHDVHG-9'
'2(62%
6RU6
3LWWLQJHGHPD
5DOHV
&KHVW[UD\SXORQDU\
+-5$-5
FRQJHVWLRQ
l%13
5HFHQWZHLJKWJDLQ

& 0LOG
YROXPH
RYHUORDG

% 6LJQVDQG6\PSRPVRI/RZ&DUGLDF2XWSXW
1DUURZSXOVHSUHVVXUH
$OWHUHGPHQWDOVWDWXV
3UHUHQDOD]RWHPLD
&RROH[WUHPLWLHV

* 0LOG0RGHUDWH

( 0RGHUDWH6HYHUH9ROXPH2YHUORDG
,QDGHTXDWHUHVSRQVHWR,9GLXUHWLFV
3UHUHQDOD]RWHPLD
,QFUHDVHGR[\JHQUHTXLUHPHQWV
&3$3RU%L3$3UHTXLUHPHQWV
)DWLJXH
,QSDWLHQWGLVSRVLWLRQXQFOHDU
2XWSDWLHQWIXURVHPLGHGRVH!PGGDLO\
6%3!PP+*

' ,9'LXUHWLFV
,9IXURVHPLGH
2QSRIXURVHPLGHDWKRPH"
*LYHWRWDOGRVHDV,9EROXV
 PD[PJ
1RSRIXURVHPLGHDWKRPH"
6&UVWDUWZLWKPJ,9SXVK
6&U!VWDUWZLWKPJ,9SXVK

'HFUHDVHGXULQHRXWSXW
,QDGHTXDWHUHVSRQVHWR
,9GLXUHWLFV

6%3!PP+J

- 9HU\/RZ
&DUGLDF2XWSXW

.O

9ES
2QDBEORFNHU
FKURQLFDOO\"

9ES

3XOPRQDU\DUWHU\
FDWKHWHUSODFHG
+LJK695
+LJK3&:3
/RZ&,
6%3!PP+J
&RQVLGHUYDVRGLODWRUV
DIWHULQLWLDWLRQRI
LQRWURSLFVXSSRUW

.O
, 0LOULQRQH

, 'REXWDPLQH

MJNJPLQ
LQIXVLRQ
$GMXVWGRVHUHQDOO\

MJNJPLQLQIXVLRQ
0D\DOVRUHTXLUH
YDVRSUHVVRUVIRU%3
VXSSRUW

,QDGHTXDWH5HVSRQH
P/ZLWKLQKRXUV
,QDGHTXDWH5HVSRQH
&RQVLGHU0RGHUDWH6HYHUH
9ROXPH2YHUORDG ( RU
/RZ&DUGLDF2XWSXW %

&RQVLGHU9HU\/RZ&DUGLDF2XWSXW -

) ,9'LXUHWLFV,99DVRGLODWRUV

!*2  ABDOMINAL JUGULAR REmEX "I0!0  BILEVEL POSITIVE AIRWAY


PRESSURE ".0  B NATRIURETIC PEPTIDE #)  CARDIAC INDEX
#0!0  CONTINUOUS POSITIVE AIRWAY PRESSURE $/%  DYSPNEA ON
EXERTION(*2HEPATOJUGULARREmEX*6$JUGULARVENOUSDISTENTION
0#70  PULMONARY CAPILLARY WEDGE PRESSURE 0.$  PAROXYSMAL
NOCTURNAL DYSPNEA 3"0  SYSTOLIC BLOOD PRESSURE 3#R  SERUM
CREATININE 3/"  SHORTNESS OF BREATH 362  SYSTEMIC VASCULAR
RESISTANCE

MAYIMPROVEWITHVASODILATORTHERAPYALONE4HERE
REMAINSCONTROVERSYABOUTTHEROLEOFINOTROPIC VASO
DILATORAGENTSSUCHASDOBUTAMINEANDMILRINONE DUE
TOTHEINCREASEDRISKFORISCHEMICEVENTSANDTACHYAR
RHYTHMIAS0ATIENTSWITHLOWCARDIACOUTPUTWITHOUT
EVIDENCE OF ELEVATED lLLING PRESSURE COLD AND DRY

,9IXURVHPLGH
,IIXURVHPLGHJLYHQSUHYLRXVO\GRXEOHSUHYLRXV,9GRVH PD[PJ
,IQRIXURVHPLGHJLYHQSUHYLRXVO\DQGVLJQVV\PSWRPVRIYROXPHRYHUORDG
JLYHPJ,9DVGHVFULEHGDERYH
3/86
1HVLULWLGHMJNJ,9SXVKWKHQMJNJYHLQLQIXVLRQ
25
1LWURJO\FHULQSJPLQLQIXVLRQ
WRDFKLHYHGHFUHDVHLQ3&:3GRVHRIMJPLQPD\EH
QHFHVVDU\

MAY BE SURPRISINGLY STABLE AND DO NOT PRESENT WITH


URGENTSYMPTOMS5NLESSTHEYHAVESUBNORMALlLLING
PRESSURESVOLUMEDEPLETED OREXCESSIVEVASODILATION
THEYOFTENDONOTIMPROVEACUTELY)NOTROPICINFUSION
WHILEHELPINGTHESYMPTOMS MAYLEADTODEPENDENCY
ANDTACHYPHYLAXIS

/, / /"
1/
"* -/  ,/
1,  /  ,
9 *,/ /

0HARMACOLOGIC/PTIONS
!NIDEALAGENTFOR!$(&WOULDBEONE
THATRAPIDLYREDUCES0#7RELIEVINGSYMP
TOMSANDHYPOXIA INDUCESBALANCEDARTE
RIAL AND VENOUS DILATION LACKS POSITIVE
INOTROPIC EFFECTS PROMOTES NATRIURESIS
ANDDOESNTCAUSEREmEXNEUROENDOCRINE
ACTIVATION
$IURETICSARETRADITIONALLYUSEDTOREDUCE
PRELOADTHEREBYIMPROVINGSYMPTOMSIN
!$(& PATIENTS 4HEY DO NOT HAVE ANY
DIRECTMYOCARDIALBENElTBUTACTIVATETHE
NEUROHORMONALSYSTEMLEADINGTOALDOSTE
RONEELEVATION$IURETICSHAVEBEENUSED
FORDECADESANDMOSTPROVIDERSAREVERY
COMFORTABLE WITH THEM DESPITE THE FACT
THAT THEY LACK OF EVIDENCE OF IMPROVED
MORTALITY)NTRAVENOUSFUROSEMIDECAUSES
ADECREASEIN0#70ANDRIGHTATRIALPRES
SUREASARESULTOFVENODILATIONANDDIURE
SIS4HEREISACONCOMITANTDECREASEIN
STROKEVOLUME INCREASEINSYSTEMICVAS
CULARRESISTANCEANDPRONOUNCEDSPIKEIN
NEUROHORMONAL ACTIVATION )NCREASES IN
THE2!!3ANDSYMPATHETICNERVOUSSYS
TEM ACTIVATION NOREPINEPHRINE LEVELS
CANBESEENSHORTLYAFTERFUROSEMIDEIN
FUSION
)N ONE TRIAL OF HIGH DOSE LOOP DIURETICS
COMPARED TO LOW DOSE DIURETICS COM
BINED WITH INTRAVENOUS VASODILATORS
PATIENTS TREATED WITH HIGH DOSE FUROSE
MIDE DID SIGNIlCANTLY WORSE IN ALL OUT
COME MEASURES ! RECENT ANALYSIS OF
EIGHT SMALL TRIALS FOUND THAT THERE WAS
GREATER DIURESIS AND A BETTER SAFETY PRO
lLEIFDIURETICSWEREGIVENASACONTINU
OUS INSTEAD OF BOLUS INFUSION 7HILE
INTRAVENOUSDIURETICSPROMOTENATRIURESIS
ANDDIURESIS THEYDOSOATTHEEXPENSEOF
NEUROHORMONAL ACTIVATION AND SYSTEMIC

VASOCONSTRICTION THAT PREVENTS REDUCTION


OF VENTRICULAR lLLING PRESSURES $IURETIC
RESISTANCE IS A CLINICAL STATE IN WHICH
DIURETIC RESPONSE IS DIMINISHED OR LOST
4HIS MAY BE CAUSED BY PRERENAL AZOTE
MIA HYPONATREMIA SODIUM RETENTION OR
ALTEREDDIURETICPHARMACOKINETICS4HERE
ISACYCLEOFLOWCARDIACOUTPUTLEADINGTO
DIMINISHEDRENALPERFUSIONWHICHINTURN
PRODUCES VOLUME OVERLOAD AND WORSENS
HEART FAILURE 4HESE DELETERIOUS EFFECTS
ARE EVEN MORE PRONOUNCED IN PATIENTS
WITH UNDERLYING RENAL INSUFlCIENCY $I
URETICREQUIREMENTSINCREASEASTHEHEART
FAILUREPROGRESSES
!RGININEVASOPRESSINISANEUROHORMONE
PRODUCEDBYTHECENTRALNERVOUSSYSTEMIN
RESPONSETOCHANGESINSERUMOSMOLARITY
SEVEREHYPOVOLEMIAORHYPOTENSION/NE
APPROACH TO ANTAGONIZING VASOPRESSINS
ACTIONISTOSELECTIVELYBLOCKITSRECEPTOR
RESULTINGINAQUARESISWITHOUTELECTROLYTE
IMBALANCES OR NEUROHORMONAL STIMULA
TION 4HE NOVEL COMPOUND TOLVAPTAN IS
ANANTAGONISTTHATCAUSESINCREASEDURINE
OUTPUT AND DECREASES BODY WEIGHT AND
EDEMA /NE STUDY LOOKED AT WEIGHT RE
DUCTIONFOLLOWINGHOURSOFINFUSIONIN
PATIENTS WITH IMPAIRED VENTRICULAR FUNC
TION%& 4HEREWASNODIFFERENCE
IN IN HOSPITAL MORTALITY OR WORSENING OF
HEART FAILURE 4HIS NOVEL AGENT SHOWS
PROMISEOFFACILITATINGmUIDLOSSWITHOUT
ADVERSESEQUELAEINPATIENTSWITHREDUCED
SYSTOLICFUNCTION

>i>`Li
}`i`Li>i
i`>Vwi

qqqqqqq

iV>iLii
i`v`iV>`i>`
`i>ii
Vv>Lii
`iiiv>V>
i>Vvi`iViv
i`>

)NOTROPESHAVEBEENAMAINSTAYOFTHERA
PYFOR!$(&BECAUSEOFTHEIRBENElCIAL
EFFECTS ON HEMODYNAMIC PARAMETERS
NAMELY INCREASING CARDIAC CONTRACTILITY
WHICHIMPROVESCARDIACOUTPUT)NOTRO
PESAREUSEDINFREQUENTLYINTHE%$DUE


%MERGENCY$IAGNOSISAND4REATMENTOF
!CUTE$ECOMPENSATED(EART&AILURE!$(&

PRIMARILYTOLOGISTICALCONCERNS2ECENTLARGESTUDIES
DEMONSTRATED A LACK OF EFlCACY IN MANY!$(& PA
TIENTSANDEXPOSEDSAFETYCONCERNS)NOTROPESINCREASE
HEARTRATEANDMYOCARDIALOXYGENDEMAND AGGRAVATE
ISCHEMIA PRECIPITATEARRHYTHMIASANDCANCAUSEHY
POTENSION!TRIALCOMPARINGDOBUTAMINEVERSUSNE
SIRITIDE DEMONSTRATEDTHATDOBUTAMINEINCREASESVEN
TRICULAR ECTOPY AND VENTRICULAR TACHYCARDIA -ILRI
NONEFAILEDTODEMONSTRATESIGNIlCANTIMPROVEMENTS
INLENGTHOFHOSPITALIZATION SYMPTOMRELIEFORMORTAL
ITY COMPAREDTOPLACEBO)TWASHOWEVERASSOCIATED
WITHSUSTAINEDHYPOTENSIONANDTACHYARRHYTHMIASIN
THE/04)-% #(&TRIAL$OBUTAMINEISPREFERRED
IN PATIENTS WHO ARE HYPOTENSIVE SYSTOLIC "0 
MM (G SINCE IT EXERTS ITS EFFECTS BY STIMULATING `
ADRENERGICRECEPTORS(IGHERDOSESAREOFTENREQUIRED
IN PATIENTS ON CHRONIC ` BLOCKER THERAPY -ILRINONE
ISAPHOSPHODIESTERASEINHIBITORANDITSACTIONISNOT
IMPACTED BY CONCOMITANT ` BLOCKER USE -ILRINONE
DOESNT INCREASE MYOCARDIAL OXYGEN CONSUMPTION
OR EFFECT HEART RATE TO THE SAME DEGREE THAT DOBUTA
MINEDOES)NGENERAL GIVENTHEIRINABILITYTOAFFECT
OUTCOMEANDINCREASEDINCIDENCEOFADVERSEEFFECTS
INOTROPICSUPPORTSHOULDBERESERVEDFORPATIENTSWITH
VERYLOWCARDIACOUTPUT4HEYSHOULDONLYBEUSEDIN
THE%$SETTINGONPATIENTSWITHSYMPTOMATICHYPOTEN
SIONUNTILFURTHERTHERAPYINTRA AORTICBALLOONPUMP
CANBEINSTITUTED
#ALCIUM SENSITIZERS SUCH AS LEVOSIMENDAN PRODUCE
INCREASED INOTROPY IN A CYCLIC !-0 INDEPENDENT
FASHIONBYINCREASINGTHESENSITIVITYOFTROPONIN#TO
INTRACELLULAR IONIZED CALCIUM AS WELL AS PERIPHERAL
VASODILATION THROUGH THE VASCULAR + !40ASE CHAN
NELS !N EFFECTIVE POSITIVE INOTROPE LEVOSIMENDAN
INCREASESINSTROKEVOLUMEANDCARDIACINDEXANDDE
CREASES 0#70 RIGHT ATRIAL PRESSURES PULMONARY AR
TERIALPRESSURESANDMEANARTERIALPRESSURES)NTHIS
STUDY THEHEMODYNAMICEFFECTSWEREMAINTAINEDDUR
INGAHOURINFUSIONANDFORATLEASTHOURSAFTER
DISCONTINUATION 7HEN LEVOSIMENDAN WAS ADDED TO
DOBUTAMINEIN.EW9ORK(EART!SSOCIATIONCLASS)6



PATIENTS REFRACTORY TO DOBUTAMINE AND FUROSEMIDE


OFPATIENTSGETTINGALLTHREEAGENTSCOMPAREDTO
NONE IN THE STANDARD GROUP EXPERIENCED A  IN
CREASEINCARDIACINDEX4HISEXCITINGAGENTISINTHE
EARLYCLINICALTRIALS
6ASODILATORSREDUCEPRELOADANDAFTERLOAD ENHANCING
VENTRICULARFUNCTIONANDCARDIACOUTPUTBYIMPROVING
RESTING HEMODYNAMICS6ASODILATORS REDUCE VENTRIC
ULAR lLING PRESSURES 0#70 AND PRELOAD AND OVER
TIMEMYOCARDIALOXYGENCONSUMPTION6ASODILATORS
ALSO DECREASE SYSTEMIC VASCULAR RESISTANCE 362 OR
AFTERLOAD REDUCE VENTRICULAR WORKLOAD INCREASE
STROKEVOLUMEANDIMPROVECARDIACOUTPUT
.ITRATES IN PARTICULAR NITROGLYCERIN HAVE BEEN THE
lRST LINEPREHOSPITALAND%$THERAPYFORPATIENTSWITH
SEVERESYMPTOMS.ITRATESNITROGLYCERINANDNITRO
PRUSSIDE ACT BY INCREASING CYCLIC GUANOSINE MONO
PHOSPHATEINTHEVASCULARSMOOTHMUSCLELEADINGTO
VASODILATION4HEY IMPROVE SYMPTOMS AND DECREASE
0#70RELATIVELYQUICKLY.ITROGLYCERINUSEISLIMITED
BYFEAROFHYPOTENSION ANDNEEDFORTITRATIONSECOND
ARY TACHYPHYLAXIS YET IT IS FREQUENTLY UNDERDOSED
.ITROGLYCERINHASDIRECTAFFECTSONLARGECORONARYAR
TERIESANDINCREASESCOLLATERALmOW MAKINGITAUSEFUL
INPATIENTSWITHMYOCARDIALISCHEMIA(OWEVER THERE
ARE NO TRIALS LOOKING AT ITS OUTCOME EFlCACY .ITRO
PRUSSIDE WHILE EFlCACIOUS IS USED INFREQUENTLY DUE
TOCONCERNSABOUTTHIOCYANATETOXICITYESPECIALLYIN
THEFACEOFHEPATICORRENALHYPOPERFUSIONDYSFUNC
TION  )T CAN ALSO PRECIPITATE PROFOUND HYPOTENSION
EXACERBATEISCHEMIABYINDUCINGCORONARYSTEAL AND
REQUIRES INVASIVE MONITORING "OTH OF THESE AGENTS
CAUSEREmEXACTIVATIONOFTHE2!!3ANDSYMPATHETIC
NERVOUSSYSTEMWHICHLIMITSTHEIRLONG TERMUSE
!NGIOTENSIN CONVERTING ENZYME !#% INHIBITION
BLOCKSCONVERSIONOFANGIOTENSIN)INTOANGIOTENSIN))
RESULTINGINDIMINISHEDSYSTEMICVASCULARRESISTANCE
BLOODPRESSURE PRELOADANDAFTERLOAD!#%INHIBITORS
ALSOBLOCKTHEDEGRADATIONOFBRADYKININS ANATURAL

/, / /"
1/
"* -/  ,/
1,  /  ,
9 *,/ /

LY OCCURRING VASODILATOR !#% INHIBITOR


THERAPYINCREASESRENALPERFUSIONANDDE
CREASE RENAL VASCULAR RESISTANCE IMPROV
INGGLOMERULARlLTRATIONRATEBYINDUCING
VASODILATIONINBOTHAFFERENTANDEFFERENT
ARTERIOLES4HEMAJORDRAWBACKTOTHEUSE
OF INTRAVENOUS !#% INHIBITORS SUCH AS
ENALAPRILATINTHEACUTESETTINGISITSPRO
PENSITYTOINDUCEHYPOTENSION)NTHESTA
BLEPATIENT THEAGENTSMAJOR LIMITATIONS
ARE RENAL INSUFlCIENCY AND ANGIOEDEMA
%NALAPRILAT HAS BEEN USED IN THE SETTING
OF!$(&SECONDARYTOUNCONTROLLEDHY
PERTENSION/RAL!#%INHIBITORSAREREC
OMMENDED EARLY OUT FOR THOSE PATIENTS
NOTALREADYRECEIVINGTHEM(OWEVER THE
PATIENTMUSTBEHEMODYNAMICALLYSTABLE
BEFORETHESEAGENTSAREINITIATED ANDTHIS
LIMITSTHEIRAGGRESSIVEUPFRONTUSEINTHE
%$!NGIOTENSIN RECEPTORBLOCKERCANBE
SUBSTITUTEDINPATIENTSWHOCANTTOLERATE
!#%INHIBITORS
2ECENTATTENTIONHASBEENFOCUSEDONTHE
ACUTE BLOCKADE OF DELETERIOUS NEUROHOR
MONES %NDOTHELIN %4 IS A VASOCON
STRICTOR PEPTIDE RELEASED FROM VASCULAR
ENDOTHELIUM AND SMOOTH MUSCLE OF THE
RENALANDPULMONARYSYSTEMS4EZOSEN
TAN IS A HIGHLY SPECIlC AND POTENT %4
RECEPTORANTAGONIST4HEREISADOSEDE
PENDENTINCREASEINCARDIACINDEXDUETO
VASODILATIONANDDECREASEIN0#70)N
THE 2)4: PROJECT TEZOSENTAN IMPROVED
HEMODYNAMICBUTNOTCLINICALOUTCOMEOF
PATIENTSWITHACUTEHEARTFAILURE!RECENT
TRIALEVALUATINGLOWERDOSES INHOSPITAL
IZED!$(&PATIENTSWITHDYSPNEADESPITE
INITIAL TREATMENT SHOWED INCREASED CAR
DIAC INDEX AND DECREASED 0#70 WITHIN
HOURSATTHEMGHOURANDMGHOUR
TREATMENTGROUPS ANDBYHOURSINTHE

MGHOURCOHORT4HEEFFECTCONTINUED
BEYOND TREATMENT DISCONTINUATION IN THE
 MGHOUR GROUP %NDOTHELIUM LEVELS
WEREINCREASEDINTHEHIGHERDOSEGROUPS
SUGGESTING SYMPATHETIC NERVOUS SYSTEM
ACTIVATION BUTNOTINTHEMGHOURSUB
SET 4EZOSENTANS EFFECT WHILE CLINICALLY
SIGNIlCANT IS NOT PRESENTLY APPROPRIATE
FORTHE%$GIVENITSDELAYEDONSET
4HE NATRIURETIC PEPTIDE FAMILY CONSISTS OF
FOUR DISTINCT PEPTIDES !TRIAL NATRIURETIC
PEPTIDES!.0 AND" TYPENATRIURETICPEP
TIDES".0 ARESTRUCTURALLYSIMILAR# TYPE
NATRIURETICPEPTIDES#.0 AND$ TYPENA
TRIURETICPEPTIDES$.0 ARELESSWELLCHAR
ACTERIZED!TRIALAND" TYPENATRIURETICPEP
TIDESHAVEIMPORTANTCENTRALANDPERIPHERAL
SYMPATHOINHIBITORYEFFECTS$AMPENINGOF
THE BARORECEPTORS SUPPRESSED RELEASE OF
CATECHOLAMINEFROMAUTONOMICNERVElND
INGS AND ESPECIALLY SUPPRESSION OF SYM
PATHETIC OUTmOW FROM THE CENTRAL NERVOUS
SYSTEMHAVEALLBEENREPORTED
4HE LONG TERM CONTINUOUS INFUSION OF
!.0 HAS BEEN SHOWN TO BE CLINICALLY
USEFULINPATIENTSWITHSEVEREACUTEHEART
FAILURE (EMODYNAMIC MEASUREMENTS
EVALUATEDBY3WAN 'ANZCATHETERSIGNIl
CANTLY IMPROVED WITH!.0 )N A RECENT
STUDY HEMODYNAMIC INDICES CHARACTER
IZED BY DECREASES IN RIGHT ATRIAL PRES
SURE MEAN PULMONARY ARTERIAL PRESSURE
AND 0#70 AND AN INCREASE IN CARDIAC
INDEX WERE OBSERVED AFTER !.0 INFU
SION ,EFT VENTRICULAR PERFORMANCE WAS
ENHANCED WITHOUT THE DEVELOPMENT OF
TOLERANCE 4HE ACTIVATION OF THE 2!!3
PROMOTES STRUCTURAL REMODELING OF THE
HEART AND PROGRESSION OF HEART FAILURE
!.0 THEREBY IMPROVED LEFT VENTRICULAR

ii>L
>vviVVi>`
Vi>i`V`iVi
v>`iiivviV]
V
`Liiii`
v>ii
V>`>V



%MERGENCY$IAGNOSISAND4REATMENTOF
!CUTE$ECOMPENSATED(EART&AILURE!$(&

FUNCTIONPOSSIBLYBYBLUNTINGMYOCARDIAL
REMODELING 7HILEAVAILABLEIN!SIA
AND%UROPE !.0ISNOTAPPROVEDFORUSE
INTHE5NITED3TATES

*>ii>i
i>i`>i
i>
>>`Lii
Vi>i
iii
>`i>i`

".0 IS AN ENDOGENOUS NEUROHORMONE


PRODUCEDINTHEVENTRICLESINRESPONSETO
INCREASEDWALLSTRESSTHATOCCURSFROMVOL
UMEOVERLOADIN!$(&PATIENTS.ESIRIT
IDEISTHElRSTNATRIURETICPEPTIDEIDENTI
CALTOENDOGENOUS".0 TOBEAVAILABLE
INTHE5NITED3TATESFORTHETREATMENTOF
!$(& 7ITHIN MINUTES OF ADMINISTRA
TIONNESIRITIDEPRODUCESSIGNIlCANTREDUC
TIONSIN0#70 RIGHTATRIALPRESSUREAND
SYSTEMIC VASCULAR RESISTANCE AS WELL AS
CONCOMITANT INCREASES IN STROKE VOLUME
ANDCARDIACOUTPUT.ESIRITIDEHASADDI
TIONALADVANTAGESOVEROTHERVASODILATORS
SUCHASNITROGLYCERIN INCLUDINGDIURESIS
NATRIURESISANDLUSITROPY4HEBENElCIAL
CORONARY ARTERY EFFECTS OF NITROGLYCERIN
AREALSOPRESENTINNESIRITIDE!DDITION
ALLY NESIRITIDE LACKS THE PROARRHYTHMIC
ANDTACHYCARDIASEENWITHINOTROPESAND
MANYVASODILATORS
4HE6ASODILATION IN THE -ANAGEMENT OF
!CUTE#ONGESTIVE(EAR&AILURE6-!#
TRIAL COMPARED THE USE OF NESIRITIDE NI
TROGLYCERINORPLACEBOINADDITIONTOSTAN
DARDTHERAPYINPATIENTSWITH!$(&
4HIS SAFETY AND EFlCACY TRIAL FOUND THAT
NESIRITIDE REDUCED 0#70 MORE THAN EI
THER NITROGLYCERIN OR PLACEBO AT  HOURS
ANDHOURS)MPROVEMENTSINDYSPNEA
AND GLOBAL CLINICAL STATUS IN THE NESIRIT
IDE TREATED PATIENTS WERE GREATER THAN
THOSEINTHEPLACEBORECIPIENTSANDSIMI
LAR TO THOSE IN THE NITROGLYCERIN GROUP



.ESIRITIDESHEMODYNAMICEFFECTERSWERE
LONG LASTINGWITHOUTTHENEEDFORUPWARD
TITRATION WHEREASTITRATIONWASNECESSARY
IN ORDER TO MAINTAIN NITROGLYCERINS EF
FECT4HISWASMOSTSTRIKINGINTHESUBSET
OF PATIENTS WITH RIGHT HEART CATHETERS ON
A CONSTANT DOSE OF NITROGLYCERIN WHERE
RAPIDATTENUATIONOFTHEDESIREDEFFECTAND
RISEIN0#70WASSEENATHOURS
".0 DOESNT INCREASE HEART RATE OR PRO
VOKE ARRHYTHMIAS AND HAS NO INOTROPIC
EFFECTS 4HIS LACK OF ARRHYTHMOGENICITY
IS ESPECIALLY IMPORTANT IN HEART FAILURE
PATIENTSWITHATRIALlBRILLATIONANDTHOSE
PREDISPOSED TO VENTRICULAR TACHYCARDIA
4HE 02%#%$%.4 STUDY COMPARED THE
PROARRHYTHMICEFFECTSOFDOBUTAMINEVER
SUSDOSESOFNESIRITIDEINPATIENTS
$OBUTAMINESIGNIlCANTLYINCREASEDVEN
TRICULAR TACHYCARDIA EVENTS .ESIRITIDE
DIDNOTINCREASEHEARTRATEDESPITEGREATER
REDUCTIONINBLOODPRESSURE"OTHAGENTS
WEREEQUALLYEFFECTIVEINIMPROVINGSIGNS
ANDSYMPTOMSOFHEARTFAILURE#OMPARED
TODOBUTAMINE NESIRITIDEREDUCED DAY
HOSPITALREADMISSIONSFORHEARTFAILUREAND
HADLOWER MONTHMORTALITY
)NTHE0ROSPECTIVE2ANDOMIZED/UTCOMES
3TUDY OF !CUTELY $ECOMPENSATED #ON
GESTIVE (EART &AILURE 4REATED )NITIALLY
IN /UTPATIENTS WITH .ATRECOR 02/!#
4)/. STUDY PATIENTSWERERANDOM
IZEDTOSTANDARDCAREORATLEASTHOURS
OF NESIRITIDE INFUSION IN AN %$ OBSERVA
TIONSETTING)MPORTANTLY NONEOFTHESEPA
TIENTSWASSUBJECTTOINVASIVEOR)#5LEVEL
MONITORINGINTHE%$ YETDIDWELL-OR
TALITYRATESANDCOMPLICATIONSWERESIMILAR

/, / /"
1/
"* -/  ,/
1,  /  ,
9 *,/ /

BETWEEN THE TWO GROUPS .ESIRITIDE WAS


ASSOCIATEDWITHAREDUCTIONINHOSPI
TALREADMISSIONWITHINDAYSCOMPARED
WITH STANDARD THERAPY AND A SUBSTANTIAL
DECREASE IN TOTAL LENGTH OF STAY OVER THE
ENSUINGMONTHSAFTERTHEINDEXVISIT
)N A POOLED ANALYSIS FROM THE 02/!#
4)/.  6-!#  AND .3'%4 TRIALS
THESHORTTERMRISKOFDEATHFROMNESIRIT
IDE WAS INVESTIGATED !S NONE OF THE
STUDIES INCLUDED IN THE POOLED ANALYSIS
WEREPOWEREDTODETERMINEMORTALITYDIF
FERENCES THEREISNOCONCLUSIVEEVIDENCE
OFHARM4HEMANUSCRIPTCONCLUDEDTHAT
WHEN COMPARED TO NONIONOTROPIC BASED
THERAPY NESIRITIDEMAYBEASSOCIATEDWITH
ANINCREASEDRISKOFDEATH&URTHERSTUDY
WITH MORTALITY OUTCOMES OF NESIRITIDE
COMPARED TO CONVENTIONAL THERAPY HAVE
YET TO OCCUR !S WITH ANY NEW THERAPY
THEFAVORABLEATTRIBUTESMUSTBEWEIGHED
AGAINSTTHEPOTENTIALRISKS
%ARLY'OAL$IRECTED4HERAPY
%ARLYGOALDIRECTEDTHERAPY%'$4 AP
PROACH EMPHASIZES AGGRESSIVE UPFRONT
TREATMENT BECAUSE PRELIMINARY EVALU
ATIONS HAVE SHOWN THAT PATIENTS TREATED
EARLY OUT TEND TO HAVE SHORTER HOSPITAL
STAYS AND BETTER OUTCOMES THAN THOSE
WHOSE INTERVENTION IS DELAYED )T AIMS
TO ACHIEVE  HEMODYNAMIC AND RESPI
RATORY IMPROVEMENT  PROMPT RELIEF OF
SYMPTOMS  ENHANCEDDECISION MAKING
IN THE %$ WITH AN EMPHASIS ON TIMELY
TRANSITIONTOINPATIENTCAREIFINDICATED 
EARLYINITIATIONOFTHERAPYALSOFACILITATES
HOSPITAL DISCHARGE AND  AVOIDANCE OF
HIGHRESOURCEUTILIZATION #ARENEEDS

TO FOCUS ON RAPID INITIATION OF PROVEN


THERAPIES THAT IMPROVE PATIENT SYMPTOM
AND CARDIORESPIRATORY STATUS WITHOUT
PLACINGTHEPATIENTATRISKFORIMMEDIATE
ARRHYTHMIA HYPOTENSION ISCHEMIA AND
DELAYED WORSENING RENAL INSUFlCIENCY
TOXICITY ADVERSEEVENTS4HEREISGROW
INGEVIDENCETHAT%'$4HASBOTHCLINICAL
ANDECONOMICADVANTAGESOVERMORECON
SERVATIVETREATMENTAPPROACHES
4HERE IS A SUBPOPULATION OF PATIENTS
MODERATELY SICK REQUIRING MORE THAN A
FEWHOURSOFCARE WHODONTNECESSARILY
NEEDHOSPITALADMISSION4HEAVAILABILITY
OF AN %$ OBSERVATION UNIT MAKES GOOD
CLINICALANDECONOMICSENSE%'$4CAN
BE INITIATED AND PATIENTS MONITORED FOR
IMPROVEMENT 0ATIENT SELECTION IS CRITI
CALLYIMPORTANTINDETERMININGWHOWILL
MOST BENElT FROM AN OBSERVATION UNIT
STAYMATCHINGACUITYWITHAVAILABLESER
VICES 'ENERALSELECTIONCRITERIAINCLUDE
THEFOLLOWING
 ADEQUATESYSTEMICPERFUSIONNORMAL
MENTALSTATUS
 EVIDENCEOFREASONABLE
HEMODYNAMICSTABILITY(2AND
BEATSMIN SYSTOLIC"0
ANDMM(G OXYGENSATURATION

 NOEVIDENCEOFACUTECARDIAC
ISCHEMIABY%#'ORBIOMARKERS
 CHESTX RAYlNDINGSCOMPATIBLEWITH
THEDIAGNOSISOFHEARTFAILURE
 DIAGNOSISOF(&".0PG
M, WITHOUTOTHERCONFOUNDING
MORBIDITIES

6>`>i`Vi
i>`>`>vi>`]
i>V}iV>
vV>`V>`>V
L}
i}i`>V



%MERGENCY$IAGNOSISAND4REATMENTOF
!CUTE$ECOMPENSATED(EART&AILURE!$(&

)NITIAL TREATMENT OF !$(& IS GENERALLY


BASEDONTHEPRESENCEORABSENCEOFPUL
MONARY CONGESTION VOLUME OVERLOAD
ANDANASSESSMENTOFPERFUSIONCARDIAC
OUTPUT Q}i R7HILETREATMENTAL
GORITHMS FOCUS ON PARENTAL THERAPY DUR
ING THE EARLY PHASE CONTINUATION OF THE
PATIENTS CHRONIC HEART FAILURE MEDICA
TION INCLUDING BLOCKERS AND !#% IN
HIBITORSAREIMPORTANT-ILDCONGESTION
IMPROVES WITH INTRAVENOUS DIURETICS
-ONITORINGOFURINEOUTPUTISCRITICAL&OR
THOSEWITHNORMALRENALFUNCTIONAGOALOF
MLHRISACCEPTABLE0ATIENTSWITHIN
ADEQUATERESPONSETOFUROSEMIDESHOULD
BEASSESSEDFORTHEPRESENCEOFMODERATE
TOSEVEREVOLUMEOVERLOAD ANDVASODILA
TOR THERAPY SHOULD BE CONSIDERED )NTRA
VENOUSNITROGLYCERINORNESIRITIDESHOULD
BESTARTEDINPATIENTSWITHADEQUATEBLOOD
PRESSURE TO SPEED RELIEF OF CONGESTION
)FNITROGLYCERINISUSEDITWILLBENECES
SARYTOUPTITRATETHEINFUSIONFREQUENTLY
0ATIENTSWITHEVIDENCEOFPOORPERFUSION

}i
*>/>}iv/i>ii>>i
,i`Vi`>`ii`ivi
] i>- }i`{n\n

}^>>Vii`V>-Vi

%HWDEORFNHUV

+($57

'LJR[LQ
LQRWURSHV

&DUGLDF
UHV\QFKURQL]DWLRQ
WKHUDS\
$&(LQKLELWRUV
DQJLRWHQVLQUHFHSWRUEORFNHUV
DOGRVWHURQHDQWDJRQLVWV
'LXUHWLFV
DOGRVWHURQH
DQWDJRQLVWV
QHVLULWLGH
.LGQH\

$&(LQKLELWRUV

3HULSKHUDO

DQJLRWHQVLQUHFHSWRUEORFNHUV
4REATMENTOPTIONSFORPATIENTSWITHHEARTFAILUREAFFECT
DUWHULHV
YDVRGLODWRUVDOSKDEORFNDGH
THEPATHOPHYSIOLOGICALMECHANISMSTHATARESTIMULATED
QHVLULWLGHH[HUFLVH
IN HEART FAILURE !NGIOTENSIN CONVERTINGnENZYME !#%
INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS DECREASE
AFTERLOADBYINTERFERINGWITHTHERENINnANGIOTENSINnALDOSTERONESYSTEM RESULTINGINPERIPHERALVASODILATATION4HEYALSO
AFFECTLEFTVENTRICULARHYPERTROPHY REMODELING ANDRENALBLOODmOW!LDOSTERONEPRODUCTIONBYTHEADRENALGLANDSIS
INCREASEDINHEARTFAILURE)TSTIMULATESRENALSODIUMRETENTIONANDPOTASSIUMEXCRETIONANDPROMOTESVENTRICULARAND
VASCULARHYPERTROPHY!LDOSTERONEANTAGONISTSCOUNTERACTTHEMANYEFFECTSOFALDOSTERONE$IURETICSDECREASEPRELOAD
BYSTIMULATINGNATRIURESISINTHEKIDNEYS$IGOXINAFFECTSTHE.A + n!40ASEPUMPINTHEMYOCARDIALCELL INCREASING
CONTRACTILITY )NOTROPES SUCH AS DOBUTAMINE AND MILRINONE INCREASE MYOCARDIAL CONTRACTILITY "ETA BLOCKERS INHIBIT THE
SYMPATHETICNERVOUSSYSTEMANDADRENERGICRECEPTORS4HEYSLOWTHEHEARTRATE DECREASEBLOODPRESSURE ANDHAVE
ADIRECTBENElCIALEFFECTONTHEMYOCARDIUM ENHANCINGREVERSEREMODELING3ELECTEDAGENTSTHATALSOBLOCKTHEALPHA
ADRENERGICRECEPTORSCANCAUSEVASODILATATION6ASODILATORTHERAPYSUCHASCOMBINATIONTHERAPYWITHHYDRALAZINEAND
ISOSORBIDEDINITRATEDECREASESAFTERLOADBYCOUNTERACTINGPERIPHERALVASOCONSTRICTION#ARDIACRESYNCHRONIZATIONTHERAPY
WITHBIVENTRICULARPACINGIMPROVESLEFTVENTRICULARFUNCTIONANDFAVORSREVERSEREMODELING.ESIRITIDEBRAINNATRIURETIC
PEPTIDE DECREASESPRELOADBYSTIMULATINGDIURESISANDDECREASESAFTERLOADBYVASODILATATION%XERCISEIMPROVESPERIPH
ERALBLOODmOWBYEVENTUALLYCOUNTERACTINGPERIPHERALVASOCONSTRICTION)TALSOIMPROVESSKELETAL MUSCLEPHYSIOLOGY



/, / /"
1/
"* -/  ,/
1,  /  ,
9 *,/ /

SHOULDBECONSIDEREDFORINOTROPICSUPPORT$OBUTA
MINE SHOULD BE STARTED IN PATIENTS WITH LOW CARDIAC
OUTPUTANDSYSTOLICBLOODPRESSUREMM(G4HEY
MAY REQUIRE VASOPRESSOR SUPPORT IF HYPOTENSION DE
VELOPS0ATIENTSWITHLOWCARDIACOUTPUTBUTADEQUATE
BLOODPRESSUREMAYBENElTFROMMILRINONE ESPECIAL
LYIFTHEYAREALREADYTAKINGBETA BLOCKERS4HOSERE
QUIRINGINOTROPICSUPPORTWILLREQUIREADMISSIONTOAN
INTENSIVECAREUNIT4HOSERECEIVINGVASODILATORSCAN
OFTENBEMANAGEDINALESSACUTESETTINGTELEMETRYOR
%$OBSERVATIONUNIT 0RELIMINARYANALYSISFROMTHE
!$(%2% REGISTRY INDICATED THAT LENGTH OF STAY WAS
REDUCED BY UP TO A THIRD IN PATIENTS RECEIVING VASO
ACTIVEAGENTSVASODILATORS NESIRITIDEORINOTROPES IN
THE %$ OR OBSERVATION UNIT COMPARED WITH PATIENTS
WHOHADVASOACTIVETHERAPYINITIATEDINTHEHOSPITAL
4HISEARLYINITIATIONOFEMERGENCYDEPARTMENTTHERAPY
ISASSOCIATEDWITHLOWERHOSPITALMORTALITY DECREASED
FREQUENCYOFINVASIVEPROCEDURESANDDECREASED)#5
LENGTHOFSTAY4HUS EARLYTARGETEDVASOACTIVETHERAPY
INTHE!$(&PATIENTSEEMSTOBEVERYPROMISING

.EWPHARMACOLOGICALAGENTSUNDERINVESTIGATION AT
TEMPT TO ENHANCE OUR UNDERSTANDING OF ABNORMAL
NEUROENDOCRINEFUNCTIONINHEARTFAILURE"YSPECIl
CALLYTARGETINGKEYPOINTSSUCHASTHEACTIVATIONAND
FEEDBACKPROCESS THEYMAYPREVENTDISEASEPROGRES
SION AND ACUTE DECOMPENSATION 7HILE WE AWAIT
NEW TREATMENT MODALITIES CURRENT %$ EFFORTS MUST
FOCUSONTHEEARLYIMPLEMENTATIONOFEFFECTIVESTRATE
GIESTOIMPROVESYMPTOMSANDCORRECTTHEUNDERLYING
PHYSIOLOGY

-1,9
)NTHEMAJORITYOFPATIENTSWHOPRESENTTOTHE%$WITH
!$(& INITIALTHERAPYWITHOXYGENANDDIURETICSWILL
NOT ADEQUATELY REDUCE lLLING PRESSURES OR IMPROVE
CARDIACOUTPUTENOUGHTOIMPROVESYMPTOMS)NOTRO
PESIMPROVESYMPTOMSINTHESHORT TERMBUTAREDEL
ETERIOUS IN THE LONG RUN6ASODILATORS ARE FREQUENTLY
NECESSARY AS THEY ADDRESS THE PRIMARY UNDERLYING
PATHOPHYSIOLOGYOFHEARTFAILURE.ITROGLYCERINAND
NITROPRUSSIDEAREEFFECTIVEBUTTHEIRUSEISHAMPERED
BY ADVERSE EFFECTS AND LIMITATIONS .ATRIURETIC PEP
TIDES SUCH AS NESIRITIDE WITH THEIR NEUROHORMONAL
ANTAGONISM MAYOFFERSEVERALBENElTSOVERCONVEN
TIONALVASODILATORSANDINOTROPESFORTHETREATMENTOF
!$(&)THASBEENSHOWNTHATNESIRITIDECANBEUSED
SAFELYINTHE%$ANDUPFRONTUSECANREDUCEHOSPITAL
LENGTHOFSTAY



%MERGENCY$IAGNOSISAND4REATMENTOF
!CUTE$ECOMPENSATED(EART&AILURE!$(&

,  ,
-

 +IVIKKO- ,EHTONEN, #OLUCCI733USTAINEDHEMODYNAMIC


EFFECTSOFINTRAVENOUSLEVOSIMENDAN #IRCULATION 



!GHABABIAN26 !CUTELYDECOMPENSATEDHEARTFAILURE
OPPORTUNITIESTOIMPROVECAREANDOUTCOMESINTHEEMERGENCY
DEPARTMENT 2EV#ARDIOVASC-EDSUPPL 3 



-AGNER** 2OYSTON$(EART&AILURE "R*!NESTH 

 .ANAS*. 0APAZOGLOU00 4ERROVITIS*6 ETAL (EMODYNAMIC


EFFECTSFLEVOSIMENDANADDEDTODOBUTAMINEINPATIENTSWITH
DECOMPENSATEDADVANCEDHEARTFAILUREREFRACTORYTODOBUTAMINE
ALONE !M*#ARDIOL 



&ONAROW'#4HETREATMENTTARGETSINACUTEDECOMPENSATEDHEART
FAILURE 2EV#ARDIOVASC-ED3 



.OHRIA! ,EWIS% 3TEVENSON,7 -EDICALMANAGEMENTOF


ADVANCEDHEARTFAILURE*!-! 



6ANDERHEYDEN- "ARTUNEK* 'OETHALS-"RAINANDOTHER


NATRIURETICPEPTIDESMOLECULARASPECTS %UR*(EART&AIL
 



3TRAIN7$4HEUSEOFRECOMBINANTHUMAN" TYPENATRIURETIC
PEPTIDEINTHEMANAGEMENTOFACUTEDECOMPENSATEDHEARTFAILURE
)NT*#LIN0RACT 



(OLLANDER* 0HARMACOLOGICMANAGEMENTOPTIONSINTHEEMERGENCY
DEPARTMENT!DVIN(EART&AIL 



6ANDER7AL-( *AARSMA4 VAN6ELDHUISEN$* .ON COMPLIANCE


INPATIENTSWITHHEARTFAILUREHOWCANWEMANAGEIT%UR*(EART
&AIL 



7ELSCH*D (EISER2- 3CHOOLER-0ETAL #HARACTERISTICS


ANDTREATMENTOFPATIENTSWITHHEARTFAILUREINTHEEMERGENCY
DEPARTMENT*%MERG.URS 

 3HARMA- 4EERLINK*2!RATIONALAPPROACHFORTHETREATMENTOF


ACUTEHEARTFAILURECURRENTSTRATEGIESANDFUTUREOPTIONS#URR/PIN
#ARDIOL 

 -OAZEMI+ #HANA* 7ILLARD!- +OCHERIL!' )NTRAVENOUS


VASODILATORTHERAPYINCONGESTIVEHEARTFAILURE$RUGS!GING
 
 4ORRE !MIONE' 9OUNG*" #OLUCCI73 ETAL (EMODYNAMIC
ANDCLINICALEFFECTSOFTEZOSENTAN ANINTRAVENOUSDUALENDOTHELIN
RECEPTORANTAGONIST INPATIENTSHOSPTIALIZEDFORACUTE
DECOMPENSATEDHEARTFAILURE *!M#OLLL#ARDIOL 
 #OTTER' +ALUSKI% 3TANGL+ ETAL 4HEHEMODYNAMICAND
NEUROHORMONALEFFECTSOFLOWDOSETEZOSENTANANENDOTHELIN!"
RECEPTORANTAGONIST INPATIENTSWITHACUTEHEARTFAILURE%UR*(EART
&AIL 
 DE$ENUS3 0(ARAND# 7ILLIAMSON$2"RAIN.ATRIURETICPEPTIDE
INTHEMANAGEMENTOFHEARTFAILURE #HEST 
 +ASAMA3 4OYAMA4 +UMAKURA( ETAL%FFECTSOFINTRAVENOUS
ATRIALNATRIURETICPEPTIDEONCARDIACSYMPATHETICNERVEACTIVITYIN
PATIENTSWITHDECOMPENSATEDCONGESTIVEHEARTFAILURE *.UCL-ED
 
 #OHN*. &ERRARI2 3HARPE.#ARDIACREMODELINGCONCEPTSAND
CLINICALIMPLICATIONSnACONSENSUSPAPERFROMANINTERNATIONAL
FORUMONCARDIACREMODELING*!M#OLL#ARDIOL 

 $I$OMENICO2* 0ARK(9 3OUTHWORTH-2 ETAL 'UIDELINESFOR


ACUTEDECOMPENSATEDHEARTFAILURETREATMENT !NN0HARMACOTHER
 

 6-!#INVESTIGATORS )NTRAVENOUSNESIRITIDEVSNITROGLYCERINFOR


TREATMENTOFDECOMPENSATEDCONGESTIVEHEARTFAILUREARANDOMIZED
CONTROLLEDTRIAL*!-! 

 #ODY2 #LINICALTRAILSOFDIURETICTHERAPYINHEARTFAILURE


RESEARCHDIRECTIONSANDCLINICALCONSIDERATIONS*!M#OLL
#ARDIOL! !

 3ILVER-! (ORTON$0 #HALI*+ %LKAYAM5 %FFECTOFNESIRITIDE


VERSUSDOBUTAMINEONSHORT TERMOUTCOMESINTHETREATMENTOF
PATIENTSWITHACTUELYDECOMPENSATEDHEARTFAILURE!M*#OLL
#ARDIOL 

 +UBO3( #LARK- ,ARAGH*( ETAL )DENTIlCATIONOFNORMAL


NEUROHORMONALACTIVITYINMILDCONGESTIVEHEARTFAILUREAND
STIMULATINGEFFECTOFUPRIGHTPOSTUREANDDIURETICS!M*#ARDIOL
 
 #OTTER' -ETZKOR% +ALUSKI% ETAL 2ANDOMIZEDTRIALOF
HIGH DOSEISOSORBIDEDINITRATEPLUSLOW DOSEFUROSEMIDEVERSUS
HIGH DOSEFUROSEMIDEPLUSLOW DOSEISOSORBIDEDINITRATEINSEVERE
PULMONARYEDEMA,ANCET 
 3ALVADOR$2+ 2EY.2 2AMOS'#0UNZALAN&%2#ONTINUOUS
INFUSIONVERSUSBOLUSINJECTIONOFLOOPDIURETICSINCONGESTIVEHEART
FAILURE#OCHRANE$ATABASE3YSTEMATIC2EVIEWS#$
 'HEORGHIADE- .IAZI) /UYANG* ETAL6ASOPRESSIN6 RECEPTOR
BLOCKADEWITHTOLVAPTANINPATIENTSWITHCHRONICHEARTFAILURE
RESULTSFROMADOUBLE BLIND RANDOMIZEDTRIAL#IRCULATION
 
 3TEVENSON,7#LINICALUSEOFINOTROPICTHERAPYFORHEARTFAILURE
LOOKINGBACKWARDORFORWARD#IRCULATION 
 "URGER!* (ORTON$0 ,E*EMETEL4 ETAL %FFECTOFNESIRITIDE
ANDDOBUTAMINEONVENTRICULARARRHYTHMIASINTHETREATMENTOF
PATIENTSWITHACUTELYDECOMPENSATEDCONGESTIVEHEARTFAILURETHE
02%#%$%.4STUDY!M(EART* 
 #UFFE-3 #ALIFF2- !DAMS+& ETAL3HORT TERMINTRAVENOUS
MILRINONEFORACUTEEXACERBATIONOFCHRONICHEARTFAILURE*!-!
 

 0EACOCK7& %MERMAN#, THE02/!#4)/.STUDYGROUP3AFETY


ANDEFlCACYOFNESIRITIDEINTHETREATMENTOFDECOMPENSATEDHEART
FAILUREINOBSERVATIONPATIENTS*!M#OLL#ARDIOL!
 #OLUCCI73 %LKAYAM5 (ORTON$ ETAL)NTRAVENOUSNESIRITIDE A
NATRIURETICPEPTIDE INTHETREATMENTOFDECOMPENSATEDCONGESTIVEHEART
FAILURE.ESIRITIDE3TUDY'ROUP.%NGL*-ED 
 3ACKNER "ERNSTEIN*$ +OWALSKI- &OX- ETAL3HORT TERM2ISK
OF$EATH!FTER4REATMENT7ITH.ESIRITIDEFOR$ECOMPENSATED
(EART&AILURE!0OOLED!NALYSISOF2ANDOMIZED#ONTROLLED4RIALS
*!-! 
 3ALTZBERG-4 "ENElCIALEFFECTSOFEARLYINITIATIONOFVASOACTIVE
AGENTSINPATIENTSWITHACUTEDECOMPENSATEDHEARTFAILURE 2EV
#ARDIOVASC-EDSUPPL  
 0EACOCK 7&(EART&AILURE-ANAGEMENTINTHEEMERGENCY
DEPARTMENTOBSERVATIONUNIT0ROGIN#ARDIOVAS$IS

 %MERMAN#, 0EACOCK7& THE!$(%2%INVESTIGATORS%VOLVING
PATETERSOFCAREFORDECOMPENSATEDHEARTFAILUREIMPLICATIONSFROM
THE!$(%2%REGISTRYDATABASE!CAD%MERG-ED
 9OUNG*".EWTHERAPEUTICCHOICESINTHEMANAGEMENTOFACUTE
CONGESTIVEHEARTFAILURE 2EV#ARDIOVASC-ED3 

#OPYRIGHT%-#2%' )NTERNATIONAL 



/ 6"6 ," " * /  "-- /, / /


"
\-1,9"/ *
" - -1-* , *",/

7&RANK0EACOCK -$
$EPARTMENTOF%MERGENCY-EDICINE 4HE#LEVELAND#LINIC&OUNDATION
#LEVELAND /(

" 
/6 -\
 $ISCUSSTHEAPPLICATIONANDLIMITATIONSOF".0TESTINGINTHEEMERGENCYSETTING
 $ESCRIBETHEAPPROPRIATECANDIDATEFOR".0THERAPY

 /," 1
/"
!".0EXPERTCONSENSUSPANEL CONSISTINGOFINDIVIDUALSWITHBASIC METHODOLOGIC AND
CLINICALEXPERTISE WASCONVENEDINTOCREATEASUMMARYDOCUMENTTOHELPGUIDE
THECLINICIANONTHERECENTEXPLOSIONOFNATRIURETICPEPTIDE.0 DATA4HISDOCUMENT
CONTAINS THE DATA FROM THEIR RECOMMENDATIONS MOST APPLICABLE TO THE EMERGENCY
PHYSICIAN
.ATRIURETIC0EPTIDE0HYSIOLOGY
-ORETHANAPUMP THEHEARTISACRITICAL
ENDOCRINE ORGAN FUNCTIONING WITH OTHER
PHYSIOLOGICAL SYSTEMS TO CONTROL mUID
VOLUME -YOCYTES MANUFACTURE A FAM
ILYOFPEPTIDEHORMONES TERMEDTHE.0S
REPRESENTED BY ATRIAL NATRIURETIC PEPTIDE
!.0 AND " TYPE NATRIURETIC PEPTIDE
".0 2ELEASEOFTHE.0SISSTIMULATED
BY VOLUME OVERLOAD  AND PHYSIOLOGI
CALLY THEY HAVE POWERFUL DIURETIC NATRI
URETIC ANDVASCULARSMOOTHMUSCLERELAX
ING ACTIONS )MPORTANTLY THEY ALSO SERVE
ASANTAGONISTSTOTHESYMPATHETICNERVOUS
SYSTEM AND THE RENIN ANGIOTENSIN ALDO
STERONE AXIS 2!!3   2ELEASE OF .0S
RESULTSFROMCARDIACWALLSTRETCH VENTRIC
ULARDILATION ORINCREASEDPRESSURESFROM
CIRCULATORYVOLUMEOVERLOAD4HEEFFECTS
OF.0SRESULTINLOWERINGBLOODVOLUME
ANDPRESSURE
".0 IS DERIVED FROM A PRECURSOR PRE
PRO".0 WHICHUNDERGOESSEVERALCLEAV

AGES 4HE ASSAY RELEVANT PRODUCTS ARE


THE INERT . TERMINAL PRO ".0 FRAGMENT
AND PHYSIOLOGICALLY ACTIVE ".0 ".0S
AREPREFERENTIALLYPRODUCEDANDSECRETED
BYTHECARDIACVENTRICLES ALTHOUGHmUID
OVERLOADMAYCAUSERAPID".0MANUFAC
TUREINBOTHHEARTCHAMBERS4HEPRIMARY
FUNCTIONOF.0SISTODEFENDAGAINSTVOL
UMEOVERLOAD!FTERRELEASEINTOCIRCULA
TION ".0ACTIONSAREMODULATEDATTARGET
SITES BY SPECIlC CELL MEMBRANE RECEP
TORS TERMED! " AND# WHICHMEDIATE
PHYSIOLOGICAL ACTIONS BY CYCLIC '-0
#YCLIC'-0HASPOTENTVASODILATORYAC
TIONS ".0 ALSO CAUSES AN INTRAVASCULAR
mUIDSHIFT FROMTHECAPILLARYBEDINTOTHE
INTERSTITIUM WHICH CONTRACTS INTRAVASCU
LARVOLUMEANDDECREASES"0 )NADDI
TION ".0ISA2!!3ANTAGONIST WHEREIT
COUNTERACTS SODIUM CONSERVATION VASO
CONSTRICTION ANDVOLUMERETENTION".0
ALSO INHIBITS THE RELEASE OF RENIN FROM
KIDNEY CELLS AND ALDOSTERONE FROM ADRE

/iivviVv *
ii}
L`i
>`ii



%MERGENCY$IAGNOSISAND4REATMENTOF
!CUTE$ECOMPENSATED(EART&AILURE!$(&

NALCELLS".0ISPRIMARILYMETABOLIZEDBYTHE.02 #
RECEPTOR ALTHOUGHSOMEADDITIONALDEGRADATIONMAY
OCCURBYNEUTRALENDOPEPTIDASE .EUTRALENDOPEP
TIDASE HAS A WIDE TISSUE DISTRIBUTION INCLUDING ADI
POSE KIDNEYS LUNG ANDBRAIN}i

}i

* 
/-

, 6
5z
6
'z z
z
z
6
z
0
6
z
z
.
*
z
z
5
z*
/
z
+
z
*
z
z
5
)
z
z& z
&
6 z
5
6 z
/z
. 9z
z
zz
*
z
3 . 0
6 zz
6
z
zz
9 4 *z
zz

&DUGLDF
/XVLWURSLF 
$QWLILEURWLF 
$QWLUHPRGHOLQJ 
0DUFXV/6HWDO&LUFXODWLRQ
=HOOQHU&HWDO$P-3K\VLRO SW ++
$EUDKDP:7HWDO-&DUG)DLO
&ODUNVRQ3%0HWDO&LUFXODWLRQ
7DPXUD1HWDO3URF1DWO$FDG6FL86$

+HPRG\QDPLF
%DODQFHGYDVRGLODWLRQ
9HLQV 
$UWHULHV 
&RURQDU\DUWHULHV 
1HXURKXPRUDO
 $OGRVWHURQH 
 (QGRWKHOLQ 
 1RUHSLQHSKULQH 
5HQDO 
 'LXUHVLV
 1DWULXUHVLV

"IOLOGIC$ETERMINANTSON".0-EASUREMENTS
"LOODLEVELSOF.0SAREAFFECTEDBYAVARIETYOFFACTORS
INCLUDING CIRCADIAN RHYTHM AGE EXERCISE AND BODY
POSTURE-ANYDRUGSINCLUDINGDIURETICS ANGIOTENSIN
CONVERTINGENZYMEINHIBITORS ADRENERGICAGONISTS SEX
ANDTHYROIDHORMONES GLUCOCORTICOIDS SODIUMINTAKE
ANDOTHERCONDITIONSIMPACTLEVELS".0INCREASESWITH
AGE AND GENDER "ASELINE AND PATHOLOGIC LEVELS ARE
HIGHER IN WOMEN 4HE AGE INDUCED ".0 INCREASE
MAYBEDUETOTHEDECLINEINMYOCARDIALFUNCTIONOR
TODECREASEDCLEARANCE
".0!SSAY
)TSHOULDBEMADECLEARTHATTHE".0ASSAYISNOTA
STAND ALONETEST)TSGREATESTVALUEISWHENITISUSED
WITHTHEPHYSICIANSCLINICALJUDGMENT ANDWITHOTHER
APPROPRIATETESTING4HE4RIAGE".0ASSAYSYSTEMIS
THE ONLY &$! APPROVED POINT OF CARE ASSAY )T RE



QUIRES MINUTESTOPERFORM ANDREPORTS".0LEVELS


FROM  TO  PGM,4HIS ASSAY IS RATED AS MOD
ERATELY COMPLEX ASSAY PER #LINICAL ,ABORATORY )M
PROVEMENT!MENDMENTS#,)! REGULATIONS
".0FOR$IAGNOSISOF(EART
&AILURE
$ESPITE ADVANCES IN OUR UNDER
STANDING OF HEART FAILURE (&
PATHOPHYSIOLOGY DIAGNOSIS IS
STILL DIFlCULT 7HILE EMERGEN
CY DEPARTMENT %$ DIAGNOSIS
NEEDSTOBERAPIDANDACCURATE 
THE SIGNS AND SYMPTOMS OF (&
ARE NONSPECIlC 2ESPIRATORY
DISTRESS CAN PRECLUDE OBTAINING
THEHISTORY ANDDYSPNEAISNON
SPECIlCINTHEELDERLYOROBESE
2OUTINE LABS %#' AND X RAYS
ARE ALSO NOT ACCURATE ENOUGH TO
ALWAYSMAKETHECORRECTDIAGNO
SIS 

#/.3%.35334!4%-%.43
'%.%2!,#/--%.43
4HELABORATORYSHOULDPERFORM".0TESTING
ONACONTINUOUS HOURBASISWITHA
TURN AROUND TIME4!4 OFMINUTESOR
LESS4HE4!4ISDElNEDASTHETIMEFROM
BLOODCOLLECTIONTONOTIlCATIONOFRESULT
TOPHYSICIANORCAREGIVER%ITHERCENTRAL
LABORATORYINSTRUMENTATIONORPOINTOFCARE
TESTINGSYSTEMSAREACCEPTABLE
% )NCONSIDERING.0MEASUREMENTS ONE
NEEDSTOCAREFULLYCONSIDERLABORATORY
ANDBIOLOGICVARIATION INCLUDINGGENDER
SEX OBESITY ANDRENALFUNCTION
% 4HERESULTSOFNATRIURETICTESTINGIS
DEPENDENTONTHETYPEOFTESTYOUARE
OBTAINING.TERMINALPRO".0AND
BIOACTIVE".0ARE./4INTERCHANGEABLE

/ 6"6 ," " * /  "-- /, / /


"
\-1,9"/ *
" - -1-* , *",/

4HE"REATHING.OT0ROPERLYSTUDYWASALARGE MUL
TINATIONAL PROSPECTIVE STUDY USING ".0 TO EVALUATE
DYSPNEA IN  DYSPNEIC %$ PATIENTS ".0 LEVELS
WERE MEASURED ON ARRIVAL AND PHYSICIANS ASSESSED
THEPROBABILITYOFTHEPATIENTHAVING(&4WOCARDI
OLOGISTS BLINDEDTOTHE".0LEVEL REVIEWEDALLDATA
AFTER HOSPITALIZATION TO PRODUCE A hGOLD STANDARDv
CLINICALDIAGNOSIS".0LEVELSALONEMOREACCURATELY
PREDICTEDTHEPRESENCEORABSENCEOF(&THANANYOTH
ERlNDING4HEPGM,CUTPOINTHADASEN
SITIVITY AND  SPECIlCITY FOR A (& DIAGNOSIS )N
MULTIVARIATEANALYSIS ".0LEVELSALWAYSCONTRIBUTED
TOTHEDIAGNOSIS EVENAFTERCONSIDERINGFEATURESOFTHE
HISTORYANDPHYSICALEXAMINATION
".0 LEVELS MAY ALSO HELP IN DISPOSITION DECISIONS
4HE2APID%MERGENCY$EPARTMENT(EART&AILURE/UT
PATIENT2%$(/4 4RIALDEMONSTRATEDAhSTRONGDIS
CONNECTv BETWEEN THE PERCEIVED SEVERITY OF (& AND
ILLNESS SEVERITY AS DETERMINED BY ".0 /N AVERAGE
PATIENTS DISCHARGED FROM THE %$ HAD A HIGHER ".0
THANTHOSEADMITTED PGM, VERSUSPGM,
RESPECTIVELY".0ALSOPREDICTEDOUTCOMESOFPATIENTS
DISCHARGED HADA".0PGM, HOWEVER
THEREWASNOMORTALITYATDAYSIFTHE".0WASLESS
THANPGM,

4HE3WISS"!3%,3TUDYEXAMINED COST EFFECTIVE
NESSOFUSING".0THROUGHTHEDIAGNOSISANDHOSPITAL
IZATIONINACUTEDECOMPENSATEDHEARTFAILURE!$(& 
)NPATIENTS %$MEASUREMENTOF".0WASASSO
CIATED WITH A  DECREASE IN HOSPITAL ADMISSIONS
A DAYDECLINEINLENGTHOFSTAY ANDANSAV
INGS WITHNOEFFECTSONMORTALITYORRE HOSPITALIZATION
RATES
".0AND2ENAL&AILURE
#HRONIC KIDNEY DISEASE #+$ INmUENCES THE CUT
POINTFOR".0)NGENERAL AS#+$ADVANCES AHIGHER
".0 CUT POINT IS IMPLIED ! CUT POINT OF APPROXI
MATELY  PGM, IS REASONABLE FOR THOSE WITH AN

#/.3%.35334!4%-%.453).'".04/
(%,042)!'%%$0!4)%.437)4($930.%!
".0ISOFDIAGNOSTICUTILITYINTHEEVALUATION
OFPATIENTSWITHACUTEDYSPNEA4HUS IN
NEWPATIENTSPRESENTINGWITHDYSPNEATO
ANEMERGENCYSETTING AHISTORY PHYSICAL
EXAMINATION CHESTX RAYAND%#'SHOULD
BEUNDERTAKENTOGETHERWITHLABORATORY
MEASUREMENTSTHATINCLUDE".0#URRENT
DATASUGGESTTHEFOLLOWINGGUIDELINES
% !S".0RISESWITHAGEANDISAFFECTED
BYGENDER COMORBIDITY ANDDRUGUSE IT
SHOULDNOTBEUSEDINISOLATIONFROMTHE
CLINICALCONTEXT
% )FTHE".0ISPGM, THEN(&IS
HIGHLYUNLIKELY.06 
% )FTHE".0ISPGM, THEN(&IS
HIGHLYLIKELY006 
% )FTHE".0ISnPGM, CONSIDER
ABASELINE".0ELEVATEDDUETOSTABLE
UNDERLYINGDYSFUNCTION RIGHTVENTRICULAR
FAILUREFROMCORPULMONALE ACUTE
PULMONARYEMBOLISM ORRENALFAILURE
% 0ATIENTSMAYPRESENTWITH(&ANDA
NORMAL".0 ORWITHLEVELSBELOWWHAT
ISEXPECTEDINTHEFOLLOWINGSITUATIONS
mASHPULMONARYEDEMAnHOURS (&
UP STREAMFROMTHELEFTVENTRICLESUCH
ASWITHACUTEMITRALREGURGITATIONFROM
PAPILLARYMUSCLERUPTUREANDOBESE
PATIENTSBODYMASSINDEX;"-)= 

ESTIMATED GLOMERULAR lLTRATION RATE '&2  M,


MINM5SINGTHISAPPROACH ".0MAINTAINSA
HIGHLEVELOFDIAGNOSTICUTILITY WITHANAREAUNDERTHE
2/#CURVEOFACROSSALL#+$GROUPS



%MERGENCY$IAGNOSISAND4REATMENTOF
!CUTE$ECOMPENSATED(EART&AILURE!$(&

#/.3%.35334!4%-%.43#/-/2")$)4)%3
!.$30%#)!,)335%34(!4).&,5%.#%4(%
).4%202%4!4)/./&".0,%6%,3
% ".0ISALTEREDWITHCHRONICRENAL
INSUFlCIENCYESTIMATED'&2M,
MIN WITHARECALIBRATIONOFTHECUTOFF
VALUETOPGM,
% ".0ISHELPFULINTHEEVALUATIONOF
DYSPNEAWHENITISVERYLOWORHIGH.4
PRO".0HASGREATERCORRELATIONWITH
E'&2THAN".0 HENCELEVELSCANBE
ELEVATEDEVENWITHTHENORMALAGERELATED
DECLINEOFRENALFUNCTIONINTHEE'&2
M,MINRANGE
% 7HENTHEE'&2ISBELOWM,MIN .
TERMINALPRO".0CANBECONSIDERABLY
ELEVATEDANDINTHISSETTINGITSUTILITYIN
THEEVALUATIONOF(&ISUNKNOWN
% "ASELINE".0LEVELSMIGHTTHEREFOREBE
IMPORTANTINDIALYSISPATIENTS ASCHANGES
MOSTLIKELYREmECTVOLUMESTATUS4HUS
APRE DIALYSIS".0MAYHELPDETERMINE
THEAMOUNTOFVOLUMEWHICHSHOULDBE
REMOVED

#ARDIOPULMONARY$ISEASE
3OME NON (& CARDIOPULMONARY DISEASE MAY CAUSE
".0 ELEVATIONS 4HESE INCLUDE COR PULMONALE LUNG
CANCER PULMONARY EMBOLISM 0% AND PRIMARY PUL
MONARYHYPERTENSION)NTHESE ".0MAYBEELEVATED
BUTNOTTOTHEEXTENTFOUNDIN!$(&)N0% ".0MAY
BEPROGNOSTICSINCEPATIENTSWITHA".0INTHEUPPER
NORMALRANGEORPGM,HAVEAHIGHERMORTAL
ITYRATE!LTHOUGH".0ISNOTANADEQUATESCREENING
TESTFOR0% INTHESETTINGOFASUSPECTEDORCONlRMED
EMBOLICEVENT A".0ELEVATIONIMPLIES26PRESSURE
OVERLOADANDINCREASEDMORTALITYRISK&INALLY INPRI
MARY PULMONARY HYPERTENSION ".0 ELEVATIONS PAR
ALLELTHEEXTENTOFPULMONARYHEMODYNAMICCHANGES
ANDRIGHT(&



#/.3%.35334!4%-%.4".0).
05,-/.!29!.$!33/#)!4%$#!2$)!#
$)3%!3%
% )NAPPROXIMATELYOFPATIENTSWITH
PULMONARYDISEASE ".0ISELEVATED
IMPLYINGCOMBINED(&ANDLUNGDISEASE
CORPULMONALE ORAMISDIAGNOSISWHEN
THETRUEETIOLOGYOFDYSPNEAIS(&
% )NTHESETTINGOF0% ".0ISELEVATEDIN
OFCASESANDISASSOCIATEDWITH26
PRESSUREOVERLOADANDAHIGHERMORTALITY
".0ISNOTDIAGNOSTICFORACUTE0%
% 0ULMONARYDISEASEWHICHRESULTS
INPULMONARYHYPERTENSIONAND26
PRESSUREORVOLUMEOVERLOADCANLEADTO
ELEVATED".0LEVELS USUALLYINTHERANGE
OF PGM,

0RESERVED3YSTOLIC&UNCTION03& (EART&AILURE
$IASTOLICMYOCARDIALDYSFUNCTION ALSOKNOWNAS03&
ISTHECAUSEOF(&INASMANYOFOFCASESAND
ISALSOASSOCIATEDWITHHIGH".0 ".0HASBEEN
FOUNDTOBEAPPROXIMATELYHALFASHIGHIN03&ASIN
CASESOFSYSTOLICDYSFUNCTION
#/.3%.35334!4%-%.4".0).
$)!34/,)#$93&5.#4)/.
% ".0MIGHTBEUSEDTODETECTPATIENTS
WITHDIASTOLICDYSFUNCTION
% ".0CONCENTRATIONSABOVEAGE ADJUSTED
CUT POINTSMAYIDENTIFYELDERLYPATIENTS
WITHDIASTOLICDYSFUNCTION

/ 6"6 ," " * /  "-- /, / /


"
\-1,9"/ *
" - -1-* , *",/

/BESITY
/BESITY IS AN IMPORTANT RISK FACTOR FOR CORONARY AR
TERYDISEASEAND(& 0HYSIOLOGICALLY ADIPOSETIS
SUEISRELATEDTOTHENATRIURETICCLEARANCERECEPTOR 
AND OBESITY CAN INTERFERE WITH THE USUAL DIAGNOSTIC
APPROACHTO(&-EHRADOCUMENTEDANINVERSERE
LATIONSHIPBETWEEN"ASAL-ETABOLIC)NDEX"-) AND
".0,OWERLEVELSOF".0INTHEOBESE"-)+G
- WERENOTED DESPITESIMILARSEVERITYOF(&COM
PAREDTOALEANCOHORT ANDNEARLYOFOBESEPA
TIENTSHAD".0PGM,

GROUPEDINTO".0QUARTILESHOURSAFTER!#3ONSET
AN INCREASING ".0 WAS ASSOCIATED WITH HIGHER 
MONTHMORTALITY ANDTHISRELATIONSHIPPERSISTEDEVEN
WITHOUTEVIDENCEOF(&ORMYOCARDIALNECROSIS
#/.3%.35334!4%-%.4".0).35$$%.
$%!4( !#3 !.$#!$

7HEN USED TOGETHER ".0 AND CARDIAC


TROPONIN PROVIDE A MORE EFFECTIVE TOOL
FOR IDENTIFYING PATIENTS AT INCREASED RISK
FORCLINICALLYIMPORTANTCARDIACEVENTSRE
LATEDTO(&AND!#3-ULTIMARKERPANELS
WITH".0ANDTROPONINARENOWAVAILABLE
WHERE EACH OF THESE MARKERS PROVIDE
UNIQUEANDINDEPENDENTOUTCOMEDATA

#/.3%.35334!4%-%.4".0)./"%3)49
% 3INCEOBESEPATIENTSBODYMASS
INDEX;"-)=KGM EXPRESSLOWER
LEVELSOF".0FORANYGIVENSEVERITY
OF(& CAUTIONSSHOULDBEEXERCISEDIN
INTERPRETING".0LEVELSINSUCHPATIENTS

".0AND!CUTE#ORONARY3YNDROMES!#3
,ARGESTUDIESREPORT.0ELEVATIONSINUNSTABLEANGINA
WITHOUTMYOCARDIALNECROSIS !SISCHEMIAMAYRE
SULTINONLYSMALL.0ELEVATIONS THEIRSENSITIVITYAND
SPECIlCITYAREINADEQUATEASAhRULEOUTvTOOL(OW
EVERIFPRESENT ANELEVATIONOF.0IN!#3ISAPOW
ERFULPREDICTOROFADVERSEEVENTS)N PATIENTS

".0AND0ROGNOSIS
".0ELEVATIONISAPOWERFULMARKEROF(&PROGNOSIS
)N  PATIENTS FOLLOWED FOR  MONTHS AFTER AN %$
VISITFORDYSPNEA THERELATIVERISKOF MONTH(&AD
MISSIONORDEATH WASTIMESHIGHERIFTHE".0WAS
PGM,}i4HISWASCONlRMEDBYTHE
6AL (E&4TRIAL WHERETHELOWESTQUARTILEOF".0
PGM, HADTHELOWESTALL CAUSEMORTALITYANDTHE
HIGHESTQUARTILEPGM, HADTHEHIGHESTMOR
TALITY ATMONTHS}i

}i



,i> v * `iii`
ii}iV `i>i V>i
`i>i>v>i>>
,ii`iv
i}i`\n




".0PGM,






".0 PGM,


".0PGM,





















$AYS


%MERGENCY$IAGNOSISAND4REATMENTOF
!CUTE$ECOMPENSATED(EART&AILURE!$(&

} *]i

".0AS4HERAPY
7HEN!$(&OCCURS THEBALANCEBETWEEN
VASOCONSTRICTORSANDENDOGENOUSVASODI
LATORS IS DISTURBED 4HIS FORMS THE BASIS
AS TO WHY EXOGENOUS ".0 IS GIVEN AS
THERAPY DESPITE HIGH ENDOGENOUS LEVELS
ISANALOGOUSTOGIVINGINSULINFORINSULIN
RESISTANCE)N!$(& HIGHLEVELSOF".0
OCCURASAhDISTRESSHORMONEv WHERESU
PRA NORMALLEVELSARENOLONGEREFFECTIVE
AT MAINTAINING THE BALANCE OF VASOCON
STRICTION AND VASODILATION (ENCE GIVING
".0 INTHEFORMOFNESIRITIDE CANRESTORE
NEUROHORMONALHOMEOSTASIS

vvi`i]V>
iii>
i>>`
>V>i`i`Vi`
w}ii]
`iVi>i`>
>V>i>Vi]
ii`Vi>
iii]
>`i`V
iV *

.0 ARE MUCH CLOSER TO IDEAL DRUGS FOR


!$(&THANOTHERAGENTS4HEUSEOFNE
SIRITIDEISASSOCIATEDWITHREDUCEDlLLING
PRESSURES DECREASED PULMONARY VASCU
LAR RESISTANCE LOWERED CENTRAL VENOUS
PRESSURES ANDREDUCTIONINSYSTEMIC"0
4HEREISALSOINCREASEDCARDIACOUTPUTDUE
TOTHEUNLOADINGEFFECTOFVASODILATATION
BUTWITHOUTREmEXTACHYCARDIA-OREOVER
REDUCING PRELOAD AND AFTERLOAD WITHOUT
INCREASING HEART RATE IS CONSISTENT WITH
DECREASEDMYOCARDIALOXYGENCONSUMP
TION AND A DECREASE IN VENTRICULAR STRESS
A STIMULUS PRESUMED TO DRIVE THE NEU
ROHORMONAL ACTIVATION OF!$(& ,ASTLY
TOLERANCETOTHESEEFFECTSDOESNOTOCCUR
ANDTHESECHANGESINHEMODYNAMICSARE
PRESENTANDPERSISTENTTHROUGHOUTTHEAD
MINISTRATIONOFNESIRITIDE
4ODATE NESIRITIDEISTHEONLYNATRIURETIC
PEPTIDEAVAILABLEINTHE53FOR)6THERA
PY#OLUCCIETAL INTHE%FlCACY4RIAL
SHOWED THAT NESIRITIDE CAUSES A DOSE RE
LATED DECREASE IN 0#70 SYSTEMIC VAS
CULARRESISTANCE MEANRIGHTARTERIALPRES
SURE DYSPNEA FATIGUE A SIGNIlCANT IN
CREASEINCARDIACINDEX ANDANIMPROVE



MENTINGLOBALSTATUS4HEMOSTCOMMON
SIDE EFFECT WAS DOSE RELATED HYPOTENSION
4HE #OMPARATIVE 4RIAL EVALUATED NE
SIRITIDE VERSUS MANY OTHER CARDIOVASCULAR
AGENTS INCLUDING DOBUTAMINE MILRINONE
NITROGLYCERIN DOPAMINE AND AMRINONE
'LOBAL CLINICAL STATUS FATIGUE AND DYS
PNEAIMPROVEDINALLGROUPS WITHNOSIG
NIlCANTDIFFERENCESBETWEENNESIRITIDEAND
STANDARDTHERAPY4HEMOSTCOMMONSIDE
EFFECTSWEREBRADYCARDIAANDDOSE RELATED
HYPOTENSION
)N  "URGER ET AL  CONDUCTED THE
02%#%$%.4 STUDY )TS PRIMARY OBJEC
TIVE WAS TO COMPARE HEART RATE AND AR
RHYTHMIAS WITH TWO DOSES OF NESIRITIDE
ORGKGMIN TODOBUTAMINE
4HEY CONCLUDED THAT ALTHOUGH INOTROPIC
(&THERAPIES INCLUDINGDOBUTAMINEAND
MILRINONE AREASSOCIATEDWITHFAVORABLE
HEMODYNAMIC AND SYMPTOMATIC EFFECTS
THEY CAUSE ARRHYTHMIAS AND TACHYCARDIA
WHICH MAY INCREASE MYOCARDIAL OXYGEN
DEMAND ISCHEMIA AND MORTALITY 4HEY
DEMONSTRATED FEWER ARRHYTHMIAS AND NO
HEART RATE INCREASE WITH NESIRITIDE &UR
THERMORE THE RATES OF  DAY READMIS
SIONAND MONTHMORTALITYWEREHIGHER
WITHDOBUTAMINE4HEAUTHORSCONCLUDED
THAT NESIRITIDE IS SAFER THAN DOBUTAMINE
FORSHORT TERM!$(&MANAGEMENT
4HE6-!# TRIAL WAS A SAFETY AND EF
lCACY STUDY OF INTRAVENOUS NESIRITIDE
VERSUS INTRAVENOUS NITROGLYCERIN OR PLA
CEBOIN!$(&PATIENTSWITHDYSPNEA
AT REST 3WAN 'ANZ CATHETERIZATION WAS
PERFORMEDINROUGHLYHALF ATTHEPHYSI
CIANSCHOICE0ATIENTSWERERANDOMIZED
INTOFOURBLINDEDGROUPS EACHRECEIVING
STANDARDTHERAPYANDlXEDDOSENESIRIT
IDE TITRATABLE NESIRITIDE TITRATABLE NITRO

/ 6"6 ," " * /  "-- /, / /


"
\-1,9"/ *
" - -1-* , *",/

GLYCERIN OR PLACEBO .ESIRITIDE HAD A FASTER ONSET


AND GREATER REDUCTION IN 0#70 THAN NITROGLYCERIN
4HEIMPROVEMENTINCLINICALSTATUSANDDYSPNEAWAS
SIMILAR IN BOTH GROUPS }i 4HEY CONCLUDED
THATWHENADDEDTOSTANDARDCARE NESIRITIDEIMPROVES
HEMODYNAMIC FUNCTION MORE EFFECTIVELY THAN )6 NI
TROGLYCERINORPLACEBO

YIELDANINTUITIVERATIONALEANDAREASONABLEEVIDENCE
BASED APPROACH FOR !$(& ASSESSMENT AND MANAGE
MENT/NEOFTHEMOSTVALUABLElNDINGSISTHATBEGIN
NINGVASOACTIVETHERAPYINTHE%$ISASSOCIATEDWITHA
 DAYREDUCTIONINHOSPITALLENGTHOFSTAYCOMPARED
TO THERAPIES NOT INITIATED UNTIL AFTER ADMISSION 4HIS
SUGGESTSTHATTHECHOICEOFTHERAPYINTHE%$MAYCRITI
CALLYIMPACTTHECOURSEOFTHEPATIENT

)NANOTHEREVALUATION ARISKADJUSTEDCOMPARISONOF
OUTCOMES FROM THE!$(%2% REGISTRY OF MORE THAN
 !$(&PATIENTSFOUNDIMPROVEDSURVIVALWITH
VASODILATORSCOMPAREDTOINOTROPES7HENCOMPARING
VASODILATORS THEREARESIMILAROUTCOMESBETWEENNE
SIRITIDEANDNITROGLYCERIN

).4%'2!4).'".0,%6%,3).4/!
2!4)/.!,53%/&.%3)2)4)$%
7HILE".0ISAPPROVEDBYTHE&$!FOR(&DIAGNOSIS
ITSUSEFULNESSTOMONITORTREATMENTISSTILLUNDERSTUDY
(OWEVER SOMESUGGESTIONSCANBEMADE7EBELIEVE
THATONECANSTRATIFYPATIENTSTOTHEHIGH RISKCATEGORYIN
PARTBYUSING".0LEVELS&ONOROWRECENTLYANALYZED
THE!$(%2%DATABASEANDFOUNDTHATHIGH"5.LEVELS
PROVIDEAPOORPROGNOSISFORPATIENTSIN!$(&4HUS

4HE CURRENT APPROVED USE OF NESIRITIDE IS FOR!$(&


!LTHOUGHGUIDELINESTATEMENTSARELACKING THETOTALITY
OFDIAGNOSTICANDTHERAPEUTICDATAREGARDINGNESIRITIDE

3ODFHER

0HDQ2EVHUYHGYDOXH PP+J



 S





1HVLULWLGH

0HDQ&KDQJH PP+J





1LWURJO\FHULQ

ss
s



S
S




s s




KU

KU



%/ P
P


KU

KU

KU

%/ P
P

KU

SYVSODFHER
SYV17*

}i
6>`>i>>}iivVi
6
>\*>i`
>V>>i`}iiiV>}ii{



%MERGENCY$IAGNOSISAND4REATMENTOF
!CUTE$ECOMPENSATED(EART&AILURE!$(&

THECOMBINATIONOFHIGH".0ANDPOORRENALFUNCTION
IDENTIlESHIGH RISKPATIENTS}i{
)FPATIENTSAREADMITTEDWITH".0LEVELSPGM,
AND"5.LEVELSARELOWERRISK ONECANOFTEN
STARTTREATMENTWITHPARENTERALDIURETICS3UBSEQUENTLY
THEYCANBERECLASSIlEDINTOLOW ORHIGH RISKGROUPS
BASED ON THEIR RESPONSE OVER THE NEXT n HOURS
4HOSEWITHANADEQUATEDIURESIS AFALLIN".0 AND
NODETERIORATIONINRENALFUNCTIONMAYBECANDIDATES
FOR CONTINUED DIURETICSVASODILATORS UNTIL EUVOLEMIA
IS REACHED (OPEFULLY THIS WILL LEAD TO A ".0 LEVEL
PGM,INTHESEPATIENTS)NONESTUDY PATIENTS
WHOSEDISCHARGE".0LEVELSWEREPGM,HADA
REASONABLELIKELIHOODOFNOTBEINGREADMITTEDWITHIN
THEFOLLOWINGDAYS)FTHE".0LEVELWAS
PGM, THE VOLUME STATUS REQUIRED RE EVALUATION )F
THEPATIENTISNOTYETEUVOLEMIC NESIRITIDEMIGHTBE
CONSIDEREDFORHOURS
)F PATIENTS AFTER RECEIVING n HOURS OF INTRAVENOUS
DIURETICSHAVEANINADEQUATEDIURESIS NOCHANGEORAN
INCREASE IN ".0 AND WORSENING RENAL FUNCTION THEY
SHOULDBECONSIDEREDATHIGHRISK)FTHEIRSYSTOLIC"0
ISATLEASTMM(G THEYCANBEGIVENnDAYSOF

*,&',(),#('+*# 
"!&%('"%"!%+&+!%" &

,#',)*+',#'!/#,"1+)'
"1+#%0&#',#('
"+,0*1%.%

NESIRITIDEWITHIVDIURETICS".0CANTHENBECHECKED
HOURSAFTERCESSATIONOFNESIRITIDEANDORALVASODILATORS
ANDDIURETICSCANBEUSEDUNTILEUVOLEMIAISACHIEVED
0ATIENTSWITHSYSTOLIC"0SMM(GOFTENNEEDVA
SOPRESSORSANDORINOTROPES SOMETIMESUNDER3WAN
'ANZ GUIDANCE )N OUR EXPERIENCE AT THE #LEVELAND
#LINIC IFTHESEINDIVIDUALSSHOWIMPROVEMENTIN"0
ANDSYMPTOMS WEWILLTHENTRANSITIONTHEIRTHERAPY
TO NESIRITIDE )F THERE IS NO IMPROVEMENT ON INOTRO
PESORPRESSORS FURTHERINVASIVESTRATEGIESSHOULDBE
CONSIDERED&INALLY ITISCONCEIVABLETHATINPATIENTS
WHOAREADMITTEDWITHVERYHIGH".0LEVELS ORHAVE
IMPAIRED RENAL FUNCTION NESIRITIDE MIGHT BE STARTED
IMMEDIATELY

-1,9
)NSUMMARY THE".0#ONSENSUS0ANELOFHAS
PROVIDEDCONSENSUSAPPROACHESFORTHEUSEOF".0
FORTHEDIAGNOSISANDTREATMENTOF(&)DEALLY THE
USEOFTHESERECOMMENDATIONSWILLIMPROVETHECARE
OFYOURPATIENTS

*,&',(),#('+ (*
/#,"  (%'&#(&!&%'
&#+*'%"!!+&&
!#( "!%+"!&'"!
"!&%!
)&"'"%&+#%'!&)
"!&%
!!"'%"#&"%#""%#%(&"!

 )!&

  )!&

 )!&

.*1-')*(%


%#'#%+-+)##('( (*
)+,"#+,(*1( 

.*1)*(% 

)*(% 
*,&',(),#('+'('*#
"!&%
#("!%+ "&

&' 
#!( "!
&#&&



*,&',(),#('+ (%'&&%$(%

"!&%!&%'#( "!%+"!&'"!
"%"%"%%! "+! !&''+
%'!!  %    !
  

*,&',(),#('+ (*
/#," (*+"($
(%'&!"'%"#&)&"'"%&
!"%!&%''"""*

}i{
*
i
}

/ 6"6 ," " * /  "-- /, / /


"
\-1,9"/ *
" - -1-* , *",/

,  ,
-




3ILVER7 -AISEL! 9ANCY#7 -C#ULLOUGH0! "URNETT*#


&RANCIS'3 -EHRA-2 0EACOCK7& &ONOROW' 'IBLER"
-ORROW$! (OLLANDER*".0#ONSENSUS0ANEL!#LINICAL
!PPROACHFORTHE$IAGNOSTIC 0ROGNOSTIC 3CREENING 4REATMENT
-ONITORING AND4HERAPEUTIC2OLESOF.ATRIURETIC0EPTIDESIN
#ARDIOVASCULAR$ISEASES#(&  3UPPL n
#LERICO! )ERVASI' -ARIANI'#LINICALRELEVANCEOFTHE
MEASUREMENTOFCARDIACNATRIURETICPEPTIDEHORMONESINHUMANS
(ORM-ETAB2ES n

 7IECZOREK3* 7U!( #HRISTENSON2 ETAL!RAPID" TYPE


NATRIURETICPEPTIDEASSAYACCURATELYDIAGNOSESLEFTVENTRICULAR
DYSFUNCTIONANDHEARTFAILUREAMULTICENTEREVALUATION!M(EART
* n
 2EDlELD-- 2ODEHEFFER2* *ACOBSEN3* ETAL0LASMABRAIN
NATRIURETICPEPTIDECONCENTRATIONIMPACTOFAGEANDGENDER*!M
#OLL#ARDIOL n
 &RIESINGER'# &RANCIS*0ROMISESANDPERILSOFMANAGEDCAREFOR
OLDERPATIENTSWITHCARDIACDISEASE #ARDIOL#LIN n



-AISEL!" TYPENATRIURETICPEPTIDELEVELSAPOTENTIALNOVEL
hWHITECOUNTvFORCONGESTIVEHEARTFAILURE*#ARD&AIL
n



"OOMAMA& 6ANDER-EIRACKER!(0LASMA! AND" TYPE


NATRIURETICPEPTIDESPHYSIOLOGY METHODOLOGYANDCLINICALUSE
#ARDIOVASC2ES n

 4HE3/,6$)NVESTIGATORS%FFECTOFENALAPRILONMORTALITYAND
THEDEVELOPMENTOFHEARTFAILUREINASYMPTOMATICPATIENTSWITH
REDUCEDVENTRICULAREJECTIONFRACTIONSANDCONGESTIVEHEARTFAILURE
.%NGL*-ED n



-AIR* (AMMERER ,ERCHER! 0UCHENDORF"4HEIMPACTOFCARDIAC


NATRIURETICPEPTIDEDETERMINATIONONTHEDIAGNOSISANDMANAGEMENT
OFHEARTFAILURE#LIN#HEM,AB-ED n

 3TEVENSON,74HELIMITEDAVAILABILITYOFPHYSICALSIGNSFOR
ESTIMATINGHEMODYNAMICSINCHRONICHEARTFAILURE*!-!
n



,UCHNER! 3TEVENS4, "ORGESON$$ ETAL$IFFERENTIALATRIAL


ANDVENTRICULAREXPRESSIONOFMYOCARDIAL".0DURINGEVOLUTIONOF
HEARTFAILURE!M*0HYSIOL (n(

 (YPERTENSIONANDGENERALPOPULATIONRESEARCH(YPERTENSION
PT ))n))



3TEIN" ,EVIN2.ATRIURETICPEPTIDESPHYSIOLOGY THERAPEUTIC


POTENTIAL ANDRISKSTRATIlCATIONINISCHEMICHEARTDISEASE!M
(EART* n



7EIDMANN0 (ASLER, 'NADINGER-0 ETAL"LOODLEVELSANDRENAL


EFFECTSOFATRIALNATRIURETICPEPTIDEINNORMALMAN*#LIN)NVEST
n



#HARLES#* %SPINER%! 2ICHARDS!-#ARDIOVASCULARACTIONSOF


!.&CONTRIBUTIONSOFRENAL NEUROHUMORAL ANDHEMODYNAMIC
FACTORSINSHEEP!M*0HYSIOL 2n2

 (UNT0* %SPINER%! .ICHOLLS-' ETAL$IFFERINGBIOLOGICAL


EFFECTSOFEQUIMOLARATRIALANDBRAINNATRIURETICPEPTIDEINFUSIONSIN
NORMALMAN*#LIN%NDOCRINOL-ETAB n
 -UKOYAMA- .AKAO+ (OSODA+ ETAL"RAINNATRIURETICPEPTIDE
ASANOVELCARDIACHORMONEINHUMANS%VIDENCEFORANEXQUISITE
DUALNATRIURETICPEPTIDESYSTEM ATRIALNATRIURETICPEPTIDEANDBRAIN
NATRIURETICPEPTIDE*#LIN)NVEST n
 $AVIDSON.# 3TRUTHERS!$"RAINNATRIURETICPEPTIDE*
(YPERTENSION n
 3AGNELLA'!-EASUREMENTANDIMPORTANCEOFPLASMABRAIN
NATRIURETICPEPTIDEANDRELATEDPEPTIDES!NN#LIN"IOCHEM
n
 #LERICO! )ERVASI' -ARIANI'#LINICALRELEVANCEOFTHE
MEASUREMENTOFCARDIACNATRIURETICPEPTIDEHORMONESINHUMANS
(ORM-ETAB2ES n

 ".0TESTFORRAPIDQUANTIlCATIONOF" TYPENATRIURETICPEPTIDE


;PACKAGEINSERT=3AN$IEGO #ALIF"IOSITE$IAGNOSTICS 

 7UERZ2# -EADOR3!%FFECTSOFPREHOSPITALMEDICATIONS


ONMORTALITYANDLENGTHOFSTAYIN(&!NN%MERG-ED
 n
 $EVERAUX2" ,IEBSON02 (ORAN-*2ECOMMENDATIONS
CONCERNINGUSEOFECHOCARDIOGRAPHYINHYPERTENSIONANDGENERAL
POPULATIONRESEARCH(YPERTENSION PT ))n))
 $AVIE!0 &RANCIS#- ,OVE-0 ETAL6ALUEOFTHE
ELECTROCARDIOGRAMINIDENTIFYINGHEARTFAILUREDUETOLEFTVENTRICULAR
SYSTOLICDYSFUNCTION"-* 
 -AISEL! +RISHNASWAMY0 .OWAK2- ETAL2APIDMEASUREMENT
OF" TYPENATRIURETICPEPTIDEINTHEEMERGENCYDIAGNOSISOFHEART
FAILURE.%NGL*-ED  n
 -UELLER# 3CHOLER! ,AULE +ILIAN+ ETAL5SEOF" TYPE
NATRIURETICPEPTIDEINTHEEVALUATIONANDMANAGEMENTOFACUTE
DYSPNEA.%NGL*-ED n
 7OLDE- 4ULEVSKI)) -ULDER*7 ETAL"RAINNATRIURETICPEPTIDE
ASAPREDICTOROFADVERSEOUTCOMEINPATIENTSWITHPULMONARY
EMBOLISM#IRCULATION   
 ,EUCHTE(( (OLZAPFEL- "AUMGARTNER2! ETAL#LINICAL
SIGNIlCANCEOFBRAINNATRIURETICPEPTIDEINPRIMARYPULMONARY
HYPERTENSION*!##  n
 ,UBIEN% $E-ARIA! +RISHNASWAMY0 ETAL5TILITYOF"
NATRIURETIC0EPTIDE".0 INDIAGNOSINGDIASTOLICDYSFUNCTION
#IRCULATION  n



%MERGENCY$IAGNOSISAND4REATMENTOF
!CUTE$ECOMPENSATED(EART&AILURE!$(&

 +RISHNASWAMY0 ,UBIEN% #LOPTON0 ETAL5TILITYOF" NATRIURETIC


PEPTIDE".0INELUCIDATINGLEFTVENTRICULARDYSFUNCTIONSYSTOLIC
ANDDIASTOLIC INPATIENTSWITHANDWITHOUTSYMPTOMSOFCONGESTIVE
HEARTFAILUREATAVETERANSHOSPITAL!M*-ED n
 -AISEL!3 -C#ORD*- .OWAK2- ETAL"EDSIDE" TYPE
NATRIURETICPEPTIDEINTHEEMERGENCYDIAGNOSISOFHEARTFAILUREWITH
REDUCEDORPRESERVEDEJECTIONFRACTIONRESULTSFROMTHE"REATHING
.OT0ROPERLY".0 MULTINATIONALSTUDY*!M#OLL#ARDIOL
 n
 (UBERT(" &EINLEIB- -C.AMARA0-AND#ASTELLI70
 /BESITYASANINDEPENDENTRISKFACTORFORCARDIOVASCULAR
DISEASEA YEARFOLLOW UPOFPARTICIPANTSINTHE&RAMINGHAM
(EART3TUDY#IRCULATION  -%$,).%
 %CKEL2( "AROUCH77 %RSHOW!'2EPORTOFTHE.ATIONAL
(EART ,UNG AND"LOOD)NSTITUTE .ATIONAL)NSTITUTEOF$IABETES
AND$IGESTIVEAND+IDNEY$ISEASES7ORKING'ROUPONTHE
0ATHOPHYSIOLOGYOF/BESITY !SSOCIATED#ARDIOVASCULAR$ISEASE
#IRCULATION n
 !LPERT-! ,AMBERT#2AND0ANAYIOTOU(ETAL
2ELATIONOFDURATIONOFMORBIDOBESITYTOLEFTVENTRICULARMASS
SYSTOLICFUNCTION ANDDIASTOLIClLLING ANDEFFECTOFWEIGHTLOSS
!M*#ARDIOL  -%$,).%
 +ENCHAIAH3 %VANS*#AND,EVY$ETAL /BESITYAND
THERISKOFHEARTFAILURE.%NGL*-ED  
 3ARZANI2 $ESSI &ULGHERI0 0ACI6- %SPINOSA%AND
2APPELLI!* %XPRESSIONOFNATRIURETICPEPTIDERECEPTORSIN
HUMANADIPOSEANDOTHERTISSUES*%NDOCRINOL)NVEST  
-%$,).%
 3ENGENES# "ERLAN- $E'LISEZINSKI) ,AFONTAN-AND
'ALITZKY* .ATRIURETICPEPTIDESANEWLIPOLYTICPATHWAYIN
HUMANADIPOCYTES&!3%"*  -%$,).%
 -EHRA-2 5BER0! 0ARK- ETAL/BESITYANDSUPPRESSED" TYPE
NATRIURETICPEPTIDELEVELSINHEARTFAILURE*!##  n

 +IKUTA+ 9ASUE( 9OSHIMURA- ETAL)NCREASEDPLASMALEVELS
OF" TYPENATRIURETICPEPTIDEINPATIENTSWITHUNSTABLEANGINA!M
(EART* n

 4ALWAR3 3QUIRE)" $OWNIE0& ETAL0LASMA.TERMINALPRO


BRAINNATRIURETICPEPTIDEANDCARDIOTROPHINARERAISEDINUNSTABLE
ANGINA(EART n
 DE,EMOS*! -ORROW$! "ENTLEY*( ETAL4HEPROGNOSTIC
VALUEOF" TYPENATRIURETICPEPTIDEINPATIENTSWITHACUTECORONARY
SYNDROMES.%NGL*-ED n
 (ARRISON! -ORRISON,+ +RISHNASWAMY0 ETAL" TYPE
NATRIURETICPEPTIDE".0 PREDICTSFUTURECARDIACEVENTSINPATIENTS
PRESENTINGTOTHEEMERGENCYDEPARTMENTWITHDYSPNEA!NN%MERG
-ED n
 #OLUCCI7 %LKAYAM5 (ORTON$ ETAL)NTRAVENOUSNESIRITIDE A
NATRIURETICPEPTIDE INTHETREATMENTOFDECOMPENSATEDCONGESTIVE
HEARTFAILURE.%NGL*-ED n
 3ILVER-! (ORTON$0 'HALI*+ ETAL%FFECTOFNESIRITIDEVERSUS
DOBUTAMINEONSHORT TERMOUTCOMESINTHETREATMENTOFPATIENTS
WITHACUTELYDECOMPENSATEDHEARTFAILURE*!M#OLL#ARDIOL
 n
 "URGER! (ORTON$ ,E*EMTEL4%FFECTSOFNESIRITIDE" TYPE
NATRIURETICPEPTIDE ANDDOBUTAMINEONVENTRICULARARRHYTHMIAS
INTHETREATMENTOFPATIENTSWITHACUTELYDECOMPENSATED
CONGESTIVEHEARTFAILURETHE02%#%$%.4STUDY!M(EART*
 n
 0UBLICATION#OMMITTEEFORTHE6-!#)NVESTIGATORS6ASODILATORS
INTHE-ANAGEMENTOF!CUTE(& )NTRAVENOUSNESIRITIDEVS
NITROGLYCERINFORTREATMENTOFDECOMPENSATEDCONGESTIVEHEART
FAILUREARANDOMIZEDCONTROLLEDTRIAL*!-! n

 !$(%2%3CIENTIlC!DVISORY#OMMITTEE4HE!CUTE
$ECOMPENSATED(EART&AILURE.ATIONAL2EGISTRY!$(%2% 
OPPORTUNITIESTOIMPROVECAREOFPATIENTSHOSPITALIZEDWITHACUTE
DECOMPENSATEDHEARTFAILURE2EV#ARDIOVASC-ED SUPPL
 3n3
 -EHRA-2 5BER0! 0OTLURI3 6ENTURA(/ 3COTT2, 0ARK-(
5SEFULNESSOFANELEVATEDB TYPENATRIURETICPEPTIDETOPREDICT
ALLOGRAFT
 #HENG6, +RISHNASWAMY0 +AZANEGRA2 ETAL!RAPIDBEDSIDE
TESTFOR" TYPENATRIURETICPEPTIDEPREDICTSTREATMENTOUTCOMESIN
PATIENTSADMITTEDWITHDECOMPENSATEDHEARTFAILURE*!M#OLL
#ARDIOL n

#OPYRIGHT%-#2%' )NTERNATIONAL 




,"1    -,"
/   , /" , -/,9
7ILLIAM4!BRAHAM -$
#HIEF $IVISIONOF#ARDIOVASCULAR-EDICINE
4HE/HIO3TATE5NIVERSITY#OLLEGEOF-EDICINE
#OLUMBUS /(

" 
/6 -\
iVLiii`>`Vivi  , i}
iVLiw`}vi  , i}V>Lii``iV>`iV>i
v >i

 /," 1
/"
!CUTEDECOMPENSATEDHEARTFAILURE!$(& REPRESENTSAMAJORPUBLICHEALTHPROBLEM
)NTHE5NITED3TATES THEREAREAPPROXIMATELYMILLIONHOSPITALIZATIONSANNUALLYWITH
APRIMARYDISCHARGEDIAGNOSISOF!$(&.EARLYTWICEASMANYHOSPITALIZATIONSAREAS
SOCIATEDWITHHEARTFAILURE ASASECONDARYDIAGNOSIS4HESENUMBERSAREEXPECTEDTO
INCREASEOVERTHENEXTTWODECADES (EARTFAILURETAKESAPARTICULARLYHIGHTOLLONTHE
ELDERLY3INCETHEEARLYS !$(&HASBEENTHELEADINGCAUSEOFHOSPITALIZATIONIN
PERSONSOVERTHEAGEOFYEARS2EPORTEDDEATHRATESAPPEAREXCESSIVEBOTHDURING
ANDAFTERHOSPITALIZATIONANDHIGHREADMISSIONRATESSUGGESTTHATINPATIENTCAREDOESNOT
RESULTINEFFECTIVELONG TERMMANAGEMENT 4HEENORMOUSDIRECTCOSTSASSOCIATEDWITH
TREATINGTHEMILLION!MERICANSWITHCHRONICHEARTFAILUREAREMOSTLYATTRIBUTABLETO
THEINPATIENTMANAGEMENTOFEPISODESOFDECOMPENSATION)THASBEENPROPOSEDTHAT
THESEDISMALSTATISTICSEXIST INPART DUETOAPOORUNDERSTANDINGOFTHECHARACTERISTICS
OFPATIENTSADMITTEDWITH!$(&ANDHOWTOTREATTHEM)NTHISREGARD MOSTINFORMA
TIONABOUT!$(&ISDERIVEDFROMCLINICALTRIALSTHATARESMALLHUNDREDSOFPATIENTS
ANDPOORLYREPRESENTATIVEOFPATIENTSHOSPITALIZEDFOR!$(& DUETOTHEMANYINCLUSION
ANDEXCLUSIONOFSUCHTRIALS
!FEWREGISTRIESHAVEBEENDEVELOPEDTOEVALUATECHRONICHEARTFAILUREINTHEOUTPA
TIENTCOMMUNITYSETTING 4HE!CUTE$ECOMPENSATED(EART&AILURE.ATIONAL2EGISTRY
!$(%2% WASDEVELOPEDTOPROVIDEALARGE NATIONALDATABASEDESCRIBINGTHECLINICAL
CHARACTERISTICS PHYSICIAN PRACTICE AND TREATMENT PATTERNS AND OUTCOMES OF PATIENTS
HOSPITALIZEDWITH!$(&
-ETHODOLOGYOF!$(%2%
!$(%2% IS A LARGE MULTICENTER REG
ISTRY DESIGNED TO AMASS A LARGE CLINICAL
DATABASE ON THE CLINICAL CHARACTERISTICS
MANAGEMENT AND OUTCOMES OF PATIENTS
HOSPITALIZEDFOR!$(&ACROSSTHE5NITED

3TATES$ATAARECOLLECTEDONTHEEPISODE
OF HOSPITALIZATION BEGINNING WITH THE
POINTOFINITIALCAREANDENDINGWITHTHE
PATIENTS DISCHARGE TRANSFER OUT OF THE
HOSPITAL OR IN HOSPITAL DEATH!$(%2%
IS SPONSORED BY 3CIOS )NC &REMONT

/iVi
iVi>i`
i>>i >>
,i}  ,
>`iii`
`i>>}i]>>
`>>L>i`iVL}i
VV>V>>ViV]
V>>VVi>`
i>i>i]
>`Viv
>i>i`
 



%MERGENCY$IAGNOSISAND4REATMENTOF
!CUTE$ECOMPENSATED(EART&AILURE!$(&

#ALIFORNIA 4HESPECIlCOBJECTIVESOF!$(%2%ARE
 TODESCRIBETHEDEMOGRAPHICANDCLINICALCHARAC
TERISTICSOFPATIENTSWHOAREHOSPITALIZEDWITH!$(&
INCLUDINGSPECIlCSUBGROUPSOFINTEREST TOCHAR
ACTERIZETHEINITIALEMERGENCYDEPARTMENTEVALUATION
AND SUBSEQUENT INPATIENT MANAGEMENT OF PATIENTS
HOSPITALIZEDWITH!$(& TOIDENTIFYPATIENTCHAR
ACTERISTICSANDMEDICALCAREPRACTICESASSOCIATEDWITH
IMPROVED HEALTH OUTCOMES IN PATIENTS HOSPITALIZED
WITH!$(&  TO CHARACTERIZE TRENDS OVER TIME IN
THEMANAGEMENTOF!$(&AND TOASSISTHOSPITALS
IN EVALUATING AND IMPROVING QUALITY OF CARE FOR PA
TIENTSHOSPITALIZEDWITHHEARTFAILURE!DDITIONALGOALS
OF!$(%2%INCLUDEDEVELOPMENTOFPREDICTIVEMOD
ELS FOR MORTALITY COMPLICATIONS AND LENGTH OF HOS
PITALSTAYANDTOLINKWITHDE IDENTIlEDDATAONLON
GITUDINALTRENDSINTHECLINICALCAREANDOUTCOMESOF
REGISTRYPATIENTS!GGREGATEDATAFROMTHE!$(%2%
DATABASE IS ALSO USED FOR THE OBSERVATIONAL STUDY OF
TREATMENTEFFECTS
3ITES WERE SELECTED TO REPRESENT THE hREAL WORLDv OF
!$(& 3ITES INCLUDED BOTH ACADEMIC  HOSPITALS
ANDNONACADEMICHOSPITALS HOSPITALSANDWERE
GEOGRAPHICALLY DIVERSE INCLUDING  HOSPITALS IN THE
.ORTHEASTERN5NITED3TATES HOSPITALSINTHE3OUTH
HOSPITALSINTHE-IDWEST HOSPITALSINTHE7EST
ANDHOSPITALSINTHE-ID !TLANTICREGION3OMEOF
THE LARGEST ACUTE CARE HOSPITALS IN THE 5NITED 3TATES
AREPARTICIPATINGBUTSITESAREDIVERSEINSIZE RANGING
FROMTOBEDS3ITESAREREIMBURSEDANOMINAL
FEEFOREACHCOMPLETEDCASEREPORTFORM
&ORTHEPURPOSEOFTHISREGISTRY !$(&ISDElNEDAS
EITHER NEW ONSET HEART FAILURE OR DECOMPENSATION OF
CHRONIC ESTABLISHEDHEARTFAILUREWITHSYMPTOMSSUF
lCIENT TO WARRANT HOSPITALIZATION 0ATIENTS ARE IDEN
TIlED FOR INCLUSION IN THE REGISTRY FROM ADMISSIONS
GIVENADISCHARGEDIAGNOSISOFHEARTFAILUREBASEDON
)NTERNATIONAL#LASSIlCATIONOF$ISEASES .INTH2EVI



SION)#$  CODING%LIGIBILITYISNOTCONTINGENTON
THEUSEOFANYPARTICULARTHERAPEUTICAGENTORREGIMEN
0ATIENTSMAYBEMALEORFEMALEANDMUSTBEATLEAST
 YEARS OLD AT THE TIME OF HOSPITAL ADMISSION 4HE
REGISTRYISACCUMULATINGDATAONINDIVIDUALHOSPITAL
IZATIONS NOTINDIVIDUALPATIENTS ANDITISPOSSIBLETHAT
SOME PATIENTS MAY BE ENROLLED IN THE REGISTRY MORE
THANONCE4HEGOALOFTHEREGISTRYISTOENROLLAREPRE
SENTATIVEPATIENTSAMPLE3ITESAREENCOURAGEDTOENROLL
ADMISSIONSMEETINGENTRYCRITERIAASCONSECUTIVELYAS
POSSIBLE(OSPITALSWITHMORETHANELIGIBLEPATIENTS
INAMONTHAREALLOWEDTOENROLLARANDOMSAMPLEOF
THESECONSECUTIVEADMISSIONSUSINGA*OINT#OMMIS
SION FOR !CCREDITATION OF (EALTHCARE /RGANIZATIONS
*#!(/ nAPPROVEDSAMPLINGMETHOD3PECIlCATIONS
-ANUALFOR.ATIONAL)MPLEMENTATIONOF(OSPITAL#ORE
-EASURES *#!(/  SECTION 
$ATAARECOLLECTEDBYCHARTREVIEWANDENTEREDUSING
A WEB BASED ELECTRONIC DATA CAPTURE %$# SYSTEM
DESIGNEDBY0HASE&ORWARD7ALTHAM -ASS ANDLI
CENSED BY THE STUDY CONTRACT RESEARCH ORGANIZATION
0HARMA,INK&()2ESEARCH4RIANGLE .# $ATAARE
RECORDED CONCERNING DEMOGRAPHICS MEDICAL HIS
TORY NON INTRAVENOUS AND INTRAVENOUS CARDIOVASCU
LAR MEDICATIONS INITIAL EVALUATION AT SITE HOSPITAL
CHRONICINFUSIONTHERAPY HOSPITALCOURSE DISPOSITION
AND PROCEDURES )NFORMATION RELATED TO FOUR SPECIlC
ASPECTSOFTHE*#!(/QUALITYIMPROVEMENTINITIATIVE
FORHEARTFAILUREAREALSOCAPTURED PATIENTINSTRUC
TIONONDIET WEIGHT ANDMEDICATIONMANAGEMENTAT
DISCHARGE ASSESSMENTOFLEFTVENTRICULARSYSTOLIC
FUNCTION DOCUMENTED OR SCHEDULED  ANGIOTENSIN
CONVERTINGENZYME!#% INHIBITORUSEATDISCHARGE
IN PATIENTS CONSIDERED CANDIDATES FOR THIS THERAPY
BASEDONACCEPTEDCLINICALCRITERIAAND COUNSEL
INGONSMOKINGCESSATIONINCURRENTSMOKERS(UMAN
SUBJECTS CONSIDERATIONS PATIENT CONlDENTIALITY SITE
MONITORING ANDOTHERSPECIlCMETHODOLOGICALISSUES
HAVEBEENPREVIOUSLYOUTLINEDINDETAIL ELSEWHERE


,"1    -,"
/   , /" , -/,9

)NSIGHTSFROM!$(%2%
&ROM/CTOBERTHROUGH$ECEMBER  
HEART FAILURE DISCHARGES WERE ENROLLED IN!$(%2%
4HE MEAN AGE OF PATIENTS WAS  YEARS AND 
WEREWOMEN-OSTPATIENTSWEREWHITE ORBLACK
 AND WERE COVERED BY -EDICARE OR -EDICAID
 3EVENTY SIXPERCENTOFPATIENTSENROLLEDHADA
PRIORHISTORYOFHEARTFAILUREANDONE THIRDHADAHISTO
RYOFADMISSIONFOR!$(&WITHINTHEPRIORMONTHS
!HISTORYOFHYPERTENSIONWASCOMMON ASWAS
CORONARY ARTERY DISEASE  AND DIABETES  
/THER IMPORTANT OR COMMON CO MORBID CONDITIONS
INCLUDED HISTORY OF ATRIAL lBRILLATION  CHRONIC
OBSTRUCTIVE PULMONARY DISEASE OR ASTHMA 
ANDCHRONICRENALINSUFlCIENCY -OSTPATIENTS
 PRESENTEDWITHDYSPNEA2ALESANDPERIPHERAL
EDEMA WERE PRESENT IN  AND  OF THE CASES
RESPECTIVELY /F PATIENTS WITH DOCUMENTED LEFT VEN
TRICULAREJECTIONFRACTIONPRIORTOADMISSION HAD
PRESERVEDORONLYMILDLYDEPRESSEDSYSTOLICFUNCTION
4HECHARACTERISTICSOFPATIENTSENROLLEDIN!$(%2%
AREVERYDIFFERENTFROMTHOSEOFPATIENTSINCLUDEDIN
CLINICALTRIALSQ/>LiR

/>Li

>v*>i i`,>`i`

i`/>v 6i  ,

4HEMEDIANLENGTHOFSTAYFORALLHOSPITALIZEDPATIENTS
WASDAYSMEANDAYS4HEIN HOSPITALMORTAL
ITY RATE WAS   FOR PATIENTS WHO RECEIVED
TREATMENT IN AN INTENSIVE CARE UNIT )#5  2EGISTRY
DATAONTHE*#!(/QUALITYOFCAREINDICATORSSHOWED
THAT ONLY  OF PATIENTS WERE GIVEN INSTRUCTION ON
DIET WEIGHT MONITORING ACTIVITY LEVEL WORSENING
SYMPTOMS FOLLOW UP APPOINTMENTS AND MEDICATION
MANAGEMENT AT DISCHARGE !SSESSMENT OF LEFT VEN
TRICULAR SYSTOLIC FUNCTION WAS EITHER DOCUMENTED OR
SCHEDULEDINOFPATIENTS!TOTALOFOFTHE
PATIENTS JUDGED ELIGIBLE TO RECEIVE AN!#% INHIBITOR
BYSTANDARDCLINICALCRITERIAWEREDISCHARGEDONTHIS
MEDICATION#OUNSELINGONSMOKINGCESSATIONFORCUR
RENTSMOKERSWASGIVENTOOFELIGIBLEPATIENTS
!$(%2%-ORTALITY!NALYSES
4ODATE TWOPRIMARYANALYSESOFMORTALITYHAVEBEEN
PERFORMEDON!$(%2%4HESEINCLUDEACLASSIlCATION
ANDREGRESSIONTREE#!24 ANALYSISINALLPATIENTSTO
DElNECOVARIATEADJUSTEDODDSRATIOSOFDEATH AND
AMULTIVARIABLEREGRESSIONANDPROPENSITYANALYSISIN
PATIENTS RECEIVING )6 VASOACTIVE MEDICATIONS TO DE
lNECOVARIATEADJUSTEDPROBABILITYOFTREATMENT 
4HEFORMERANALYSISALLOWSTHEDEVELOPMENTANDVALI
DATIONOFAPREDICTIVEMODELFORIN HOSPITALMORTALITY
BASEDONPATIENTCHARACTERISTICSDISCERNEDATTHETIME

#HARACTERISTIC

#LINICAL4RIALS

!$(%2%

!VERAGE!GEYEARS

 



'ENDER7OMEN

 



)SCHEMIC%TIOLOGY





2ENAL)NSUFlCIENCY

5SUALLYEXCLUDED



0RESERVED,63YSTOLIC&UNCTION

5SUALLYEXCLUDED



!TRIAL&IBRILLATION





$IABETES

 





%MERGENCY$IAGNOSISAND4REATMENTOF
!CUTE$ECOMPENSATED(EART&AILURE!$(&

OFPRESENTATION4HATIS THE#!24ANALYSISPROVIDES
nFORTHElRSTTIMEnAWAYTOSTRATIFYPATIENTSFORRISK
OF IN HOSPITAL MORTALITY 4HE LATTER ANALYSIS PERMITS
THECOMPARISONOFTREATMENTCHOICEONOUTCOME3PE
CIlCALLY THECOVARIATEANDPROPENSITYSCOREADJUSTED
RISKOFIN PATIENTMORTALITYWASEVALUATEDBYTREATMENT
STATUSCOMPARINGINTRAVENOUSDOBUTAMINE MILRINONE
NESIRITIDE ANDNITROGLYCERINE
)NORDERTODEVELOPAPRACTICALUSER FRIENDLYBEDSIDE
TOOL FOR RISK STRATIlCATION FOR PATIENTS HOSPITALIZED
WITH!$(& #!24 ANALYSIS OF THE!$(%2% DATA
BASEWASPERFORMEDUSINGTHElRST DISCHARGES
ENROLLED 4HE lRST   HOSPITALIZATIONS FROM
/CTOBERTHROUGH&EBRUARY SERVEDASTHE
DERIVATION COHORT AND WERE ANALYZED TO DEVELOP THE
RISKPREDICTIONMODEL4HEN THEVALIDITYOFTHEMODEL
WASPROSPECTIVELYTESTEDUSINGDATAFROM SUB
SEQUENT HOSPITALIZATIONS VALIDATION COHORT ENROLLED
IN!$(%2%FROM-ARCHTHROUGH*ULY)N
HOSPITALMORTALITYWASSIMILARINTHEDERIVATION
ANDVALIDATION COHORTS2ECURSIVEPARTITIONING
OFTHEDERIVATIONCOHORTFORVARIABLESINDICATEDTHAT
THE BEST SINGLE PREDICTOR FOR MORTALITY WAS HIGH AD
MISSIONLEVELSOFBLOODUREANITROGEN*MGD,

}i
  , ,
ii/iiv

,/>`>i`
v>i>]
x\x
xni
viiV>
i`V>V>

FOLLOWED BY LOW ADMISSION SYSTOLIC BLOOD PRESSURE


  MM (G AND THEN BY HIGH LEVELS OF SERUM
CREATININE*MGD, !SIMPLERISKTREEIDENTI
lEDPATIENTGROUPSWITHMORTALITYRANGINGFROM
TO  }i  4HE ODDS RATIO FOR MORTALITY
BETWEENPATIENTSIDENTIlEDASHIGHANDLOWRISKWAS
CONlDENCEINTERVAL   ANDSIMI
LARRESULTSWERESEENWHENTHISRISKSTRATIlCATIONWAS
APPLIEDPROSPECTIVELYTOTHEVALIDATIONCOHORT4HESE
RESULTS SUGGEST THAT!$(& PATIENTS AT LOW INTERME
DIATE AND HIGH RISK FOR IN HOSPITAL MORTALITY CAN BE
EASILYIDENTIlEDUSINGVITALSIGNANDLABORATORYDATA
OBTAINED ON HOSPITAL ADMISSION 4HE!$(%2% RISK
ASSESSMENTTOOLPROVIDESCLINICIANSWITHAVALIDATED
PRACTICALBEDSIDEINSTRUMENTFORMORTALITYRISKSTRATI
lCATION3IMILARTOTHECONTEMPORARYAPPROACHTOTHE
TRIAGEANDMANAGEMENTOFCHESTPAINPATIENTSBASEDON
RISKASSESSMENTATPRESENTATION THE!$(%2%#!24
ANALYSISMAYULTIMATELYHELPDIRECTTHEPLACEMENTAND
THERAPYOFPATIENTSPRESENTINGWITH!$(&
4O COMPARE IN HOSPITAL MORTALITY OF!$(& PATIENTS
RECEIVINGPARENTERALTREATMENTWITHONEOFFOURINTRA
VENOUSVASOACTIVEMEDICATIONS ARETROSPECTIVEANAL
YSIS OF DATA FROM !$(%2% WAS PERFORMED $ATA

 


 


 








 

 
 

 

 





 


 

  


 







 




,"1    -,"
/   , /" , -/,9

WITH MILRINONE AND DOBUTAMINE RESPECTIVELY 4HE


CORRESPONDING VALUES FOR NESIRITIDE COMPARED WITH
MILRINONE AND DOBUTAMINE WERE  n P
) ANDn P) RESPECTIVELY
4HEADJUSTED/2FORNESIRITIDECOMPAREDWITHNITRO
GLYCERINWASn P 4HUS THERA
PYWITHEITHERANATRIURETICPEPTIDEORVASODILATORWAS
ASSOCIATED WITH SIGNIlCANTLY LOWER IN HOSPITAL MOR
TALITY THAN POSITIVE INOTROPIC THERAPY IN HOSPITALIZED
!$(&PATIENTSIN!$(%2%4HERISKOFIN HOSPITAL
MORTALITYWASSIMILARFORNESIRITIDEANDNITROGLYCERIN
/>Li  4HESE OBSERVATIONS ARE CONSISTENT WITH
lNDINGS FROM RANDOMIZED CONTROLLED TRIALS AND SUP
PORT THE USE OF VASODILATORS NESIRITIDE OR NITROGLYC
ERIN ASlRST LINEINTRAVENOUSAGENTSFORTHETREATMENT
OF!$(&4HESELECTIONOFASPECIlCINTRAVENOUSVA
SODILATORMAYBEGUIDEDBYTHERESULTSOFRANDOMIZED
CONTROLLEDTRIALS/FCOURSE INOTROPESMAYSTILLPLAY
AROLEFORTHOSEWHOPRESENTINORINIMPENDINGCAR
DIOGENICSHOCK

FROMTHElRST PATIENTEPISODESFROM/CTOBER
THROUGH*ULY WEREINCLUDEDINTHISANALY
SIS #ASES IN WHICH PATIENTS RECEIVED NITROGLYCERIN
NESIRITIDE MILRINONE OR DOBUTAMINE WERE IDENTIlED
ANDREVIEWEDN  TODETERMINEIFTHECHOICE
OFINTRAVENOUSVASOACTIVETHERAPYAFFECTEDIN HOSPITAL
MORTALITY3INCETHECHOICEOFTHERAPYWASNOTDIRECT
EDBYAPROTOCOLBUTBYCLINICIANJUDGMENTORPREFER
ENCE PROPERADJUSTMENTBASEDONFACTORSINmUENCING
TREATMENT DECISION USING ADJUSTMENT FOR COVARIATES
ANDPROPENSITYSCORING WEREMADE2ISKFACTORAND
PROPENSITY SCORE ADJUSTED ODDS RATIOS /2S FOR IN
HOSPITALMORTALITYWERECALCULATED
0ATIENTS WHO RECEIVED INTRAVENOUS NITROGLYCERIN OR
NESIRITIDEHADLOWERIN HOSPITALMORTALITYTHANTHOSE
TREATEDWITHDOBUTAMINEORMILRINONE4HERISKFACTOR
ANDPROPENSITYSCORE ADJUSTED/2SFORNITROGLYCERIN
WERECONlDENCEINTERVAL;#)=n
P) ANDn P) COMPARED

/>Li
>"``,>*>7i/i>i
>i  , ,i}
,ii`ivL>>i>]

x*i
!NALYSIS


.4'N
VS
-),N

.4'N
VS
$/"N

.%3N
VS
-),N

.%3N
VS
$/"N

.%3N
VS
.4'N

$/"N
VS
-),N

5NADJUSTED

  o

  o

  o

  o

  o

  o

!DJUSTEDFORCOVARIATES\\

  o

  o

  o

  o

  p

  e

!DJUSTEDFORCOVARIATES
ANDPROPENSITYSCOREr

  o

  o

  o

  o

  p

  e

XCLUDEFROMAHPI TNSKGBW
0

WISEANLY

ATION DYSPE123MUR 6%& 5. ," 3"0 -), .4'VS

P  
p
P 
e
P    OR F AR ITE V CO ADJUSTMEN AND   OR F AR ITE V CO AND
SCORE
ADJUSTMEN
SODIUM5.CREATN" \ $"0 X 3"0ASERITNCLUDGV#O
AND YSP E 
r
YTREAMNCOPISLUDHBV#
6%& EIGHT ,WA5.CRNSODUM" 3"0 $/ .%VS
EIGHT DYSPNAW 6%& ,AGE 3"0 -), .%VS
AT SYMPODUR 6%& 5. HEARSODIUM",T 3"0 $/ .4'VS

PROENSITY
HEAR T
ISONARE
ED MA
ION

ASCULRIZTONVEP
ED NOITARUMPYS &%6 , ENITARC.5" 0"3 '4. SV3%
123MS
 64& HEMOGLBINARDYSPT 3"0 -), $/VS
.OTE
W(OSMER ,H GDNFlT ES NOT SIGlCA T ELV
MODELS ADJUSTE ORF RISK ACTOF ANDOR PROENSITYXC F
$/"COMPAR!EISNUDWHT.4V'
U L T I" PE C A S RO F W M N     H G
ERONICTSDGlAU"FW
5."  LODB UREA NITOG$"0  DIASTOLC B PRESU$/"
-),  MILRNOE .%3  NESIRTD .4'  NITROGLYCE /2  OD
YCARDIlBLTENUH64&V LODPRSYTICB

MS
RP AM &( OI
S ORF THE
ARITE DJUSVCO
ATORPECUV
AL U E S     Y P V
 UTAMINE DOB
DS ATIO R 3"0 
ION



%MERGENCY$IAGNOSISAND4REATMENTOF
!CUTE$ECOMPENSATED(EART&AILURE!$(&

-1,9

,  ,
-

2EGISTRIES SUCH AS !$(%2% MAY PROVIDE INSIGHTS


THATCANNOTBEDISCERNEDFROMRANDOMIZEDCONTROLLED
TRIALS(EARTFAILUREPATIENTSENROLLEDINCLINICALTRIALS
ARE VERY DIFFERENT THAN HEART FAILURE PATIENTS IN THE
COMMUNITY AS DEMONSTRATED BY THE CHARACTERISTICS
OF MORE THAN   DISCHARGES FOR!$(& IN!$
(%2% 4HE !$(%2% REGISTRY PROVIDES IMPORTANT
INSIGHTSINTO!$(&TREATMENTANDOUTCOMESTHATMAY
FAVORABLYIMPACTFUTURECARE3PECIlCALLY ITPROVIDES
USWITHAVALUABLERISK ASSESSMENTTOOLANDWITHIN
SIGHTSINTOTHEEFFECTSOFTREATMENTSELECTIONONOUT
COMESIN!$(&PATIENTS



"ONNEUX, "ARENDREGT** -EETER+ ETAL%STIMATINGCLINICAL


MORBIDITYDUETOISCHEMICHEARTDISEASEANDCONGESTIVEHEART
FAILURETHEFUTURERISEOFHEARTFAILURE!M*0UBLIC(EALTH
 



'HALI*+ #OOPER2 &ORD%4RENDSINHOSPITALIZATIONRATES


FORHEARTFAILUREINTHE5NITED3TATES  EVIDENCEFOR
INCREASINGPOPULATIONPREVALENCE!RCH)NTERN-ED




!MERICAN(EART!SSOCIATIONHEARTANDSTROKESTATISTICAL
UPDATE$ALLAS4EX !MERICAN(EART!SSOCIATION



#UFFE-3 #ALIFF2- !DAMS+& ETAL3HORT TERMINTRAVENOUS


MILRINONEFORACUTEEXACERBATIONOFCHRONICHEARTFAILUREA
RANDOMIZEDCONTROLLEDTRIAL*!-! 



+RUMHOLZ(- 0ARENT%- 4U. ETAL2EADMISSIONAFTER


HOSPITALIZATIONFORCONGESTIVEHEARTFAILUREAMONG-EDICARE
BENElCIARIES!RCH)NTERN-ED 



/#ONNELL*"4HEECONOMICBURDENOFHEARTFAILURE#LIN#ARDIOL
3UPPL )))  



4HE3/,6$)NVESTIGATORS3TUDIESOFLEFTVENTRICULARDYSFUNCTION
3/,6$ RATIONALE DESIGNANDMETHODSTWOTRIALSTHATEVALUATE
THEEFFECTOFENALAPRILINPATIENTSWITHREDUCEDEJECTIONFRACTION
!M*#ARDIOL 



&RANCIOSA*! !BRAHAM74 &OWLER- ETAL2ATIONALE DESIGNAND


METHODSFORACOREGCARVEDILOL HEARTFAILUREREGISTRY#/(%2% 
*#ARD&AIL 



!DAMS+& /#ONNOR#- /REN2- ETAL$EVELOPMENTOFA


MULTICENTERHEARTFAILUREDATABASEINITIALREPORTFROMTHEUNITED
INVESTIGATORSTOEVALUATEHEARTFAILURE*#ARD&AIL 

!CKNOWLEDGMENTS
4HE!$(%2%3CIENTIlC!DVISORY#OMMITTEE !$(%2%
)NVESTIGATORSAND#OORDINATORS AND3CIOS)NC-EMBERSOF
THE!$(%2%3CIENTIlC!DVISORY#OMMITTEEARE7ILLIAM
4!BRAHAM -$ &!#0 &!## 4HE/HIO3TATE5NIVERSITY
(EART#ENTER #OLUMBUS /( +IRKWOOD&!DAMS *R -$
5NIVERSITYOF.ORTH#AROLINA #HAPEL(ILL .# 2OBERT,
"ERKOWITZ -$ 0H$ (ACKENSACK 5NIVERSITY (OSPITAL
(ACKENSACK .* -ARIA2OSA#OSTANZO -$ -IDWEST(EART
3PECIALISTS .APERVILLE ), 4ERESA$E-ARCO -$ 5NIVER
SITYOF#ALIFORNIA 3AN&RANCISCO #! #HARLES,%MERMAN
-$ #LEVELAND#LINIC #LEVELAND /( 'REGG#&ONAROW
-$ !HMANSON 5#,!#ARDIOMYOPATHY#ENTER ,OS!N
GELES #! -ARIE'ALVAO -3. !.0 # -ONTElORE-EDI
CAL#ENTER "RONX .9 *4HOMAS(EYWOOD -$ &!##
,OMA,INDA5NIVERSITY-EDICAL#ENTER ,OMA,INDA #!
4HIERRY(,E*EMTEL -$ !LBERT%INSTEIN(OSPITAL "RONX
.9 ,YNNE7ARNER3TEVENSON -$ "RIGHAMAND7OMENS
(OSPITAL "OSTON -! AND#LYDE79ANCY -$ &!##
5NIVERSITYOF4EXAS3OUTHWESTERN-EDICAL#ENTER-EDICAL
#ENTER $ALLAS 48

 !DAMS+& &ONAROW'# %MERMAN#, ETALFORTHE!$(%2%


3CIENTIlC!DVISORY#OMMITTEEAND)NVESTIGATORS#HARACTERISTICS
ANDOUTCOMESOFPATIENTSHOSPITALIZEDFORHEARTFAILUREINTHE
5NITED3TATESRATIONALE DESIGN ANDPRELIMINARYOBSERVATIONS
FROMTHElRST CASESINTHE!CUTE$ECOMPENSATED(EART
&AILURE.ATIONAL2EGISTRY!$(%2% !M(EART*

 &ONAROW'# !DAMS+& !BRAHAM74 9ANCY#7 FORTHE
!$(%2%3CIENTIlC!DVISORY#OMMITTEEAND3TUDY'ROUP2ISK
STRATIlCATIONFORIN HOSPITALMORTALITYINACUTELYDECOMPENSATED
HEARTFAILURECLASSIlCATIONANDREGRESSIONTREE#!24 ANALYSISOF
THE!$(%2%2EGISTRY*!-! 
 !BRAHAM74 !DAMS+& &ONAROW'# ETAL FORTHE!$(%2%
3CIENTIlC!DVISORY#OMMITTEEAND)NVESTIGATORSANDTHE!$(%2%
3TUDY'ROUP)N HOSPITALMORTALITYINPATIENTSWITHACUTE
DECOMPENSATEDHEARTFAILURETREATEDWITHINTRAVENOUSVASOACTIVE
MEDICATIONSANANALYSISFROMTHE!$(%2%2EGISTRY*!M#OLL
#ARDIOLINPRESS 
 0UBLICATION#OMMITTEEFORTHE6-!#)NVESTIGATORS)NTRAVENOUS
NESIRITIDEVSNITROGLYCERINFORTREATMENTOFDECOMPENSATED
CONGESTIVEHEARTFAILUREARANDOMIZEDCONTROLLEDTRIAL*!-!
 

#OPYRIGHT%-#2%' )NTERNATIONAL 



- -    /"
1/
"* -/  ,/
1, \/   ,  ,
9 
 " 1
2ICHARD,3UMMERS -$
$EPARTMENTOF%MERGENCY-EDICINE 5NIVERSITYOF-ISSISSIPPI-EDICAL#ENTER
*ACKSON -3

" 
/6 -\
,iiiiVi>iii>`Viii`v>iVi>i``i>i
>>}ii}>
ViLiVi]`i}>`}Vvi  , i}iVi`Vi`i

 /," 1
/"
!MAJORFACTORLIMITINGTHELONG TERMEFlCACYOFCURRENTCONGESTIVEHEARTFAILURE#(&
TREATMENT STRATEGIES IS A LACK OF COMPELLING DATA CONlRMING WHICH APPROACHES AND
THERAPIESWORKBESTINMOSTCLINICALSITUATIONS3TUDIESHAVESHOWNTHATTHECAREGIVEN
TO#(&PATIENTSVARIESWIDELY BASEDONTHELOCATIONWHEREPATIENTSRECEIVETREATMENT
ANDTHESPECIALTYOFTHEPHYSICIANWHOTREATSTHEM)NTHEABSENCEOFANYESTABLISHED
STANDARDSORBEST PRACTICEGUIDELINES PHYSICIANSHAVELITTLEEVIDENCEONWHICHTOBASE
TREATMENTDECISIONS"ECAUSEOFTHISLACKOFCONSENSUSSTANDARDS MANY#(&PATIENTS
RECEIVE LESS THAN OPTIMAL CARE4HE .ATIONAL 2EGISTRY!$(%2% IS THE lRST NATIONAL
REGISTRYTHATPROSPECTIVELYCOLLECTSOBSERVATIONALDATAFROMACROSSTHE5NITED3TATESIN
ORDERTOTRACKANDSTUDYTHEMEDICALMANAGEMENTOFPATIENTSHOSPITALIZEDWITHACUTE
DECOMPENSATEDHEARTFAILURE!$(& !$(%2%ISSPONSOREDBY3CIOSANDOVERSEEN
BYANINDEPENDENTSCIENTIlCADVISORYCOMMITTEEOFNATIONALLYRECOGNIZEDHEARTFAILURE
EXPERTS4ODATE MORETHANHOSPITALSANDMORETHAN PATIENTCASESHAVE
BEENENTEREDINTOTHE!$(%2%REGISTRY MAKINGITTHELARGEST MOSTEXTENSIVEREGISTRY
OFITSKIND

/i >>,i}
  , iw
>>i}>
iViViV

4HEORIGINALREGISTRYISREFERREDTOASTHE
#ORE 2EGISTRY !S INTEREST IN THE LONG
TERMOUTCOMESOFTHESEPATIENTSEMERGED
THE,ONGITUDINAL-ODULEWASDEVELOPED
TO FOLLOW THE COURSE OF THESE PATIENTS
BEYOND THE IMMEDIATE HOSPITALIZATION
AND INTO THE OUTPATIENT SETTING -ORE
RECENTLY THE!$(%2%$ISEASE-ANAGE
MENT 1UALITY )NITIATIVE FOR #ARE "EGIN
NINGINTHE%MERGENCY$EPARTMENT-OD
ULE!$(%2%%$$- WASINITIATEDTO
GIVE INSIGHT INTO THE TREATMENT PATTERNS
AND OVERALL QUALITY OF DISEASE MANAGE
MENT $- OF!$(& IN THE EMERGENCY
SETTING

$ISEASE-ANAGEMENT
4RADITIONAL APPROACHES TO THE TREATMENT
OFDISEASEHAVEBEENAhCOMPONENT BASED
MANAGEMENT MODELv WHEREBY SELECTED
PORTIONS OF THE DISEASE ARE MANAGED BY
CERTAIN SPECIALISTS THAT ADDRESS SPECIlC
ASPECTS OF THE PATIENTS ILLNESS )N THIS
SYSTEM THE INTERNIST OR CARDIOLOGIST FO
CUSES ON THE LONG TERM MANAGEMENT OF
#(&WHEREASTHEEMERGENCYPHYSICIANIS
CONCERNEDWITHTHEACUTESTABILIZATIONOF
ADECOMPENSATEDSTATE4HENEWERCON
CEPTSOFDISEASEMANAGEMENTINCORPORATE
THE ENTIRE SPECTRUM OF PATIENT CARE AND
INCLUDE THE FULL USE OF ANCILLARY HEALTH

Li>>`>>
v>Vi1i`
->i`i
>V>``i
i`V>>>}ii
v>i
>i`>Vi
`iVi>i`i>
v>i 



%MERGENCY$IAGNOSISAND4REATMENTOF
!CUTE$ECOMPENSATED(EART&AILURE!$(&

CAREANDSOCIALSERVICES"ECAUSE!$(&PATIENTSHAVE
ACOMBINATIONOFBOTHANACUTEANDCHRONICCONDITIONIT
ISIMPORTANTTOBEGINTOCONSIDERTHELONGITUDINALCOURSE
OFTHEIRMANAGEMENTEVENASWEBEGINTHESTABILIZATION
PROCESSINTHEEMERGENCYDEPARTMENT%$ 4HISCON
SIDERATIONHASBECOMEMOREIMPORTANTINRECENTYEARS
ASTHE%$HASBECOMETHESAFETY NETANDPRIMARYCARE
PROVIDERFORMANYOFTHESEPATIENTS)TISNOTUNCOM
MONFOR!$(&PATIENTSTOBECOMEFREQUENTPATIENTS
INOUREMERGENCYDEPARTMENTS"YDEFAULT THEEMER
GENCY PHYSICIAN THEN BECOMES RESPONSIBLE FOR THEIR
OVERALLCAREANDMUSTCONSIDERISSUESSUCHASACCESSTO
OUTPATIENTMEDICATIONS THERAMIlCATIONSOFTHEIRINPA
TIENTMANAGEMENTANDTHELONGITUDINALIMPACTOFEARLY
TREATMENT DECISIONS WITHIN THE EMERGENCY SETTING 
4HEREISCONSIDERABLEEVIDENCETOSUGGESTTHATTHETREAT
MENTPLANINITIATEDBYTHEEMERGENCYPHYSICIANHASA
SIGNIlCANTIMPACTONTHELONG TERMOUTCOMESOFOTHER
COMMON DISEASE PROCESSES SUCH AS PNEUMONIA AND
ACUTE CORONARY SYNDROMES )T IS REASONABLE TO EXPECT
THATTHESAMEWOULDBETRUEINTHETREATMENTOF!$(& 
4HERE ARE TYPICALLY THREE COMMON ELEMENTS TO ANY
WELL ORCHESTRATEDDISEASEMANAGEMENTPROGRAM
 )DENTIFYPATIENTSATELEVATEDRISKOFADVERSE
OUTCOMES
 )NTERVENTIONTOREDUCETHOSERISKS
 3YSTEMATICEVALUATIONTOASSESSTHEIMPACTOFTHE
INTERVENTION

}i
/iV}i>`y`ii
vii>v>i>i>
>>}V>`i
>`vV>->}6i
,ii>
"rV>`>V
6,rii



'OODDISEASEMANAGEMENTPRACTICEALSOREQUIRESTHE
PHYSICIANTOTHINKABOUTTHEPATIENTSPATHOLOGYFROM
BOTHTHESHORT TERMANDLONG TERMMANAGEMENTPER
SPECTIVES4HIS IS PARTICULARLY IMPORTANT WHEN TREAT
ING CHRONIC DISEASES SUCH AS #(& DUE TO THE DIFFER
ENCES IN THE PATHOPHYSIOLOGIC MECHANISMS INVOLVED
IN THE ACUTE AND CHRONIC PRESENTATIONS #(& IN ITS
ACUTELY DECOMPENSATED FORM IS PRIMARILY A PROBLEM
OFPLUMBING7ITHINTHEVASCULARCONDUITSINVOLVED
IN!$(& THEREISAMISMATCHINTHEPRESSURES RESIS
TANCESANDmUIDVOLUMESREQUIREDTOMAINTAINBLOOD
mOWORCARDIACOUTPUTWHICHFURTHERRESULTSINACON
GESTIVE STATE THAT LIMITS OXYGENATION BY THE LUNGS
4HISCONDITIONHASTHEPOTENTIALFORPOSITIVEFEEDBACK
ANDCANRAPIDLYSPIRALTOANUNSTABLESTATE4RADITIONAL
THERAPIESSUCHASNITROGLYCERIN MORPHINEANDDIURET
ICS CAN AMELIORATE THE CONGESTION BY MANIPULATION
OFTHEACUTEPLUMBINGDERANGEMENT4HERESULTISA
DRAMATIC CHANGE IN THE IMMEDIATE CLINICAL SITUATION
ANDTHEPATIENTOFTENAPPEARSALMOSTBACKTONORMAL
INTERMSOFSYMPTOMS(OWEVER DESPITETHISILLUSION
OFSTABILITY THECHRONICPATHOPHYSIOLOGYOF#(&AND
THE UNDERLYING CAUSE OF THE DECOMPENSATION IS STILL
PRESENT 4HECONGESTIONANDmUIDRETENTIONOFTHE
HEARTFAILURESTATEISANATURALPHYSIOLOGICADJUSTMENT
TO A DYSFUNCTIONAL 3TARLING 6ENOUS 2ETURN RELATION
SHIPANDISNECESSARYTOBRINGCARDIACOUTPUTBACKTO
NORMAL}i  4HECOSTOFTHISADJUSTMENTIS

- -    /"
1/
"* -/  ,/
1, \/   ,  ,
9 
 " 1

HIGHER ATRIAL PRESSURES THAT CAN LEAD TO


PULMONARY EDEMA AND DYSPNEA WHICH
BRINGS THE PATIENT ACUTELY TO THE %$ )F
THISMECHANISMISNOTTAKENINTOCONSID
ERATION IN THE DISPOSITION OF STABILIZED
!$(& PATIENT THEN THERE IS TREMENDOUS
POTENTIAL FOR OVERALL TREATMENT FAILURE
0ROPERDISEASEMANAGEMENTALSOREQUIRES
AGLOBALPERSPECTIVEOFALLASPECTSOFTHE
PATIENTSPATHOPHYSIOLOGYTOBESUCCESS
FUL
)N THE PAST FEW DECADES WE SAW AN EM
PHASISONANEVIDENCE BASEDAPPROACHTO
$-WITHAFOCUSONUTILIZINGRESULTSFROM
CLINICALTRIALSTODICTATETHEBESTTREATMENT
OPTIONSFORPATIENTSWITHSPECIlCDISEASE
STATES OR PRESENTATIONS -ORE RECENTLY
WEHAVEBEGUNTOREALIZETHENECESSITYOF
BALANCING THIS POPULATION BASED PROBA
BILISTIC VIEW OF TREATMENT WITH A SCIEN
TIlC ORIENTEDANALYSISOFTHEPHYSIOLOGIC
NUANCES OF THE INDIVIDUAL PATIENT IN A
GOALDIRECTEDAPPROACHTOMANAGEMENT
!$(&$-ISESPECIALLYAMENABLETOTHIS
NOTIONSINCETHEREISLITTLECURRENTTRIALS
BASED INFORMATION AND THE PATHOPHYSI
OLOGIC SPECTRUM OF DISEASE PRESENTATION
IS VARIED (OWEVER AS WE DEVELOP AN
EMERGENCYMEDICINE!$(&$-STRATEGY
ITISIMPORTANTTHATWELOOKATTHEPROCESS
AS A WHOLE AND THE IMPACT OF TREATMENT
PLANSONOUTCOMES
&ORALLTHESEREASONSAREGISTRYTHATTRACKS
THE COURSE OF PATIENTS WITH!$(& FROM
THEEMERGENCYMEDICINEPERSPECTIVECAN
BEINSTRUMENTALINDElNINGTHEBESTPRAC
TICESFORFUTURE$-

!$(%2%%MERGENCY-EDICINE
-ODULE
4HE !$(%2% %MERGENCY -EDICINE
-ODULE IS EXPECTED TO BE THE VEHICLE
THROUGH WHICH A COMPREHENSIVE DISEASE
MANAGEMENT PROCESS IS DEVELOPED FROM
THE UNIQUE PERSPECTIVE OF EMERGENCY
MEDICINEASASPECIALTY"UILDINGONPRIOR
!$(%2%PROGRAMS THISMODULEWASDE
SIGNEDBYEMERGENCYPHYSICIANSWITHTHE
INTENTIONOFANSWERINGSPECIlCQUESTIONS
OFINTERESTTOTHOSEMANAGING!$(&PA
TIENTSTHATPRESENTTOTHE%$ANDFOLLOWS
THEIRHOSPITALCOURSEANDOUTCOMES
0ROGRAM/BJECTIVES
4HEMAINOBJECTIVESOF!(%2%%$$-
ARE
 $EVELOPALARGECLINICAL!$(&
DATABASEFROMACUTECAREHOSPITALS
ACROSSTHE5NITED3TATES
 %XAMINETHECURRENTNATIONALSTATE
OFMEDICALMANAGEMENTOFPATIENTS
PRESENTINGTOTHE%$FOR!$(&
 #OMPAREPREPOSTOUTCOMESOF
IMPLEMENTATIONOFA$ISEASE
-ANAGEMENTPROGRAMFOR%$
PRESENTATIONSOF!$(&

i`ii>
ii}iVi`Vi
  >i}
>>i
>iVi>>
i>`i
>Vvi>i
>Vi

3OMEOFTHESECONDARYOBJECTIVESINCLUDE
 !SSISTHOSPITALSINEVALUATINGAND
IMPROVINGQUALITYOFCAREBY
A TRACKINGQUALITYINDICATORS
B PROVIDINGMONTHLYANDQUARTERLY
SITESPECIlCAND5NITED3TATES
BENCHMARKDATA
 #HARACTERIZETRENDSOVERTIMEINTHE
MANAGEMENTOF!$(&



%MERGENCY$IAGNOSISAND4REATMENTOF
!CUTE$ECOMPENSATED(EART&AILURE!$(&

 &ORTHE!$(&PATIENTINAN%$
SETTING
A $ESCRIBEDEMOGRAPHICANDCLINI
CALCHARACTERISTICSOF!$(&
B #HARACTERIZETHEINITIAL%$
EVALUATIONSUBSEQUENTMAN
AGEMENT
C )DENTIFYCHARACTERISTICSAND
MEDICALCAREASSOCIATEDWITH
IMPROVEDOUTCOMES

ivi
}>V`i\
/i>i>}
"`i-i
*V>,
i`V>
{ *>i `V>
x V>}iV
ii`L>V`>>
}

0ROGRAM$ESIGN
/VERVIEW4HE STUDY DESIGN IS THAT OF A
MULTI CENTER CONTINUOUS OBSERVATIONAL
QUALITY IMPROVEMENT INITIATIVE FOCUSING
ON THE MANAGEMENT OF PATIENTS TREATED
IN THE HOSPITAL FOR!$(& IN THE 5NITED
3TATES WITH AN EMPHASIS ON EMERGENCY
MEDICAL CARE )T IS EXPECTED THAT THERE
WILLAPPROXIMATELYHOSPITALSPARTICI
PATING CONTINUOUSLY ENROLLING PATIENTS
FORABOUTMONTHSORUPTO PA
TIENTEPISODES3ITESAREELIGIBLETOPAR
TICIPATE IF THEY ARE A CURRENT !$(%2%
SITEORIFTHEYAREINTHETOP LARGEST
5NITED3TATESACUTECAREHOSPITALSWITHA
MEDIANNUMBEROFANNUAL(&DISCHARGES
OF^PATIENTS3ELECTEDACADEMICAND
COMMUNITYHOSPITALSWILLBEEQUALLYDIS
TRIBUTEDALONGTHESPECTRUMOF(&PATIENT
VOLUMEANDGEOGRAPHY#OMPONENTSOF
THE%$$-PROGRAMINCLUDE









4REATMENTALGORITHMS
/RDER3ETS
0HYSICIAN2.EDUCATION
0ATIENT%DUCATION
$ISCHARGE)NSTRUCTIONS
&EEDBACKLOOPDATAMONITORING
TOOLS

0ATIENTPOPULATION0ATIENTELIGIBILITYIS
NOTLINKEDTOASPECIlCTHERAPEUTICAGENT
OR REGIMEN 0ATIENTS ELIGIBLE FOR ENTRY
INTOTHE!$(%2%2EGISTRYINCLUDETHOSE
OVER THE AGE OF  ADMITTED TO AN ACUTE
CARE HOSPITAL AND TREATED ACTIVELY FOR
!$(& EITHERASANEWONSETWITHDECOM
PENSATIONORASCHRONICHEARTFAILUREWITH
DECOMPENSATION4HISWOULDINCLUDETHOSE
PATIENTS WHO RECEIVE A PRINCIPAL %$ OR
HOSPITALDISCHARGEDIAGNOSISOF!$(&OR
ISDIAGNOSEDCLINICALLYANDISDOCUMENTED
INTHE$2'CODES0ATIENTSAREEXCLUDED
IF!$(&ISACOnMORBIDCONDITION BUTIS
NOTAPRINCIPALFOCUSOFDIAGNOSISORTREAT
MENTDURINGTHE%$ORHOSPITALEPISODE
3TAFFAND)NSTITUTIONALREQUIREMENTS
 3ITESMUSTCOMMITTOUTILIZINGA
$-STRATEGYANDWILLBEREQUIRED
TOIMPLEMENTATLEASTTHREEOFlVE
COMPONENTSLISTEDBELOW
 %ACHSITEMUSTHAVE
s /NE%$0HYSICIANASTHE0RINCIPAL
OR#O PRINCIPALINVESTIGATOR
s /NEDEDICATED2EGISTRY
#OORDINATOR
A 2EQUIRESACCESSTOALL%$AND
HOSPITALCHARTDATA
B #ANPERFORMELECTRONICDATA
CAPTURE%$# ENTRY
s )NPATIENTPHYSICIANSSUCHAS
CARDIOLOGISTS
A %NCOURAGEDTOPARTICIPATEAS
A#O PRINCIPALINVESTIGATOR
TOFACILITATEAFULLYINTEGRATED
$-1UALITY)MPROVEMENT
PROGRAM
s %$(&ALGORITHM
s (&ADMISSIONORDERS

- -    /"
1/
"* -/  ,/
1, \/   ,  ,
9 
 " 1

s 0ATIENTDISCHARGEINSTRUCTIONS
s 0HYSICIAN(&EDUCATION
s 0ATIENT(&EDUCATION
$ATA#OLLECTION4HE!$(%2%2EGISTRYISALARGE

DATABASEOFPRIMARYCLINICALINFORMATIONCOLLECT
EDFROMHOSPITALRECORDSOFPATIENTSATSELECTIN
STITUTIONSNATIONWIDE.OPRIORREGISTRYHASCON
DUCTEDRESEARCHATTHISLEVELONTHECLINICALCARE
OF PATIENTS WITH!$(& 5SING MEDICAL RECORDS
DATA ARE COLLECTED FROM THE POINT OF INITIAL CARE
THROUGHPATIENTDISCHARGEFROMTHEHOSPITAL4HE
REGISTRY IS COMPLETELY CONlDENTIAL AND ALL PA
TIENTDATAAREKEPTANONYMOUSTHROUGHENCRYPTED
TREATMENT$ATAINCLUDE

%
%
%
%
%
%
%
%

$EMOGRAPHICS
%-3DATA
-EDICALHISTORY
)NITIALMEDICALEVALUATION
(OSPITALCOURSE
-EDICATIONS
0ROCEDURES

% %$#SYSTEMACCESSISCONTROLLEDBYTHEDATA
COORDINATIONCENTERANDSYSTEMENTRYISLIMITED
BYUSERNAMEPASSWORDnPROTECTEDLOGON
PROCEDURES
% (OSPITALSWILLBEPREVENTEDFROMACCESSING
ELECTRONICCASEREPORTFORMSORAGGREGATEDATA
FROMANYHOSPITALOTHERTHANTHEIROWN
4OFOLLOWTHEPATIENTACROSSRECURRINGVISITSTHE,ON
GITUDINAL 5NIQUE )DENTIlER ,5)$ SYSTEM WILL BE
UTILIZEDFORCONlDENTIALITY
s

s

s

$ISPOSITION

4HEPROGRAMISDESIGNEDTOCOLLECTDATASURROUNDING
THEEPISODEOFHOSPITALCARETHATBEGINSINTHE%$AS
THEPOINTOFINITIALCAREANDENDSWITH%$ORHOSPITAL
DISCHARGE TRANSFERORDEATH)FTHEINSTITUTIONISALSO
APARTOFTHE!$(%2%CORETHEPATIENTMAYTRACKED
UP TO  DAYS AFTER ADMISSION $ATA ARE COLLECTED
THROUGHAN)NTERNET BASED%$#SYSTEM0ARTICIPATING
INSTITUTIONSENTERDATAUSINGASTANDARDWEBBROWSER
CONNECTEDTOAN%$#SYSTEMCUSTOMIZEDFORTHE!$
(%2%REGISTRY4HESYSTEMHASBEENFULLYTESTEDAND
ISCOMPLIANTWITHFEDERALREGULATIONS
% #&2 'UIDANCEON#OMPUTERIZED3YSTEMS
USEDIN#LINICAL4RIALS AND)#('#0GUIDELINES
% !LLSITESTAFFWILLBETRAINEDONTHESEREGULATIONS

s

#OMPUTERGENERATEDUNIQUEIDENTIlER
A ,5)$ENCRYPTIONUSESTHE53&EDERAL
3TANDARD3(! 
B 4HE,5)$ALGORITHMWILLBEINDEPENDENTLY
VALIDATEDBY"OOZ!LLEN (OMELAND3ECURITY
)NFORMATION!SSURANCE #IVIL"USINESS
3EGMENT
7ITHAGIVENSETOFVARIABLES A,5)$IS
GENERATEDTHATCANNOTBERELATEDBACKTOAN
INDIVIDUAL
0ATIENTLEVELVARIABLESUSEDTOCONSTRUCTTHE
,5)$ARENOTSTOREDINTHESYSTEM ANDTHIS
INFORMATIONCANNOTBEDE ENCRYPTEDFROMTHE
,5)$STOREDINTHEDATABASE
4HE,5)$ISSTOREDINTHEDATABASEALONGWITH
PATIENTDATAANDALLOWSFORLONGITUDINALTRACKING
OFHOSPITALREADMISSIONSANDPATIENTOUTCOMES

%NDPOINTS )N ORDER TO MEET THE OVERALL OBJECTIVES


OF THE 0ROGRAM A NUMBER OF SPECIlC ENDPOINTS ARE
TARGETEDFROMWITHINTHEDATACOLLECTIONPROCESS4HE
MOSTIMPORTANTOFTHESEAREASOFFOCUSINCLUDE
)MPACTOF$ISEASE-ANAGEMENT4OOLSON/UTCOMES
s ,ENGTHOFSTAY SYMPTOMATOLOGY
s 2ECIDIVISM TIMETOTREATMENT
$ISPOSITIONOF0ATIENT
s BASEDONPRESENTATIONPARAMETERSIE
#R



%MERGENCY$IAGNOSISAND4REATMENTOF
!CUTE$ECOMPENSATED(EART&AILURE!$(&

)MPACTOFDIURETICSRELATIVETOOUTCOMES
s $OSEANDTIMING
s $ElNINGWHICHPATIENTSARERESPONDERS
"I0!0#0!0
s )MPACTONDRUGTHERAPY
s )MPACTONSYMPTOMSOUTCOMES
s /XYGEN3ATURATIONS
2ESOURCEUTILIZATION
s "ENElTOFOBSERVATIONUNITS
4REATING0HYSICIANS
s 0RIMARY#ARE 3PECIALISTSAND#ONSULTANTS
1UALITY )NITIATIVE 4HE!$(%2% 2EGISTRY ISSUES A
"ENCHMARK2EPORTEACHQUARTERTOPARTICIPATINGCLIN
ICS AND HOSPITALS 4HESE REPORTS SUMMARIZE REGISTRY
DATACOLLECTEDONACUTEHEARTFAILURETREATMENTDURING
THE PREVIOUS YEAR 4HE REPORTS ALSO MAKE AVAILABLE
INSTITUTION SPECIlC REGIONAL AND NATIONAL STATISTICS
SUCHASQUALITYINDICATORS TOPARTICIPATINGHOSPITALS
INORDERTOHELPTHEMEVALUATEANDIMPROVETHECARE
THEYPROVIDETOPATIENTS4HEGOALISFORTHEINDIVIDUAL
HOSPITALTOUTILIZETHISINFORMATIONTOEFFECTCHANGEIN
ORDERTOOPTIMIZEOVERALLDISEASEMANAGEMENT

,  ,


&ONAROW'#!$(%2%3CIENTIlC!DVISORY#OMMITTEE4HE!CUTE
$ECOMPENSATED(EART&AILURE.ATIONAL2EGISTRY!$(%2% 
OPPORTUNITIESTOIMPROVECAREOFPATIENTSHOSPITALIZEDWITHACUTE
DECOMPENSATEDHEARTFAILURE2EV#ARDIOVASC-ED
3UPPL3 



0EACOCK7&2APIDOPTIMIZATIONSTRATEGIESFOROPTIMALCAREOF
DECOMPENSATEDCONGESTIVEHEART FAILUREPATIENTSINTHEEMERGENCY
DEPARTMENT2EV#ARDIOVASC-ED3UPPL3 



%MERMAN#, #OSTANZO-2 "ERKOWITZ2, #HENG- !$(%2%


3CIENTIlC!DVISORY#OMMITTEE%ARLYINITIATIONOF)6VASOACTIVE
THERAPYIMPROVESHEARTFAILUREOUTCOMESANANALYSISFROMTHE
!$(%2%2EGISTRYDATABASE!NN%MERG-ED 



0EACOCK7&(EARTFAILUREMANAGEMENTINTHEEMERGENCY
DEPARTMENTOBSERVATIONUNIT0ROG#ARDIOVASC$IS
 



'UYTON!#0HYSIOLOGYOFHEARTFAILURE4RANS!M#OLL#ARDIOL
 



(ALL*% 'UYTON!# -IZELLE(,2OLEOFTHERENIN ANGIOTENSIN


SYSTEMINCONTROLOFSODIUMEXCRETIONANDARTERIALPRESSURE!CTA
0HYSIOL3CAND3UPPL 



3UMMERS2, %VIDENCED BASEDMEDICINEVSSCIENTIlCREASONING


!CAD%MERG-ED   



0EACOCK7& !LLEGRA* !NDER$ #OLLINS3 $IERCKS$ %MERMAN


# +IRK*$ 3TARLING2 3ILVER- 3UMMERS2,-ANAGEMENT
OF!CUTE$ECOMPENSATED(EART&AILUREINTHE%MERGENCY
$EPARTMENT#ONG(EART&AILSUPPL  

-1,9\
!$(& IS EXPECTED TO BECOME ON THE MOST DIFlCULT
MEDICALANDlNANCIALPROBLEMSFACINGOURHEALTHCARE
SYSTEMS 0RELIMINARY EVIDENCE FROM THE !$(%2%
#ORE 2EGISTRY AND A NUMBER OF OTHER CLINICAL TRIALS
INDICATETHATTHEEMERGENCYDEPARTMENTSHOULDBETHE
FOCAL POINT FOR THE DISEASE MANAGEMENT PROCESS OF
!$(&4HE!$(%2%%$$-PROGRAMPRESENTSA
REALOPPORTUNITYFORTHEEMERGENCYMEDICINECOMMU
NITYTOBETTERUNDERSTANDTHEISSUESSURROUNDINGTHIS
DISEASESTATEANDTOOBJECTIVELYOUTLINETHEBESTCOURSE
FOROVERALLDISEASEMANAGEMENT

#OPYRIGHT%-#2%' )NTERNATIONAL 




1/
"* -/  ,/1,
- -    //""3EAN0#OLLINS -$
$EPARTMENTOF%MERGENCY-EDICINE 5NIVERSITYOF#INCINNATI#OLLEGEOF-EDICINE
#INCINNATI /(

" 
/6 -\
VVivii}iV`i>ii>v>i`i>i>>}ii

/`i>``i>i>>}iiV`iiV>ivii}iV
`i>i>ii>v>i

 /," 1
/"
4HERISINGPREVALENCEANDCOSTOFCAREFORHEARTFAILUREISSTAGGERING!LMOSTMILLION
!MERICANSHAVEHEARTFAILURE WITH NEWCASESDIAGNOSEDEACHYEARATATOTAL
COSTOFBILLION4HEINCIDENCEISEXPECTEDTOCONTINUETOINCREASEDRAMATICALLY
DUETOOURAGINGPOPULATIONPREVALENCEOFHEARTFAILUREININDIVIDUALSOVERAGE
 IMPROVEDSURVIVALFROMACUTECORONARYSYNDROMES!#3 ANDMANAGEMENTAD
VANCES IN CARDIOVASCULAR DISEASES  (OSPITALIZATION ACCOUNTS FOR OVER  OF HEART
FAILURECOSTS /VERHALFOFPATIENTSOLDERTHANYEARSWITHCONGESTIVEHEARTFAILURE
#(& AREREADMITTEDWITHINMONTHSOFHOSPITALDISCHARGE
7HILEMEDICALRISKFACTORSAREWELLKNOWTOBEASSOCIATEDWITHHOSPITALREADMISSIONAGE
INCREASEDLENGTH OF STAYANDNUMBEROFCOMORBIDITIES  OFTENOVERLOOKEDSOCIALFACTORS
SUCHASSINGLEMARITALSTATUS READINESSFORDISCHARGE MEDICATIONANDDIETARYNONCOM
PLIANCE ALSOINmUENCETHECHANCEOF#(&READMISSION (EARTFAILUREDISEASEMAN
AGEMENT$- PROGRAMSAREDESIGNEDTOTARGETSOCIALRISKFACTORSRESULTINGINDECREASED
RECIDIVISM
(EART&AILURE$ISEASE-ANAGEMENT
(EARTFAILURE$-PROGRAMSHAVEPROVEN
TO BE EFFECTIVE AT REDUCING SUBSEQUENT
READMISSIONSINTHOSEDISCHARGEDAFTERA
#(&ADMISSION  )THASBEENSUGGEST
EDTHAT$-PROGRAMSARENEARLYASEFFEC
TIVE AS THAT SEEN WITH ANGIOTENSIN CON
VERTINGENZYMEINHIBITORS BETA BLOCKERS
OR DIGOXIN $- PROGRAMS STRESS THE
NEED FOR COORDINATED COMPREHENSIVE
CARE BOTH DURING HOSPITALIZATION AND AF
TERDISCHARGE4HEYGENERALLYCONSISTOFA
MULTI FACETEDAPPROACHINCLUDINGPATIENT
EDUCATION AND TEACHING DIETARY ASSESS

MENT MEDICATIONANALYSISANDSOCIALSER
VICESCONSULTATION4HESEPROCESSESHAVE
TRADITIONALLYOCCURREDONCETHEPATIENTIS
HOSPITALIZED

i>v>i 
}>>ii
LiivviVi>
i`V}Lii
i>`i
`V>}i`>vi>

>`

7HY$ISEASE-ANAGEMENTINTHE%$
"ECAUSETHEEMERGENCYDEPARTMENT%$
ISTHEPORTALFOROFHOSPITALADMIS
SIONS FOR HEART FAILURE IT REPRESENTS AN
IDEALPLACETOBEGINA$-PROGRAM#(&
PATIENTS DISCHARGED DIRECTLY FROM THE
%$ HAVE A HIGH RATE OF RECIDIVISM AND
DISEASE MANAGEMENT MAY HELP AVOID
UNNECESSARY READMISSIONS  4HOSE PA


%MERGENCY$IAGNOSISAND4REATMENTOF
!CUTE$ECOMPENSATED(EART&AILURE!$(&

TIENTS MANAGED IN AN OBSERVATION UNIT


/5 RECEIVE DElNITIVE CARE INCLUDING
MEDICATIONADJUSTMENTANDFOLLOW UPAR
RANGEMENTS AND$-HASBEENSUGGESTED
TOIMPACTRECIDIVISMINTHESEPATIENTS 
7HETHERITISINITIATIONOF#(&STANDARD
IZEDORDERSFORANINPATIENTADMISSION OR
COMPREHENSIVEEDUCATION ANDTEACHINGIN
THEPATIENTDISCHARGEDFROMTHE%$OR/5
DISEASE MANAGEMENT CAN BE POTENTIALLY
INITIATEDONEVERY%$PATIENTWITH#(&

HOURSOFHOSPITALADMISSIONHAVEADECREASEDLIKELIHOODOFIN HOSPITAL
MORBIDITYANDMORTALITYCOMPAREDWITHTHOSEPATIENTSTHATRECEIVETREAT
MENTAFTERHOURSP />Li  0ATIENTSWITHPNEUMONIA
THATRECEIVEANTIBIOTICSWITHINHOURSOFHOSPITALARRIVALHAVEAREDUCED
HOSPITAL LENGTH OF STAY ,/3 AND IN HOSPITAL MORTALITY />Li  !
SEPARATEANALYSISFOUNDTHATAFTERADJUSTMENTFORCLINICALANDDEMOGRAPHIC
VARIABLES INITIAL ANTIBIOTIC ADMINISTRATION IN THE %$ AND DOOR TO NEEDLE
TIMEWASASSOCIATEDWITHREDUCED,/3

4HEIMPACTOFEARLY%$INTERVENTIONAND
TREATMENTHASBEENSEENINOTHERDISEASE
PROCESSES SUCH AS PNEUMONIA AND!#3
4HE#253!$%INITIATIVEHASSUGGESTED
THAT THOSEPATIENTSWITHNON34 SEGMENT
ELEVATION MYOCARDIAL INFARCTION .34%
-) THAT RECEIVE TREATMENT WITH GLYCO
PROTEIN '0 ))B)))A INHIBITORS WITHIN

,QKRVSLWDORXWFRPHVVWUDWLILHGE\WLPHWR,,E,,,DLQKLELWRUWUHDWPHQW

/>Li

*3,,%,,,$K

1R*3,,E,,,DK

Q  

Q  

3

'HDWK  





5H ,QIDUFWLRQ  







&DUGLRJHQLF6KRFN  







&+)  
5%&WUDQVIXVLRQ  















/>Li
$QWLELRWLFDGPLQLVWUDWLRQZLWKLQKRXUVRIDUULYDODQGSDWLHQWRXWFRPHV
VWUDWLILHGE\ULVNFODVVHV
$GMXVWHG
$QWLELRWLF:LWKLQ
K &,

$QWLELRWLF$IWHU
K &,

$25 &,

39DOXH

GPRUWDOLW\
,QKRVSLWDOPRUWDOLW\
/HQJWKRIVWD\aG
GUHDGPLVVLRQ
36,ULVNFODVVHV,,DQG,,,

 
 
 
 

 
 
 
 

 
 
 
 






GPRUWDOLW\
,QKRVSLWDOPRUWDOLW\
/HQJWKRIVWD\aG
GUHDGPLVVLRQ

 
 
 
 

 
 
 
 

 
 
 
 






 
 
 
 

 
 
 
 

 
 
 
 






2XWFRPH0HDVXUHV
$OOSDWLHQWV

36,ULVNFODVVHV,9DQG9
GPRUWDOLW\
,QKRVSLWDOPRUWDOLW\
/HQJWKRIVWD\aG
GUHDGPLVVLRQ



!BBREVIATIONS!/2 ADJUSTEDODDSRA
TIO #) CONlDENCE INTERVAL /2 ODDS
RATIO03) 0NEUMONIA3EVERITY)NDEX

0ATIENTS WITHOUT PREHOSPITAL ANTIBI


OTICTREATMENT
o5NIVARIATE ANALYSIS COMPARING THE
ANTIBIOTICTIMINGSUBGROUPShWITHIN
HvVShAFTERHv
p-ULTIVARIATE ANALYSIS COMPARING THE
ANTIBIOTICTIMINGSUBGROUPShWITHIN
HvVShAFTERHvUSINGLOGISTICREGRES
SION 4HE LOGISTIC REGRESSION MODEL
INCLUDEDTHETIMINGOFINITIALANTIBIOTIC
03) ADMISSION TO THE INTENSIVE CARE
UNIT CENSUSREGIONSOFHOSPITALIZATION
RACEETHNICITY ANDOTHERPROCESSESOF
CAREOXYGENATIONASSESSMENT BLOOD
CULTUREWITHINHOURS ANDINITIALAN
TIBIOTICCONSISTENTWITHCURRENTGUIDE
LINES  !DAPTED AND REPRINTED WITH
PERMISSION FROM (OUCK ET AL !RCH
)NTERN-ED 


1/
"* -/  ,/1,
- -    //""-

%$(EART&AILURE$ISEASE-ANAGEMENT4OOLS
4HEREARESEVERALASPECTSTO%$DISEASEMANAGEMENT4HElRSTCOMPONENTISIMPLE
MENTINGAN%$HEARTFAILURETREATMENTALGORITHM}i #ATEGORIZINGAPATIENT
BASED ON THEIR PERFUSION STATUS WARM VERSUS COLD mUID STATUS HYPERVOLEMIC EU
VOLEMIC HYPOVOLEMIC ANDLEVELOFDISEASESEVERITYWILLHELPDICTATEINITIALTHERAPY
4HEMAJORITYOFPATIENTSWILLBEHYPERVOLEMICANDWELL PERFUSEDANDWILLRESPONDTO
DIURETICSANDVASODILATORS
4HESECONDCOMPONENTOF$-ISTHEINTRODUCTIONOF%$#(&ADMISSIONORDERS!D
MISSIONORDERSENSURECONTINUITYOFCAREFROMTHE%$TOTHEINPATIENTWARDWITHREGARD
TOMEDICATIONS LABS ANDANCILLARYTESTS)TALSOENSURESTHATTHEPATIENTTHATSPENDSSEV
ERALHOURSINTHE%$WAITINGFORANINPATIENTBEDISAPPROPRIATELYMANAGEDWHILECARE
6WDW('+)&RQVHQVXV3DQHO

(PHUJHQF\'HSDUWPHQW3DWLHQWZLWK6XVSHFWHG
$FXWHRU'HFRPSHQVDWHG+HDUW)DLOXUH

,PPLQHQW5HVSLUDWRU\)DLOXUH$QWLFLSDWHG

<(6
2SWLRQV
",QRWURSHV
"&RQVLGHU+HPRG\QDPLF
0RQLWRULQJ
",&8$GPLVVLRQ

iV>iiii}iV

<(6

&DUGLRJHQLF6KRFNRU
6\PSWRPDWLF+\SRWHQVLRQ"

3HUIRUP+LVWRU\DQG3K\VLFDO([DP

`i>ii

2SWLRQV

<(6

"%L3$3&3$37ULDO
"(QGRWUDFKHDO
,QWXEDWLRQ
",I%3HOHYDWHG
&RQVLGHU5DSLG
9DVRGLODWLRQ
ZLWK1LWURJO\FHULQ
RU1LWURSUXVVLGH
",&8$GPLVVLRQ

>vn
v>>`
vi>v>i]

+\SRSHUIXVLRQ FRROH[WUHPLWLHV
RU$OWHUHG0HQWDO6WDWXV

12
&RQVLGHU2WKHU'LDJQRLVLV
DQG7UHDWPHQW

12

'HFRPSHQVDWHG+HDUW)DLOXUH
/LNHO\"

<(6
7KH(VWLPDWHRI6HYHULW\
,V,QFUHDVHGE\
"$EGRPLQDO6LJQVRI2[LPHWU\
"+LVWRU\RI0XOWLSOH+)$GPLWV
"%81!PJG/
"6%3PP+J
"&UHDWLQLQH!PJG/
":HLJKW$ERYH1RUPDO'U\:HLJKW
"(&*ZLWK/9+(OHYDWHG%3
"l%81+\SRQDWUHPLD
".QRZQ/RZ(MHFWLRQ)UDFWLRQ
"3RRU5HVSRQVHWR7KHUDS\

&ULWLFDO6HYHULW\
aRIDOO+)SDWLHQWV
"2[\JHQ
"/RRS'LXUHWLF
"1HVLULWLGH1LWURJO\FHULQ
RU1LWURSUXVVLGH

iii>`i>

3HUIRUP:RUNXS
"%13
"(&*
"&;5
"26$7

"&DUGLDF0DUNHUV
"&%&
"(OHFWURO\WHV

>Vi>i>
}>

&RQFXUUHQW
ZLWK:RUNXS
,QLWLDWH(DUO\('
7KHUDS\%DVHGRQ
&OLQLFDO(VWLPDWH
RI6HYHULW\

0RGHUDWH6HYHULW\
aRIDOO+)SDWLHQWV

/RZ6HYHULW\
aRIDOO+)SDWLHQWV

"2[\JHQ
"/RRS'LXUHWLF
"1HVLULWLGH
"1LWURSDVWHRU6/
1LWURJO\FHULQSUQ
"3DWLHQW(GXFDWLRQ

"2[\JHQ
"1LWURSDVWHRU6/
1LWURJO\FHULQSUQ
"/RRS'LXUHWLFV7ULDO
"3DWLHQW(GXFDWLRQ

,&8

}i
 /i>i}`ii
vii>>L>>``
v>Vi`iVi>i`i>v>i
iii}iV`i>i

7HOHPHWU\RU2EVHUYDWLRQ8QLW
2EVHUYDWLRQ8QLWRU0HGLFDO)ORRU

'LVFKDUJH+RPH



%MERGENCY$IAGNOSISAND4REATMENTOF
!CUTE$ECOMPENSATED(EART&AILURE!$(&

ISTRANSITIONINGFROMTHEEMERGENCYPHYSICIANTOTHE
ADMITTING TEAM4HERE ARE OTHER ADVANTAGES TO STAN
DARDIZEDORDERS4HEAMOUNTOFEVOLVINGLITERATUREIS
OVERWHELMING IN  THERE WERE   RANDOM
IZED CONTROLLED TRIALS PUBLISHED 3TANDING ORDERS
ENSUREGUIDELINECOMPLIANCEFROMTHELITERATURE YET
ALLOWPHYSICIANSSOMEAUTONOMYBYALLOWINGFORIN
DIVIDUALPATIENTADJUSTMENTS
4HETHIRDCOMPONENTOF$-ISTHECOMPLETIONOFAPA
TIENTDISCHARGECHECKLIST4HISCHECKLISTISAMETHODOF
ENSURINGTHOSEPATIENTSTHATMEETCRITERIAFORSPECIlC
INTERVENTIONS MEDICATIONS SMOKING CESSATION CAR
DIACREHABILITATION AREGIVENTHEAPPROPRIATEMEDICA
TIONSANDINSTRUCTIONSUPONDISCHARGE4HEINSTITUTION
OFADISCHARGEMEDICATIONPROGRAMATHOSPITALSIN
5TAHWASASSOCIATEDWITHDRAMATICIMPROVEMENTSIN
APPROPRIATE DISCHARGE PRESCRIPTIONS AND THE RELATIVE
RISKOFDEATHANDREADMISSIONAT DAYSAND YEAR
AFTERHOSPITALDISCHARGE}i >` 4HIS
PROGRAM FOCUSED ON NURSING INITIATED DOCUMENTA
TIONOFAPPROPRIATEMEDICATIONSUPONDISCHARGEFROM
THEHOSPITAL7HENANAPPROPRIATEMEDICINEWASNOT
PRESCRIBEDATDISCHARGE THEDISCHARGE PLANNINGNURSE

}i
* v >i iVi} i
>>i`V>}iiV
/i x >}ii` i`V> ii
}i > `V>i` >i
`Vii`V>`V>
Livi >` i > i> >vi
ii> vi `V>}i
i`V> }> n >`
] iiVi >> v n
>`iiViVi`}i
>i Vi 
r>}i
Vi} ii ,ii`
i v >i i > 
ii`{{\{{



CONTACTEDTHEATTENDINGPHYSICIANORRESIDENTDIRECTLY
AFTERWHICHTHEMISSINGMEDICATIONCOULDBEADDEDTO
THEDISCHARGELISTIFTHEREWERENOCONTRAINDICATIONS
4HE lNAL COMPONENT OF $- IS PATIENT EDUCATION
5NLIKEOTHERACUTEINPATIENTDISEASEPROCESSSUCHAS
PNEUMONIA AND PYELONEPHRITIS ACUTE #(& EXACER
BATIONS ARE TREATED UNTIL THE SUBJECT IS BACK TO THEIR
BASELINE COMPENSATED STATE THE UNDERLYING DISEASE
PROCESSISNEVERCOMPLETELYCURED!SARESULT PATIENT
BEHAVIORAFTERHOSPITALIZATIONMAYHAVEATREMENDOUS
INmUENCEONTHEPROGRESSIONOFTHEIRDISEASEPROCESS
ANDSUBSEQUENTMORBIDITYANDMORTALITY)THASBEEN
SUGGESTED THAT OVER  OF READMISSIONS ARE POSSI
BLYORPROBABLYPREVENTABLE ANDTHATMEDICATIONAND
DIETARY NONCOMPLIANCE INADEQUATE DISCHARGE PLAN
NINGORFOLLOW UP FAILEDSOCIALSUPPORT ANDNOTREC
OGNIZINGSYMPTOMRECURRENCEWEREABIGCONTRIBUTOR
TOTHESEPREVENTABLEREADMISSIONS !$-PROGRAM
THATEMPOWERSTHEPATIENTWITHKNOWLEDGEABOUTTHEIR
DISEASEPROCESS APPROPRIATEFOLLOW UP ANDSIGNSOF
DECOMPENSATION INCREASESTHELIKELIHOODOFAVOIDING
READMISSIONS


1/
"* -/  ,/1,
- -    //""-

}i



DAYS

(&



#($



-)


#!"'



(&

9EAR


#($


-)


#!"'





















2ELATIVE2ISKFOR$EATH

(&

`i`i>i
v i>>`
,i>`>
`>>`i>v
>iLivi>`
>viii>
vi`V>}i
i`V>}>
,i`Vi`>`
ii`
iv
>ii>
ii`{
{\{{

DAYS


#($

/iiiiv
iv`>i>


-)


VL> 

#!"'


}>V>>i



(&

9EAR



i>>}iivi

#($


-)
#!"'


i>v>i>i
















2ELATIVE2ISKFOR2EADMISSION

i>`]
V>}iii>i`L
>`}>>i]

!0RACTICAL%XAMPLE$ISEASE-ANAGEMENTINTHE/BSERVATION5NIT
)N*ANUARY THE5NIVERSITYOF#INCINNATI$EPARTMENTOF%MERGENCY-EDICINEINI
TIATEDANACUTEDECOMPENSATEDHEARTFAILUREOBSERVATIONUNIT/5 PROTOCOL4HEPROTO
COLSELECTSNON HIGH RISKPATIENTSFORMANAGEMENTOVERA HOURPERIOD$URINGTHIS
TIMEPATIENTSRECEIVEVASODILATORSANDDIURETICSASWELLASFURTHEREVALUATIONINCLUDING
ECHOCARDIOGRAPHYAND!#3RISKSTRATIlCATIONEVALUATIONSERIALCARDIACMARKERSWITH
THEOPTIONFORRESTISCHEMIAIMAGING }i{!NEDUCATIONALVIDEOHASBEENDE
VELOPEDTHATINSTRUCTSTHEPATIENTSABOUTTHEIRDISEASEPROCESS DIET MEDICATIONS AND
WARNING SIGNS THAT THEIR HEART FAILURE MAY BE WORSENING $ISCHARGE PLANNING OCCURS
THROUGHACOMBINATIONOFCARDIOLOGYNURSEPRACTITIONEREVALUATION ASWELLASFOLLOW
UPINTHEHEARTFAILUREANDGENERALINTERNALMEDICINECLINIC

>`>>i>}ivi
Li``>>>i`
iLi>>
>i



%MERGENCY$IAGNOSISAND4REATMENTOF
!CUTE$ECOMPENSATED(EART&AILURE!$(&

}i{
)NCLUSION%XCLUSION#RITERIA&ULFILLED

1iv
V>
 >>

)6DIURETICEQUIVALENTTOHOMEDAILYDOSE
2ESTARTHOME!#%)p)6!#%)
.ITRATES

%LECTROLYTES STANDING
REPLACEMENT
".0LEVELS

 HOURREASSESSMENT
5/ *6$ DYSPNEA 63 ".0

.ITRATE$IURETIC!#%)
0ATHWAY

$IAGNOSTICS
  HOURCARDIACENZYMES
%CHOCARDIOGRAPHY
2ESTPERFUSIONSCAN

.ITRATE$IURETIC
0ATHWAY

2EASSESSEVERY HOURS
(&EDUCATIONVIDEO
$ISCHARGECRITERIAMET
#ARDIOLOGISTCONSULT
$ISCHARGEHOME
&5IN DAYS

9%3

./

7EEVALUATEDTHEEFFECTIVENESSOFTHE/5PROTOCOLBY
COMPARINGPATIENTSMANAGEDINTHE/5WITHASIMILAR
RISK MATCHED COHORT OF INPATIENTS /VERALL  PA
TIENTSWHOWEREBEINGADMITTEDTOTHEHOSPITALWITH
PRESUMEDDECOMPENSATEDHEARTFAILUREWEREENROLLED
INTHESTUDY!LLPATIENTSHADAHISTORYOFHEARTFAILURE
ANDSATISlEDTWOMAJOR ORONEMAJORANDTWOMINOR
MODIlED&RAMINGHAM#RITERIA)NCLUSIONANDEXCLU
SIONCRITERIAWERESELECTEDBASEDUPONPRIORRISKSTUD
IES SO AS TO IDENTIFY WHAT CURRENT PRACTICE INDICATES
IS A LOW TO MODERATE RISK PATIENT 0ATIENTS CURRENTLY
BELIEVEDTOBEATHIGHRISKANDPATIENTSWITHNEWONSET
HEARTFAILUREWERENOTINCLUDED
/NE PATIENT WAS FOUND TO HAVE NO PRIOR HISTORY OF
HEARTFAILURE ANDTWOPATIENTSLEFTTHEINPATIENTSETTING
AGAINST MEDICAL ADVICE )NCLUSION OF THESE SUBJECTS
MAY AFFECT THE DATA BUT THIS REPRESENTS THE CLINICAL
SCENARIOANDITISIMPORTANTTOINCLUDETHESESOURCES
OF ERROR IN OUTCOMES ANALYSIS 4HIRTY TWO PATIENTS



!DMIT

WEREADMITTEDTOHOSPITALWHILEWEREPLACEDINTHE
OBSERVATIONUNIT%IGHT /5PATIENTSREQUIRED
SUBSEQUENTADMISSION
/UTCOMES MEASURED IN THIS STUDY INCLUDED READ
MISSIONS FOR #(& REPEAT VISITS TO THE %$ FOR HEART
FAILURE AND DEATH 4HERE WERE  EVENTS AMONG AD
MITTEDPATIENTS ANDEVENTSAMONG/5PA
TIENTS   !NY DIFFERENCE WAS NOT SIGNIlCANT
P !LLEVENTSINCLUDEDAREADMISSIONFORHEART
FAILURE!LLBUTONEEVENTINCLUDEDAHEARTFAILURE RE
LATED%$VISIT7EALSOCOMPAREDCRUDEESTIMATESOF
BED HOURSANDCOSTSBETWEENTHETWOGROUPS5SEOF
THE/5AVOIDEDADMISSIONINOFCASES-EDIAN
TIME FROM TRIAGE TO DISCHARGE FOR /5 PATIENTS WAS
HOURSRANGEnHOURS WHILEPATIENTS
ADMITTED DIRECTLY FROM THE %$ HAD A MEDIAN LENGTH
OFSTAYOFHOURSRANGEnHOURS 4HE
LENGTH OF HOSPITAL STAY WAS SIGNIlCANTLY SHORTER FOR
/5 PATIENTS THAN FOR ADMITTED PATIENTS P 


1/
"* -/  ,/1,
- -    //""-

#HARGES FOR THE TWO GROUPS OF PATIENTS


WEREOBTAINED CATEGORIZEDBYTHESOURCE
OFTHECHARGE}ixSHOWSTHESOURCE
OFCHARGESFORADMITTEDAND/5PATIENTS
OUTLIERSNOTSHOWN 
4HE TOTAL CHARGE WAS SIGNIlCANTLY LOW
ER FOR THE /5 PATIENTS -EDIAN 
2ANGEn THANFORADMIT
TEDPATIENTS-EDIAN RANGE
n  0  )NPATIENT CHARGES
AND PHARMACY CHARGES WERE DIFFERENT
BETWEEN THE TWO GROUPS 0 AND
0 RESPECTIVELY  4HESE RESULTS
TESTIFYTOTHEFUNDAMENTALCONTRIBUTIONA
$- PROGRAM CAN MAKE TO THE MANAGE
MENT OF THE HEART FAILURE PATIENT IN THIS
PRELIMINARY STUDY CHARGES WERE HALVED
BYNOTADMITTINGAPATIENT ANDANAVERAGE
OFBED DAYWASSAVEDPER/5PATIENT
! COMBINATION OF A TREATMENT PATHWAY
PATIENTEDUCATIONANDDISCHARGEPLANNING
ARE INTEGRAL COMPONENTS IN MAKING /5
TREATMENTSUCCESSFUL

-1,9
$ISEASEMANAGEMENTISANINTEGRALCOM
PONENTINTHECOMPREHENSIVECAREOFHEART
FAILURE PATIENTS AND HAS BEEN SHOWN TO
REDUCEREADMISSIONSANDTHEOVERALLCOST
OFCARE4HE%$ACTSASAMAJORPORTAL
FORHEARTFAILUREADMISSIONSANDBECAUSE
OF THIS EMERGENCY PHYSICIANS HAVE THE
POTENTIALTOSIGNIlCANTLYIMPACTTHECARE
OF (& PATIENTS4HE MAJORITY OF %$ PA
TIENTS WHETHERADMITTED MANAGEDINAN
/5 ORDISCHARGEDHOME WILLLIKELYBEN
ElTFROMONEORMOREOFTHECOMPONENTS
OF$-
/i>v
>i]ii
>`i`]>>}i`
>"1]`V>}i`
i]iLiiw
viiv



#HARGES$OLLARS

!DMITTED
/5

iViv 



}ix


,ABORATORY

)NPATIENT

%$

0HARMACY

}iVi
>`>vV>}iv
Li>>`>`i`
>iI`V>i>
}wV>`vviiVi


%MERGENCY$IAGNOSISAND4REATMENTOF
!CUTE$ECOMPENSATED(EART&AILURE!$(&

,  ,


!SSOCIATION!((EARTDISEASEANDSTROKESTATISTICS UPDATE




/#ONNELL*"4HEECONOMICBURDENOFHEARTFAILURE#LIN#ARDIOL
))) 



#ROFT*" 'ILES7( 0OLLARD2! +EENAN., #ASPER-, !NDA


2&(EARTFAILURESURVIVALAMONGOLDERADULTSINTHEUNITEDSTATES
!POORPROGNOSISFORANEMERGINGEPIDEMICINTHEMEDICARE
POPULATION!RCH)NTERN-ED 



-C#ULLOUGH0! 0HILBIN%& 3PERTUS*! +AATZ3 3ANDBERG+2


7EAVER7$#ONlRMATIONOFAHEARTFAILUREEPIDEMIC&INDINGS
FROMTHERESOURCEUTILIZATIONAMONGCONGESTIVEHEARTFAILURE
REACH STUDY*!M#OLL#ARDIOL 

 2AME*% 3HEFlELD-! $RIES$, 'ARDNER%" 4OTO+(


9ANCY#7 $RAZNER-(/UTCOMESAFTEREMERGENCYDEPARTMENT
DISCHARGEWITHAPRIMARYDIAGNOSISOFHEARTFAILURE!M(EART*
 
 0EACOCK7&T 2EMER%% !PONTE* -OFFA$! %MERMAN#%
!LBERT.-%FFECTIVEOBSERVATIONUNITTREATMENTOFDECOMPENSATED
HEARTFAILURE#ONGEST(EART&AIL 
 3TORROW!" #OLLINS30 ,INDSELL#*%MERGENCYDEPARTMENT
OBSERVATIONOFHEARTFAILUREISSAFEANDCOSTEFFECTIVE!CAD%MERG
-ED
 (OEKSTRA* 2OE-4 0ETERSON% -6 *- 0OLLACK#6 *R -ILLER
# 40 (ARRINGTON2! /HMAN%- 'IBLER7"%ARLYGLYCOPROTEIN
IIBIIIAINHIBITORUSEFORNON ST SEGMENTELEVATIONACUTECORONARY
SYNDROMES0ATIENTSELECTIONANDASSOCIATEDTREATMENTPATTERNS
!CAD%MERG-EDINPRESS



/#ONNELL*""-%CONOMICIMPACTOFHEARTFAILUREINTHEUNITED
STATES!TIMEFORADIFFERENTAPPROACH*(EART,UNG4RANS
3 3



0HILLIPS#/ 7RIGHT3- +ERN$% 3INGA2- 3HEPPERD3 2UBIN


(2#OMPREHENSIVEDISCHARGEPLANNINGWITHPOSTDISCHARGESUPPORT
FOROLDERPATIENTSWITHCONGESTIVEHEARTFAILURE!META ANALYSIS
*AMA 

 (OEKSTRA* -6 9, 2OE-4 0ETERSON% 0OLLACK#6 *R 40


"RINDIS2' 'IBLER7" /HMAN%-%ARLYGPIIBIIIAINHIBITORUSE
INNONSTELEVATIONACUTECORONARYSYNDROMESISASSOCIATEDWITH
LOWERMORTALITYINTROPONINPOSITIVEPATIENTS*!M#OLL#ARDIOL
3UPPL)6 



+RUMHOLZ(- 0ARENT%- 4U. 6ACCARINO6 7ANG9 2ADFORD


-* (ENNEN*2EADMISSIONAFTERHOSPITALIZATIONFORCONGESTIVE
HEARTFAILUREAMONGMEDICAREBENElCIARIES!RCH)NTERN-ED
 

 (OUCK0- "RATZLER$7 .SA7 -A! "ARTLETT*'4IMINGOF


ANTIBIOTICADMINISTRATIONANDOUTCOMESFORMEDICAREPATIENTS
HOSPITALIZEDWITHCOMMUNITY ACQUIREDPNEUMONIA!RCH)NTERN
-ED 



#HIN-( 'OLDMAN,#ORRELATESOFEARLYHOSPITALREADMISSION
ORDEATHINPATIENTSWITHCONGESTIVEHEARTFAILURE!M*#ARDIOL
 



6INSON*- 2ICH-7 3PERRY*# 3HAH!3 -C.AMARA4%ARLY


READMISSIONOFELDERLYPATIENTSWITHCONGESTIVEHEARTFAILURE*!M
'ERIATR3OC 

 "ATTLEMAN$3 #ALLAHAN- 4HALER(42APIDANTIBIOTICDELIVERY


ANDAPPROPRIATEANTIBIOTICSELECTIONREDUCELENGTHOFHOSPITAL
STAYOFPATIENTSWITHCOMMUNITY ACQUIREDPNEUMONIA,INK
BETWEENQUALITYOFCAREANDRESOURCEUTILIZATION!RCH)NTERN-ED
 

 +OSSOVSKY-0 3ARASIN&0 0ERNEGER46 #HOPARD0 3IGAUD0


'ASPOZ*5NPLANNEDREADMISSIONSOFPATIENTSWITHCONGESTIVE
HEARTFAILURE$OTHEYREmECTIN HOSPITALQUALITYOFCAREORPATIENT
CHARACTERISTICS!M*-ED 
 2ICH-7 "ECKHAM6 7ITTENBERG# ,EVEN#, &REEDLAND
+% #ARNEY2-!MULTIDISCIPLINARYINTERVENTIONTOPREVENTTHE
READMISSIONOFELDERLYPATIENTSWITHCONGESTIVEHEARTFAILURE.
%NGL*-ED 
 2ICH-7 6INSON*- 3PERRY*# 3HAH!3 3PINNER,2 #HUNG
-+ $AVILA 2OMAN60REVENTIONOFREADMISSIONINELDERLY
PATIENTSWITHCONGESTIVEHEARTFAILURE2ESULTSOFAPROSPECTIVE
RANDOMIZEDPILOTSTUDY*'EN)NTERN-ED 

 #HASSIN-2)SHEALTHCAREREADYFORSIXSIGMAQUALITY-ILBANK
1  
 ,APPE*- -UHLESTEIN*" ,APPE$, "ADGER23 "AIR4,
"ROCKMAN2 &RENCH4+ (OFMANN,# (ORNE"$ +RALICK
'OLDBERG3 .ICPONSKI. /RTON*! 0EARSON22 2ENLUND$'
2IMMASCH( 2OBERTS# !NDERSON*,)MPROVEMENTSIN YEAR
CARDIOVASCULARCLINICALOUTCOMESASSOCIATEDWITHAHOSPITAL BASED
DISCHARGEMEDICATIONPROGRAM!NN)NTERN-ED 
 #OLLINS30 ,INDSELL#* ,YONS-3 'IBLER7" 3TORROW!"
"NPLEVELSARERELATEDTO DAYEVENTSINHEARTFAILUREPATIENTS
DISCHARGEDFROMANOBSEVATIONUNIT!MERICAN#OLLEGEOF
%MERGENCY0HYSICIANS

 'ONSETH* 'UALLAR #ASTILLON0 "ANEGAS*2 2ODRIGUEZ !RTALEJO


&4HEEFFECTIVENESSOFDISEASEMANAGEMENTPROGRAMMESIN
REDUCINGHOSPITALRE ADMISSIONINOLDERPATIENTSWITHHEARTFAILURE
!SYSTEMATICREVIEWANDMETA ANALYSISOFPUBLISHEDREPORTS%UR
(EART* 

#OPYRIGHT%-#2%' )NTERNATIONAL 




}i`V> `V>*/i
"ASEDONTHEINFORMATIONPRESENTEDINTHISMONOGRAPH PLEASECHOOSEONECORRECTRESPONSEFOREACHOFTHEFOLLOWING
QUESTIONSORSTATEMENTS2ECORDYOURANSWERSONTHEANSWERSHEETONPAGE4ORECEIVE#ATEGORY)CREDIT COMPLETE
THEPOST TESTANDRECORDYOURRESPONSESONTHEANSWERSHEET-AILINTHERETURNENVELOPENOLATERTHAN*UNE !
PASSINGGRADEOFISNEEDED!CERTIlCATEWILLBESENTTOYOUUPONYOURSUCCESSFULCOMPLETIONOFTHEPOST TEST
>}vVi iVi>i`i>
>ii
 ! YEAR OLDMALETOBACCOSMOKERWITHAHISTORY
OFASTHMAPRESENTSTOTHEEMERGENCYDEPARTMENT
WITHSHORTNESSOFBREATHOFDAYSDURATION(E
HASEXERTIONALDYSPNEA ORTHOPNEAANDHEARS
SOMEWHEEZINGWHENHEISBREATHING0HYSICAL
EXAMINATIONREVEALSSCANTCRACKLESATTHEBASES
BILATERALLYWITHCMOFJUGULARVENOUSDISTENTION
AN3HEARTSOUND ANDNOMURMUR7HICHOFTHE
FOLLOWINGBESTSUPPORTSADIAGNOSISOFCONGESTIVE
HEARTFAILURE
A #ARDIOMEGALYONCHESTRADIOGRAPHY
B !".0LEVELOFPGD,
C .ORMALCHESTRADIOGRAPHY
D !".0LEVELOFPGD,
 7HICHOFTHEFOLLOWINGDISEASESCANRESULTINLOW
GRADE".0ELEVATIONSPGDL 
A 2IGHTVENTRICULARFAILUREFROMCORPULMONALE
B !CUTEPULMONARYEMBOLISM
C #(&INANOBESEPATIENT
D #(&INAPATIENTWITHNORMALBODYMASSINDEX
E !LLOFTHEABOVE
/i>ivVi iVi>i`i>
>ii i}iV i>i
 4HEPATIENTSCLINICALSTATUSCANBEDETERMINEDBY
ASSESSINGTHENFORWHICHOFTHEFOLLOWING
A $EGREEOFCARDIACPERFUSIONANDPRESENCEOF
CONGESTION
B $EGREEOFCARDIACPERFUSIONANDBLOODPRESSURE
C "LOODPRESSUREANDPRESENCEOFCONGESTION
D 2ENALFUNCTIONANDVOLUMESTATUS
E 2ENALFUNCTIONANDPERIPHERALEDEMA

 7HICHOFTHEFOLLOWINGISNOTTRUEABOUTTHEROLEOF
VASODILATORSINACUTELYDECOMPENSATEDHEART
A 4HEYREDUCEPRELOADANDAFTERLOAD
B -YOCARDIALOXYGENCONSUMPTIONISOFTEN
INCREASED
C 4HEYINCREASESTROKEVOLUMEANDIMPROVE
CARDIACOUTPUT
D 4HEYMAYCAUSEHYPOTENSION
E 4HEBESTHEMODYNAMICINDICATOROFVASODILATOR
THERAPYRESPONSEISADROPINTHEPULMONARY
CAPILLARYWEDGEPRESSURE
*ii *
i*>i
,iVi`>
 )NANANALYSISOFMORETHAN PATIENTSENROLLED
INTHE!$(%2%REGISTRY THE%$USEOFVASOACTIVE
THERAPY ASCOMPAREDTODELAYEDUSAGEONTHE
INPATIENTUNIT WASASSOCIATEDWITHWHICHOFTHE
FOLLOWING
A DECREASEDMORTALITY
B LOWER)#5ADMISSIONRATE
C SHORTERHOSPITALIZATIONS
D FEWERINVASIVEPROCEDURES
E ALLOFTHEABOVE
 !NELEVATEDTROPONIN INTHESETTINGOFACUTE
DECOMPENSATEDHEARTFAILUREISASSOCIATEDWITH
A LONGER)#5HOSPITALIZATION
B INCREASEDMORTALITY
C LONGERHOSPITALIZATION
D AHIGHERRATEOFINTUBATIONANDBALLOONPUMP
USAGE
E ALLOFTHEABOVE




}i`V> `V>*/iV
>V}`>``}vi
  , >>,i}
 7HENDESCRIBINGTHEPATIENTPOPULATIONINTHE
!$(%2%REGISTRYINCOMPARISONTOOTHER!$(&
TRIALS ALLOFTHEFOLLOWINGARETRUE%8#%04
A 0ATIENTSIN!$(%2%TENDTOBEOLDER
B !BOUTHALFTHEPATIENTSIN!$(%2%AREWOMEN
C 2ENALINSUFlCIENCYPATIENTSAREEXCLUDEDFROM
!$(%2%
D 4HE!$(%2%POPULATIONINCLUDESACADEMICAND
COMMUNITYCENTER
E !LLOFTHEABOVEARETRUE
 )NTHE!$(%2%INTRAVENOUSVASOACTIVEMORTALITY
ANALYSIS WHICHOFTHEFOLLOWINGSTATEMENTSARETRUE
A 0ATIENTSWHORECEIVEDIN HOSPITALNITROGLYCERIN
HADLOWERIN HOSPITALMORTALITY
B 0ATIENTSWHORECEIVEDINTRAVENOUSNESIRITIDEHAD
LOWERINHOSPITALMORALITY
C 0ATIENTSTREATEDWITHDOBUTAMINEORMILRINONE
HADHIGHERIN HOSPITALMORTALITY
D !AND#ARECORRECT
E ! " AND#ARECORRECT
i>i>>}iivVi
iVi>i`i>>i\/i
  , i}iVi`Vi`i
 7HICHOFTHEFOLLOWINGAREREQUIREDFORASUCCESSFUL
POINT OF CAREPROGRAM
A 1UALITYCONTROL
B %DUCATIONOFPHYSICIANS
C ,ABORATORYACCREDITATIONANDREGULATION
D $ElNEDANDREGULATEDTESTINGPROCEDURES
E !LLOFTHEABOVE



 &ACTORSTHATSHOULDBECONSIDEREDINTHECOSTANALYSIS
OFAPOINT OF CARETESTINGPROGRAMINCLUDEALLOFTHE
FOLLOWING%8#%04
A ,ABORATORYRESULTTURN AROUND TIME4!4
B 4IMETODISPOSITION
C 0ATIENTANDPHYSICIANCONSUMER DEMAND
D #OSTOFTESTINGPLATFORMANDREAGENTS
E !LLOFTHEABOVEARECORRECT

Vi iVi>i`i>>i i>i


>>}ii/
 4HECOMPONENTSOFDISEASEMANAGEMENTINCLUDEALL
OFTHEFOLLOWINGEXCEPT
A 4REATMENTALGORITHM
B !DMISSIONORDERS
C 0ATIENTDISCHARGECHECKLIST
D 0ATIENTEDUCATION
E !LLOFTHEABOVE
 0ATIENTEDUCATIONANDADISCHARGECHECKLISTARETWO
DISEASEMANAGEMENTTOOLSTHATAREUSEDTOIMPROVE
MEDICATIONANDDIETARYCOMPLIANCEINANEFFORTTO
DECREASE DAYHOSPITALREADMISSION4HECURRENT
 DAYREADMISSIONRATEFORHEARTFAILUREPATIENTS
DISCHARGEDFROMTHEHOSPITALISAPPROXIMATELY
A 
B 
C 
D 

%MERGENCY$IAGNOSISAND4REATMENTOF
!CUTE$ECOMPENSATED(EART&AILURE!$(&

}i`V> `V> */ii>` >>


!FTERYOUHAVEREADTHEMONOGRAPH CAREFULLYRECORD
YOURANSWERSBYCIRCLINGTHEAPPROPRIATELETTERFOREACH
QUESTIONANDCOMPLETETHEEVALUATIONQUESTIONNAIRE

61/" +1 -/"

-AILTHEANSWERSHEETTO

,

/NASCALEOFTO WITHBEINGHIGHLYSATISlEDAND
BEINGHIGHLYDISSATISlED PLEASERATETHISPROGRAMWITH
RESPECTTO

(IGHLYSATISlED (IGHLYDISSATISlED

/FlCEOF#ONTINUING-EDICAL%DUCATION
5NIVERSITYOF#INCINNATI#OLLEGEOF-EDICINE
0/"OX
#INCINNATI/( 

/VERALLQUALITYOFMATERIAL

#ONTENTOFMONOGRAPH

/THERSIMILAR#-%PROGRAMS

(OWWELLCOURSEOBJECTIVESWEREMET

#-%EXPIRATIONDATE*UNE 

7HATTOPICSWOULDBEOFINTERESTTOYOUFORFUTURE#-%
PROGRAMS
?????????????????????????????????????????????
?????????????????????????????????????????????

D

?????????????????????????????????????????????
?????????????????????????????????????????????





A
A

B
B

C
C



A

B

C

D



A

B

C

D



A

B

C

D



A

B

C

D



A

B

C

D

E



A

B

C

D



A

B

C

D



A

B

C

D



A

B

C

D



A

B

C

D





















7ASTHERECOMMERCIALORPROMOTIONALBIASINTHE
PRESENTATIONQ9%3Q./)F9%3 PLEASEEXPLAIN
?????????????????????????????????????????????
?????????????????????????????????????????????
?????????????????????????????????????????????
?????????????????????????????????????????????
(OWLONGDIDITTAKEFORYOUTOCOMPLETETHISMONOGRAPH
?????????????????????????????????????????????
?????????????????????????????????????????????
.AME0LEASEPRINTCLEARLY ??????????????????????
?????????????????????????????????????????????
$EGREE ??????????????????????????????????????
?????????????????????????????????????????????
3PECIALTY?????????????????????????????????????
!CADEMIC!FlLIATIONIFAPPLICABLE  ???????????????
?????????????????????????????????????????????
?????????????????????????????????????????????
!DDRESS ?????????????????????????????????????
?????????????????????????????????????????????
#ITY ??????????????3TATE??? :IP#ODE?????????
4ELEPHONE.UMBER ??????????????????????


Viv>V`,i>
)NACCORDANCEWITH#-%3TANDARDSFOR#OMMERCIAL3UPPORTOF#-% THEAUTHORSHAVEDISCLOSEDTHEFOLLOWING
RELEVANTRELATIONSHIPSWITHPHARMACEUTICALORDEVICEMANUFACTURERS

*UDD%(OLLANDER -$

2ESEARCH'RANTS#ONSULTANT "IOSITE#ONSULTANT 3CIOS

$OUGLAS-#HAR -$ #ONSULTANT 3CIOS

7&RANK0EACOCK -$ 'RANT2ESEARCH#ONSULTANT 3CIOS

7ILLIAM!BRAHAM -$

2ICHARD,3UMMERS -$ #ONSULTANTANDSPEAKERSBUREAU 3CIOS

3EAN0#OLLINS -$

3PEAKERHONORARIA RESEARCHGRANTS ANDCONSULTINGFEESFOR3CIOS

.ONE

"vv>Li Vi
&ACULTYMEMBERSAREREQUIREDTOINFORMTHEAUDIENCEWHENTHEYAREDISCUSSINGOFF LABEL UNAPPROVEDUSES
OFDEVICESANDDRUGS0HYSICIANSSHOULDCONSULTFULLPRESCRIBINGINFORMATIONBEFOREUSINGANYPRODUCT
MENTIONEDINTHISMONOGRAPH

4HISEDUCATIONALMONOGRAPHWASSUPPORTEDINPARTBYANUNRESTRICTEDEDUCATIONALGRANTFROM3CIOS

#OPYRIGHT%-#2%' )NTERNATIONAL 

)NTERNATIONAL
W W W  E M C R E G  O R G



0RODUCEDBY

^x 
, i>>
iVi}}

/i`V>>}>>i`>L
>iVi`i`V>>}>v-V

0R INTE DIN TH E 5 3!